Heterocyclic janus kinase 3 inhibitors

ABSTRACT

The present invention provides a compound having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. 
     As a result of studies on a novel condensed heterocyclic derivative, the inventors have found that a compound having a cross-linked structure has an excellent JAK3 inhibition activity, and have completed the present invention. 
     In other words, it is verified that the compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer&#39;s disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).

The present invention relates to a novel condensed heterocyclic compound and to a medicament containing the compound as an active ingredient, and more particularly, to an immune disease treating agent.

BACKGROUND ART

Janus kinase 3 (hereafter referred to as JAK3) is a family of protein kinases. Although kinases in this family, other than JAK3, are expressed in a wide range of tissues, JAK3 is expressed locally in hematopoietic cells. This does not contradict the fact that JAK3 plays an important role in signal transmission via various receptors, such as interleukin (hereafter referred to as IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21 by noncovalent association with the common γ chain (refer to nonpatent literature 1 and nonpatent literature 2).

In XSCID (X-linked severe combined immunodeficiency) patient populations, JAK3 protein level lowers or a genetic defect is found in the common γ chain. It is indicated that this problem occurs because immunosuppression blocks JAK3-dependent signaling pathways (refer to nonpatent literature 3 and nonpatent literature 4). Animal experiments have shown that JAK3 not only plays an important role in maturation of B-lymphocytes and T-lymphocytes but also in maintaining the function of T-cells. Hence, it is expected that diseases involving proliferative abnormality of T-cells, such as rejection during organ/tissue transplantation and autoimmune diseases, can be treated by controlling immune response through this mechanism.

On the other hand, a pyrrolopyridine derivative (patent literature 1) represented by formula (A) or (B) or an imidazopyridine derivative (refer to patent literature 2) is known as a compound having JAK3 inhibition activity.

(For the symbols in the formulas, refer to the corresponding patent publications.)

Furthermore, a pyrrolopyrimidine derivative (refer to patent literature 3, patent literature 4, patent literature 5, and patent literature 6) represented by formula (C) is also known as a compound having JAK3 inhibition activity.

(For the symbols in the formula, refer to the corresponding patent publications.)

Still further, a pyrrolopyridine derivative (refer to patent literature 7) represented by formula (D) is also known as a compound having JAK3 inhibition activity.

(For the symbols in the formula, refer to the corresponding patent publication.)

However, in any literature, the compound according to the present invention is not disclosed specifically.

[Nonpatent literature 1] J. J. O'shea et al, Cell, Vol. 109 (suppl.), 5121, 2002 [Nonpatent literature 2] K. Ozaki et al, Science, Vol. 298, p. 1630, 2002 [Nonpatent literature 3] P. Macchi et al, Nature, Vol. 377, p. 65, 1995 [Nonpatent literature 4] S. M. Russell et al, Science, Vol. 270, p. 797, 1995 [Patent literature 1] WO 2004/099205 [Patent literature 2] WO 2004/099204 [Patent literature 3] WO 99/065908 [Patent literature 4] WO 99/065909 [Patent literature 5] WO 01/042246 [Patent literature 6] WO 02/000661 [Patent literature 7] WO 2006/069080

DISCLOSURE OF THE INVENTION Problem to be Solved by the Invention

As a result of intensive studies with an object of providing a useful pharmaceutical composition having JAK3 inhibition activity, the inventors have found that a novel condensed heterocyclic compound has an excellent JAK3 inhibition activity, and have completed the present invention.

More specifically, the present invention provides a novel condensed heterocyclic compound represented by the following formula (I) or pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the compound, more particularly, a pharmaceutical composition serving as an agent for treating and/or preventing autoimmune diseases, inflammatory diseases, and allergic diseases.

The condensed heterocyclic compound is a condensed pyridine compound represented by the following formula (I):

wherein

X is N or CR³,

M is (CH₂)_(m); m is 0 or 1,

R¹ is —H or lower alkyl which may be substituted,

R² is —H or lower alkyl which may be substituted,

R³ is —H, halogen, or lower alkyl which may be substituted,

R⁴¹ is —H or heteroaryl which may be substituted,

R⁴² is a bridged ring group which may be substituted,

R⁵ is a group selected from the group consisting of halogen, cyano, acyl, acylamino, lower alkyl, lower alkenyl, —O-lower alkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heterocycloalkenyl, and 5-membered heteroaryl, each of which may be substituted,

provided that when R⁵ is 5-membered heteroaryl, X is —CR³,

or R⁴¹ and R⁵ may be linked via a specific functional group to form bivalent groups shown below:

wherein R^(A) is —H or acyl which may be substituted, or pharmaceutically acceptable salts thereof.

EFFECT OF THE INVENTION

The compound according to the present invention has JAK3 inhibition activity and is thus useful as an active ingredient of an agent for treating and/or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).

BEST MODES FOR CARRYING OUT THE INVENTION

The compound according to the present invention represented by the formula (I) is characterized in its chemical structure that the compound has a cross-linked amine and also has a skeleton in which 5- and 6-membered heterocycles are condensed, just as in 1H-pyrrolo[2,3-b]pyridine, 1H-imidazo[4,5-b]pyridine, or pyrazolo[1,5-a]pyrimidine, and is further characterized in pharmacology that the compound has a JAK3 inhibition activity.

The present invention is described below in detail.

The term “alkyl” in this specification is a straight or branched monovalent group.

The term “lower alkyl” in the specification is a C₁-C₆ straight or branched alkyl and may include, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, neopentyl, and n-hexyl, preferably methyl, ethyl, n-propyl, isopropyl, and isobutyl, and particularly preferably methyl and ethyl.

The term “lower alkenyl” in the specification is C₂-C₆ straight or branched alkenyl having a double bond at each possible site, and may include, such as ethenyl (vinyl), 1-propenyl, 2-propenyl(allyl), 1-methylethen-1-yl, 1-buten-1-yl, 2-buten-1-yl, 3-buten-1-yl, 1-methyl-1-propen-1-yl, 2-methyl-1-propen-1-yl, 1-methyl-2-propen-1-yl, and 2-methyl-2-propen-1-yl, preferably 1-methyl-2-propen-1-yl.

The term “halogen” means fluoro, chloro, bromo, and iodo, preferably fluoro.

The term “cycloalkyl” is a C₃-C₈ monovalent nonaromatic carbocyclic group, and may partially have unsaturated bonds or may be condensed with a benzene ring. However, bridged cycloc hydrocarbons are excluded. Cycloalkyl may include, such as cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutenyl, cyclohexenyl, cyclooctadienyl, indanyl, and tetrahydronaphthyl, preferably cyclohexyl.

The term “heterocycloalkyl” is a 5- to 6-membered nonaromatic saturated heterocycle which may have one or more identical or different hetero atoms selected from the group consisting of nitrogen atoms, oxygen atoms, and sulfur atoms which may be oxidized. Heterocycloalkyl may be partially unsaturated or may be condensed with a benzene ring. However, aza-bridged cyclic hydrocarbons are excluded. Heterocycloalkyl may include, such as aziridinyl, azetidinyl, pyrrolizinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothiophenyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, indolynyl, tetrahydroquinolyl, tetrahydroisoquinolyl, and benzoxazinyl, preferably dihydrooxazolyl, oxadiazolyl, oxadiazolanyl, and furanyl.

The term “heterocycloalkenyl” is partially substituted “heterocycloalkyl”.

The term “cyclic amino” is, among groups defined in “heterocycloalkyl” a monovalent 3- to 8-membered nonaromatic cyclic amine which has at least one nitrogen atom, and may have one or more identical or different hetero atoms selected from the group consisting of nitrogen atoms, oxygen atoms, and sulfur atoms which may be oxidized, wherein at least one nitrogen atom has a bond. However, aza-bridged cyclic hydrocarbons are excluded. The “Cyclic amino” may include, such as aziridino, azetidino, pyrrolidino, piperidino, homopiperidino, morpholino, thiomorpholino, and piperazino.

The term “aryl” is an aromatic hydrocarbon group and may include, phenyl, naphthyl, and indenyl, preferably C₆-C₁₀ aryl, and more preferably phenyl.

The term “heteroaryl” is a monovalent 5- or 6-membered aromatic heterocyclic group having one or more identical or different hetero atoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, and may be condensed with a benzene ring. “Heteroaryl” may include, such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, thienyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indolyl, indazolyl, quinoxalyl, and quinazolyl, preferably pyridazinyl, pyridyl, pyrazinyl, thiazolyl, pyrazolyl, and thioxazolyl.

The term “bridged ring group” means “bridged cyclic hydrocarbon” and “aza-bridged cyclic hydrocarbon”.

The term “bridged cyclic hydrocarbon” is a saturated or unsaturated, bicyclic or polycyclic bridged hydrocarbon group having two or three C₃-C₁₀ cycloalkyl rings. Non bridged cycloalkyls are excluded. Bicyclic or polycyclic C₄-C₁₆ bridged hydrocarbon groups are particularly preferable. Bridged cyclic hydrocarbon may include, such as bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[4.3.1]decyl, bicyclo[3.3.1]nonyl, bornyl, bornenyl, norbornyl, norbornenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, tricyclobutyl, and adamantyl, preferably adamantyl or bicyclo[2.2.1]heptyl.

The term “aza-bridged cyclic hydrocarbon” is a saturated or unsaturated, bicyclic or polycyclic bridged hydrocarbon group in which at least one of atoms constituting a ring is a nitrogen atom. Non bridged heterocycloalkyls are excluded. Bicyclic or polycyclic C₄-C₁₆ aza-bridged hydrocarbon groups are particularly preferable. The term “aza-bridged cyclic hydrocarbon” may include, such as azanorbornyl, quinuclidinyl, isoquinuclidinyl, tropanyl, azabicyclo[3.2.1]octanyl, azabicyclo[2.2.1]heptanyl, 2-azabicyclo[3.2.1]octanyl, azabicyclo[3.2.1]octanyl, azabicyclo[3.2.2]nonanyl, azabicyclo[3.3.0]nonanyl, and azabicyclo[3.3.1]nonanyl, preferably tropanyl, 2-oxa-5-azabicyclo[2.2.1]hept-5-yl.

The term “acyl” means —C(=0)-lower alkyl, —C(=0)-cycloalkyl, —C(=0)-heterocycloalkyl, —C(=0)-aryl, —C(=0)-heteroaryl, carbamoyl, lower alkylcarbamoyl, —C(=0)-C (=0)-NH-lower alkyl, cycloalkylcarbamoyl, heterocycloalkylcarbamoyl, arylcarbamoyl, and heteroarylcarbamoyl. The term “lower alkyl,” “cycloalkyl,” “heterocycloalkyl,” “aryl” and “heteroaryl” have the above-mentioned meanings.

X in the formula (I) is preferably CH.

R¹ in the formula (I) is preferably —H. R² in the formula (I) is preferably —H or CH₃, and more preferably —H.

R⁴¹ in the formula (I) is preferably —H.

Furthermore, R⁴² in the formula (I) is preferably adamantyl or tropanyl, each of which may be substituted with OH.

Still further, R⁵ in the formula (I) is preferably carbamoyl which may be substituted or —C(═O)-lower alkyl which may have OH more preferably —CONH₂ or hydroxyacetyl. As another embodiment, R⁴¹ and R⁵ are bonded via a specific functional group to form a cyclic structure described above, preferably formula (I-C).

As substituents which are allowed to be used for “which may be substituted” of R¹, R², R³, R⁴¹, R⁴² and/or R⁵, the following groups described in items (a) to (g) are included:

-   (a) Halogen -   (b) —OH, —O—R^(Z), —O-phenyl, —OCO—R^(Z), —OCONH—R^(Z), oxo (═O); -   (c) —SH, —S—R^(Z), —S-phenyl, —S-heteroaryl, —SO—R^(Z), —SO-phenyl,     —SO-heteroaryl, —SO₃H, —SO₂—R^(Z), —SO₂-phenyl, —SO₂-heteroaryl,     sulfamoyl which may be substituted with one or two R^(Z) groups. -   (d) Amino which may be substituted with one or two R^(Z) groups,     —NHCO—R^(Z), —NHCO-phenyl, —NHCO₂—R^(Z), —NHCONH₂, —NHCONH—R^(Z),     —NHSO₂—R⁰, —NHSO₂-phenyl, —NHSO₂NH₂, —NO₂, ═N—O—R^(Z); -   (e) —CHO, —CO—R^(Z), —CO₂H, —CO₂—R^(Z), carbamoyl which may be     substituted with one or two R^(Z) groups, —CO-cyclic amino,     —COCO—R^(Z), cyano; -   (f) R^(Z) -   (g) Phenyl which may be substituted with one or more groups selected     from the substituents described in the above items (a) to (f), 5- or     6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, 5- or     6-membered heterocycloaryl.

R^(Z) in the above items (a) to (g) may include “cyano; —OH; and lower alkyl which may be substituted with one to three groups selected from the group consisting of —O-lower alkyl, —NH-lower alkyl, —CONH-lower alkyl, 5- or 6-membered heterocycloalkyl, and 5- or 6-membered heteroaryl.”

The compound according to the present invention may include geometric isomers and tautomeric isomers depending on the type of constituent. In addition, the compound according to the present invention may have asymmetric carbon atoms. All of the isomers, including separated isomers and mixtures thereof, are included within the scope of the present invention. Furthermore, labeled compounds, that is, compounds obtained by substituting one or more atoms of the compound according to the present invention with radioactive or nonradioactive isotopes are also included in the scope of the present invention.

Furthermore, the pharmaceutically acceptable prodrug of the compound of the present invention is also included in the scope of the present invention. The pharmaceutically acceptable prodrug is a compound having a group that can be converted into amino group, hydroxyl group, carboxyl group, etc. through solvolysis or under physiological conditions. The groups described in Prog. Med., Vol. 5, p. 2157-2161, 1985 and “Iyakuhin No Kaihatsu (Development of Medicines)” (Hirokawa Pub. Co., 1990), Vol. 7, Molecular Design, p. 163-198 are taken as examples of groups forming such prodrugs.

The compound represented by the formula (I) may form acid or base addition salts. These salts should only be pharmaceutically acceptable salts. More specifically, the salts may include an acid addition salt with an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, and phosphoric acid), and an acid addition salt with an organic acid (e.g., formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, aspartic acid, and glutamic acid); a salt with an inorganic base (e.g., sodium, potassium, magnesium, calcium, and aluminum), and a salt with an organic base (e.g., methylamine, ethylamine, ethanolamine, lysine, and ornithine); an ammonium salt; and the like.

Still further, various hydrates, solvates, and crystalline polymorphic forms of the compound represented by the formula (I) and salts thereof are also included in the scope of the present invention.

Process

The compound according to the present invention can be produced using the characteristics based on the basic skeleton or the type of substituent thereof and by applying various known synthesis methods. During the production, protecting the relevant functional group with a suitable protective group or replacing the relevant functional group with a group that can be easily converted into the functional group at the stage of a starting substance or an intermediate may occasionally be effective depending on the type of the functional group in production technology. This kind of functional group may include, for example, amino group, hydroxyl group, and carboxyl group. The protective group for such a functional group may include, for example, the protective groups described in “Protective Groups in Organic Synthesis (3rd. Ed, 1999)” written by T. W. Greene and P. G. Wuts, and one of these should only be selected and used as necessary depending on reaction conditions. In this kind of method, the desired component can be obtained by introducing the protective group, by carrying out reaction and by eliminating the protective group as necessary, or by converting the group into a desired group.

In addition, the prodrug of the compound according to the present invention can be produced by introducing a specific group or by carrying out reaction using the obtained compound represented by the formula (I) at the stage of a starting substance or an intermediate, just as in the case of the above-mentioned protective group. The reaction can be carried out using methods known to those skilled in the art, such as ordinary esterification, amidation, and dehydration.

The abbreviations used in the specification are as follows:

Pr: Preparation number; Ex: Example number; Structure: chemical structure; Rf-Syn: the number of an Example to which reference was made (the number indicates that the relevant compound was produced according to a production method similar to that for producing the compound described in the Example designated by the number.); HPLC: high performance liquid chromatography; TLC: thin layer chromatography; Rf: rate of flow value; Data: NMR data and/or MS data; 1H-NMR: ¹H-nuclear magnetic resonance; MS: mass spectrometry; (M+H)+:(M+H)⁺; (M+Na)+:(M+Na)⁺; (M−H)−:(M−H)⁻.

<First Process>

[wherein R¹, R², R⁴¹, R⁴², R⁵, M and X are as defined above, and Lv is a leaving group.]

In this process, the compound represented by the formula (I-a) and having a leaving group is reacted with the amine represented by the formula (I-b) to produce the compound according to the present invention represented by the formula (I). The leaving group Lv may include halogen (e.g., chloro and bromo); sulfonyloxy (e.g., methanesulfonyloxy, ethanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy, p-nitrobenzenesulfonyloxy, and trifluorometanesulfonyloxy); etc.

In Step 1, the leaving group Lv of the compound represented by the formula (I-a) is substituted with amine. This reaction is carried out under atmospheric pressure or under pressure in the absence of a solvent or in the presence of a suitable solvent.

The solvent may include, for example, aromatic hydrocarbons (e.g., toluene and xylene); ketones (e.g., acetone and methyl ethyl ketone); ethers (e.g., diethylether, tetrahydrofuran(THF), dioxane, and diethoxyethane); alcohols (e.g., methanol (MeOH), ethanol (EtOH), 2-propanol (i-PrOH), and 1-butanol (n-BuOH)); halogenated hydrocarbons (e.g., dichloromethane, 1,2-dichloroethane, chloroform, and carbon tetrachloride); acetonitrile; aprotic solvents (e.g., dimethylformamide (DMF), 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone (NMP), and dimethylsulfoxide (DMSO)); water; or a mixture of these. It is preferable that the reaction is carried out in the presence of a base, and the base may include, for example, alkaline carbonates (e.g., sodium carbonate and potassium carbonate); alkaline hydrogencarbonates (e.g., sodium hydrogencarbonate and potassium hydrogencarbonate); alkoxides (e.g., sodium methoxide, sodium ethoxide, and potassium t-butoxide); tertiary amines (e.g., triethylamine, tributylamine, and diisopropylethylamine); organic bases (e.g., 1,8-diazabicyclo[5.4.0]undeca-7-ene, pyridine, and lutidine). However, an excess amount of the compound (I-b) can also be used. Although the reaction temperature differs depending on the type of a starting compound and reaction conditions, the reaction can usually be carried out at a temperature approximately ranging from ambient temperature to the refluxing temperature of a solvent. The reaction can also usually be carried out in the presence of a base, such as sodium hydroxide and sodium carbonate, in an organic solvent inert to the reaction, such as N,N-dimethylformamide and N,N-dimethylacetamide, under ambient temperature to heating. In addition, the amine represented by the formula (I-b) can also be used as a salt thereof for the reaction.

Furthermore, microwave irradiation can also be carried out under heating. Still further, the reaction can also be carried out by a coupling reaction using a phosphorus reagent, such as 2-(di-t-butylphosphino)biphenyl, and a palladium catalyst, such as palladium acetate, in the presence of a base, such as cesium carbonate.

For the reaction, it is possible to use the methods described in the Preparations) or the Example(s) of the present specification or methods similar to those. The compound represented by the formula (I-a) can thus be produced using known methods, methods obvious to those skilled in the art, or the methods described in the reference examples or the Examples of the present specification or methods similar to those.

<Second Process>

[wherein R¹, R², R⁴¹, R⁴², R⁵, M and Lv are as defined forgoing.]

In this process, the nitropyridine compound represented by the formula (2-a) is reacted with the amine represented by the formula (2-b), and the leaving group at the second position is substituted with the amine to derive the aminonitropyridine compound represented by the formula (2-c). The derived compound is used to produce the compound according to the present invention represented by the formula (I-2).

The method used in Step 1 of the first process can be incorporated in Step 2-1. The amine represented by the formula (2-b) can also be used as a salt thereof for the reaction.

In Step 2-2 in the case that —R² is —H, an imidazole ring can be constructed by reacting an orthoformate, such as ethyl orthoformate, in the presence of an acid catalyst. It is desirable that the nitro group should be reduced before the orthoformate is used for the reaction. Furthermore, the method to be used in the case that the compound represented by the formula (I-2) wherein —R² is not —H is synthesized may include, for example, the method in which the amino group of the compound represented by the formula (2-c) is acylated in advance, the method in which tetraalkylorthocarbonate or alkylisothiocyanate is used instead of the orthoformate, and the method in which carboxylic acid or carboxylic anhydride is reacted with a strong acid, such as sulfonic acid. These actions can be carried out in a solvent inert to the reactions or in the absence of a solvent, under ambient temperature to heating or under heating and refluxing.

<Third Process>

[wherein R¹, R², R⁴², X, and M are as defined forgoing.]

In this process, the compound according to the present invention represented by the formula (3-a) and having a carboxyl group is used as a starting compound to produce the compound according to the present invention represented by the formula (I-3).

In Step 3, the carboxyl group of the compound represented by the formula (3-a) is reacted with an azidation agent, such as diphenylphosphoryl azide (DPPA) and sodium azide, to construct an imidazolone ring according to the so-called Curtius rearrangement reaction. It is advantageous that the reaction is carried out in the presence of a base.

Usually, triethylamine, pyridine, etc. can be used as a base, and the reaction can be carried out under ambient temperature to heating or under heating and refluxing.

<Fourth Process>

[wherein R¹, R², R⁴², M, X and Lv are as defined forgoing.]

In this process, the carboxylic compound represented by the formula (4-a) is reacted with the hydrazine derivative represented by the formula (4-b) to obtain the hydrazide represented by the formula (4-c). From the hydrazide, the compound according to the present invention represented by the formula (I-4) is produced.

Step 4-1 can be carried out similarly to the reaction in which the compound represented by the formula (4-a) and the compound represented by the formula (4-b) are condensed by amidation. The compound (4-a) can be used as a free acid for the reaction, and the reactive derivative thereof can also be used for the reaction. The reactive derivative of the compound (4-a) may include an acid halide (e.g., acid chloride and acid bromide); an ordinary ester (e.g., methyl ester, ethyl ester, and benzyl ester); acid azide; an activated ester with N-hydroxybenzotriazole (HOBt), p-nitrophenyl, or N-hydroxysuccinimide); a symmetric acid anhydride; a mixed acid anhydride with a halocarboxylic acid alkyl ester (e.g., alkyl halide carbonate), pivaloyl halide, p-toluenesulfonic acid chloride, etc.; and a mixed acid anhydride, such as a phosphoric acid-type mixed acid anhydride obtained by reaction with diphenylphosphoryl chloride or N-methylmorpholine; etc.

When the compound (4-a) is reacted in the form of a free acid or reacted without isolating the activated ester, it is preferable to use a condensing agent, such as dicyclohexyl-carbodiimide (DCC), 1,1′-carbonylbis-1H-imidazole (CDI), diphenylphosphoryl azide (DPPA), diethyphosphoryl cyanide(DEPC), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI HCl).

The reaction is carried out in an organic solvent inert to the reaction, such as halogenated hydrocarbons, aromatic hydrocarbons, ethers, esters (e.g., ethyl acetate), acetonitrile, DMF, and DMSO, under cooling, under cooling to ambient temperature, or under ambient temperature to heating, although the conditions differ depending on the reactive derivative or the condensing agent to be used.

In order to smoothly advance the reaction, it is occasionally advantageous that an excess amount of the compound (4-b) is used for the reaction or the reaction is carried out in the presence of a base, such as N-methylmorpholine, trimethylamine, triethylamine, diisopropylethylamine, N,N-dimethylaniline, pyridine, 4-(N,N-dimethylamino)pyridine, picoline, and lutidine. Pyridine can also be used as a solvent.

The method used in Step 1 of the first process can be incorporated in Step 4-2.

<Fifth Process>

[wherein R¹, R², R⁴¹, R⁴² and M are as defined above, R′ is suitable substituent. The carboxylic acid represented by the formula (5-f) is a marketed product or can be prepared using a marketed product.]

In step 5-2, step 5-4 and step 5-6, a reaction for constructing an oxadiazole ring at R⁵ is carried out.

In Step 5-1, a reaction for synthesizing an acid hydrazide from the carboxylic acid represented by the formula (5-a) is carried out. Furthermore, the intermediate represented by the formula (5-c) can also be synthesized from the carboxylic acid represented by the formula (5-a). The reaction in Step 4-1 can be incorporated in each of these reactions.

In Step 5-2, Step 5-4, and step 5-6, a reaction for constructing an oxadiazole ring is carried out under ambient temperature to heating. An organic base may be added to advance the reaction.

In Step 5-5, the aromatic nitrile compound represented by the formula (5-d) is reacted with hydroxylamine to obtain hydroxyamidine represented by the formula (5-e). The obtained hydroxyamidine is reacted with the carboxylic acid represented by the formula (5-f) to produce the compound according to the present invention represented by the formula (I-53).

In Step 5-5, the reaction with free hydroxylamine or hydroxylamine hydrochloride is carried out in the presence of a base, whereby the hydroxyamidine represented by the formula (5-e) can be produced.

The reaction can be carried out in a solvent inert to the reaction. The solvent may include, for example, alcohols (e.g., methanol (MeOH), ethanol (EtOH), and 2-propanol (iPrOH)); aromatic hydrocarbons (e.g., toluene and xylene); ethers (e.g., diethylether, tetrahydrofuran (THF), dioxane, and diethoxyethane); halogenated hydrocarbons (e.g., dichloromethane, 1,2-dichloroethane, chloroform, and carbon tetrachloride); aprotic solvents (e.g., DMF, 1,3-dimethyl-2-imidazolidinone, and DMSO); water; or a mixture of these. Usually, alcohols are used for the reaction. In the case that hydroxylamine hydrochloride is used for the reaction as described above, it is preferable that the reaction is carried out in the presence of a base, and the base may include, for example, alkaline carbonates (e.g., sodium carbonate and potassium carbonate); alkaline hydrogencarbonates (e.g., sodium hydrogencarbonate and potassium hydrogencarbonate); alkoxides (e.g., sodium methoxide, sodium ethoxide, and potassium t-butoxide); tertiary amines (e.g., triethylamine and diisopropylethylamine); and organic bases (e.g., 1,8-diazabicyclo[5.4.0]undeca-7-ene, pyridine, and lutidine). Although the reaction temperature differs depending on the type of a starting compound and reaction conditions, the reaction can usually be carried out at a temperature approximately ranging from ambient temperature to the refluxing temperature of a solvent. The reaction can usually be carried out in the presence of a base, such as sodium carbonate, in an organic solvent inert to the reaction, such as methanol, under ambient temperature to heating.

Step 5-6 consists of two stages: acylation of hydroxyamidine and subsequent cyclization. The intermediate producing method in Step 4-1 can be incorporated in the acylation in the first stage. However, the reaction is usually carried out under ambient temperature to heating, or under heating and refluxing. The cyclization in the second stage can be carried out by isolating and purifying an acyl and by heating the acyl in an organic solvent inert to the reaction, such as ethanol and dioxane, in the presence or absence of a base. The base may include an inorganic base, such as sodium acetate, or an organic base, such as diisopropylethylamine. The reaction consisting of the two stages can be carried out by one operation by performing ordinary acylation and then by directly heating the reaction mixture or by carrying out reaction under microwave irradiation.

The solvent may include, for example, aromatics (e.g., toluene, xylene, and pyridine); ethers (e.g., diethylether, tetrahydrofuran, dioxane, and diethoxyethane); halogenated hydrocarbons (e.g., dichloromethane, 1,2-dichloroethane, chloroform, and carbon tetrachloride); acetonitrile; aprotic solvents (e.g., DMF, N,N-dimethylacetamide (DMA), 1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone (NMP), and DMSO)); water; or a mixture of these. Although the reaction temperature differs depending on the type of a starting compound and reaction conditions, the reaction can be carried out under ambient temperature to heating.

<Sixth Process>

[wherein R¹, R², R⁴², M, m and Lv are as defined above; R″ is suitable substituent.]

In Step 6, in the case that the compound represented by the formula (6-a) is reacted with the primary amine represented by the formula (6-b), after ipso substitution, the oxadiazole ring is opened to construct an aminopyrazolone ring. The reaction conditions described in Step 1 can be incorporated herein as the reaction conditions. The reaction can be carrying out under ambient temperature to refluxing temperature.

In addition, some of the compounds represented by the formula (I) can also be produced from the compound according to the present invention produced as described above by appropriately combining processes usually used by those skilled in the art, such as known alkylation, acylation, substitution, oxidation, reduction, hydrolysis, deprotection, halogenation, and Mannich reaction. For example, when the compound according to the present invention wherein —R⁵ is —CO₂H is produced from the compound according to the present invention wherein R⁵ is lower alkyloxycarbonyl, hydrolysis can be used referring to the method described in “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Ed., 2003).” Moreover, when the compound according to the present invention wherein R⁵ is halogen is produced from the compound according to the present invention wherein both R³ and R⁵ are —H, halogenation can be used referring to the method described in “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Ed., 2003).” Still further, when the compound according to the present invention wherein R³ is a lower alkyl substituted with a group selected from the group consisting of mono (lower alkyl)amino, di(lower alkyl)amino, and cyclic amino is produced from the compound according to the present invention wherein R³ is —H, the Mannich reaction can be used referring to the methods described in “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Ed., 2003)”; C. Mannich et al., Arch. Pharm., 1912, Vol. 250, p. 647; J. H. Brewster et al., Org. React., 1953, Vol. 7, p. 99; F. F. Blicke, Org. React., 1942, Vol. 1, p. 303; K. W. Merz et al., Pharmazie, 1956, Vol. 11, p. 505; etc.

The processes capable of being usually used by those skilled in the art are not only used for the compound according to the present invention but can also be used for intermediates formed during production. The processes can also advance to subsequent processes.

The compound produced as described above is in a free form or subjected to salt-forming processing using a conventional method and isolated and purified as a salt thereof. The isolation and purification are carried out by performing ordinary chemical operations, such as extraction, concentration, evaporation, crystallization, filtration, recrystallization, and various types of chromatography.

Various types of isomers can be isolated by utilizing the difference in physicochemical properties between the isomers using a conventional method. For example, a racemic mixture can be converted into an optically pure isomer using a general racemic resolution method, such as the method in which the racemic mixture is converted into a diastereomer salt with a general optically-active acid, such as tartaric acid, and subjected to optical resolution. Furthermore, the diastereo mixture can be separated by fractional crystallization or various types of chromatography, for example. Still further, the optically-active compound can also be produced using a suitable optically-active material.

The pharmacological activity of the compound according to the present invention was verified by carrying out the following test.

Test Example 1 JAK3 Inhibition Test

The JAK3 inhibition test was performed as described below according to the method of Okimoto et al.

(1) Preparation of Human JAK3

Purified human JAK3 kinase domain was purchased from Carna Biosciences, Inc. (Kobe, Japan). This is obtained as described below. His-tag (41 kDa) was attached to the N-terminal of the 796-1124 (C-terminal) fragment of the human JAK3 protein (accession number #NM_(—)000215), expressed using baculovirus expression system, and then purified using Ni-NTA affinity column chromatography.

(2) Measurement of JAK3 Activity

As substrates, Biotin-Lyn-Substrate-2 (Biotin-XEQED EPEGF YFEWL EPE, X=ε-Acp (PEPTIDE INSTITUTE, INC., Osaka, Japan) and ATP were used. As an assay buffer, 15 mM Tris-HCl pH 7.5 containing 0.01% Tween 20 and 2 mM DTT was used. Normally, 20 μL of a substrate solution (an assay buffer containing 627 nM Biotin-Lyn-Substrate-2, 20 μM ATP, and 25 mM MgCl₂), an assay buffer containing 10 μL of a substance to be tested, and 20 μL of an enzyme solution were added to a microplate, and stirred sufficiently.

After incubation at ambient temperature for one hour, the plate was washed with a cleaning buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.02% Tween 20), and a blocking buffer (a cleaning buffer containing 0.1% bovine serum albumin) was added to the plate. After incubation at ambient temperature for 30 minutes, the blocking buffer was removed, and an HRP-PY-20 solution (obtained by diluting HRP-PY-20 solution with the blocking buffer 500 times) was added. After incubation at ambient temperature for 30 minutes, the plate was washed four times, and a TMB substrate solution (Sigma) was added to the plate. After incubation at ambient temperature for four minutes, 1M sulfuric acid was added to stop the reaction. Enzyme activity was measured as absorbance at 450 nm. The efficacy of the test compound as a JAK3 inhibitor was expressed as an IC₅₀ value.

The IC₅₀ values described below are results obtained in the test.

The results of those tests are shown in the Table 1. Table 1: JAK3 inhibitory activity of the compound of the present invention.

TABLE 1 Ex IC₅₀ (nM) Ex IC₅₀ (nM) 29 2.3 379 1.2 32 1.9 384 0.28 33 2.1 405 0.65 34 0.17 426 2.3 121 1.1 434 0.86 122 0.43 484 0.31 133 4.4 498 1.3 143 0.69 543 0.33

It is verified that the compound according to the present invention has inhibition activity against JAK3 and is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).

In addition, on the basis of the JAK3 inhibition activity, the compound according to the present invention is useful for treating and/or preventing the following diseases.

The pharmaceutical composition of the present invention comprising JAK3 inhibitor such as the compound (I) is useful as a therapeutic or prophylactic agent for diseases or conditions caused by undesirable cytokine signal transduction, such as rejection reaction in organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, Alzheimer's disease, atherosclerosis, tumors, myelomas, and leukemia as exemplified below:

rejection reactions by transplantation of organs or tissues such as the heart, kidney, liver, bone marrow, skin, cornea, lung, pancreas, islet, small intestine, limb, muscle, nerve, intervertebral disc, trachea, myoblast, cartilage, etc.; and graft-versus-host reactions following bone marrow transplantation; autoimmune diseases such as rheumatoid arthritis, systemic lupus, erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes and complications from diabetes, etc.

Furthermore, pharmaceutical preparations of the JAK3 inhibitor, such as the compound (I), are useful for the therapy or prophylaxis of the following diseases.

Inflammatory or hyperproliferative skin diseases or cutaneous manifestations of immunologically-mediated diseases (e.g., psoriasis, atopic dermatitis, contact dermatitis, eczematoid dermatitis, seborrheic dermatitis, lichen planus, pemphigus, bullous penphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, erythema, dermal eosinophilia, lupus erythematosus, acne, alopecia greata, etc.);

autoimmune diseases of the eye (e.g., keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular premphigus, Mooren's ulcer, scleritis, Grave's ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, etc.); reversible obstructive airways diseases [asthma (e.g., bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, etc.), particularly chronic or inveterate asthma (e.g., late asthma, airway hyper-responsiveness, etc.), bronchitis, etc.]; mucosal or vascular inflammations (e.g., gastric ulcer, ischemic or thrombotic vascular injury, ischemic bowel diseases, enteritis, necrotizing enterocolitis, intestinal damages associated with thermal burns, leukotriene B4-mediated diseases, etc.); intestinal inflammations/allergies (e.g., coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, etc.); food-related allergic diseases with symptomatic manifestation remote from the gastrointestinal tract (e.g., migrain, rhinitis, eczema, etc.); autoimmune diseases and inflammatory conditions (e.g., primary mucosal edema, autoimmune atrophic gastritis, premature menopause, male sterility, juvenile diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active chronic hepatitis, idiopathic cirrhosis, discoid lupus erythematosus, autoimmune orchitis, arthritis (e.g., arthritis deformans, etc.), polychondritis, etc.); allergic conjunctivitis.

Therefore, the pharmaceutical composition of the present invention is useful for the therapy and prophylaxis of liver diseases [e.g., immunogenic diseases (e.g., chronic autoimmune liver diseases such as autoimmune hepatic diseases, primary biliary cirrhosis, sclerosing cholangitis, etc.), partial liver resection, acute liver necrosis (e.g., necrosis caused by toxins, viral hepatitis, shock, anoxia, etc.), hepatitis B, non-A/non-B hepatitis, hepatocirrhosis, hepatic failure (e.g., fulminant hepatitis, late-onset hepatitis, “acute-on-chronic” liver failure (acute liver failure on chronic liver diseases, etc.), etc.), etc.]. Pharmaceutical preparations of the JAK3 inhibitor, such as the compound (I), either from alone or in combination with one or more additional agents which may include but are not limited to cyclosporin A, tacrolimus, sirolimus, everolimus, micophenolate (e.g. Cellcept®, Myfortic®, etc.), azathioprine, brequinar, leflunomide, sphingosine-1-phosphate receptor agonist (e.g. fingolimod, KRP-203, etc.), LEA-29Y, anti-IL-2 receptor antibody (e.g. daclizumab, etc.), anti-CD3 antibody (e.g. OKT3, etc.), Anti-T cell immunogloblin (e.g. AtGam, etc.) aspirin, CD28-B7 blocking molecules (e.g. Belatacept, Abatacept, etc.), CD40-CD154 blocking molecules (e.g. Anti-CD40 antibody, etc.), protein kinase C inhibitor (e.g. AEB-071, etc.), acetaminophen, ibuprofen, naproxen, piroxicam, and anti inflammatory steroid (e.g. prednisolone or dexamethasone) may be administrated as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice.

The pharmaceutical composition containing one or two or more kinds of the compound represented by the formula (I) or pharmaceutically acceptable salts thereof as an active ingredient can be prepared using carriers, excipients, and other additives usually used for pharmaceutical preparation.

Therapeutic administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, etc., or parenteral administration via intravenous or intramascular injections, suppositories, transdermal agents, transnasal agents, inhalers, etc. The dose of the compound is determined appropriately in consideration of the symptoms, age, sex, and the like of each patient to be treated. Usually, in the case of oral administration, a daily dose of approximately 0.001 to 100 mg/kg of the compound can be administered one or two to four times per day for an adult patient. When intravenous administration is required depending on symptoms, a dose of 0.0001 to 10 mg/kg of the compound can usually be administered one to multiple times per day for an adult patient. In the case of inhalation, a dose of 0.0001 to 1 mg/kg of the compound can usually be administered one to multiple times per day for an adult patient.

The solid composition for use in the oral administration according to the present invention is used in the form of tablets, powders, granules, etc. In such a solid composition, one or more active ingredients are mixed with at least one inactive excipient, such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone, and magnesium aluminometasilicate. According to a usual method, the composition may contain inactive additives, such as a lubricant (e.g., magnesium stearate), a disintegrating agent (e.g., carboxymethyl starch sodium), and a solubilization assisting agent. If necessary, tablets or pills may be coated with sugar or a film of a gastric or enteric coating substance.

The liquid composition for oral administration contains pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or elixirs, and also contains a generally used inert diluent, such as purified water or ethanol. In addition to the inert diluent, the composition may also contain auxiliary agents, such as a solubilization assisting agent, a moistening agent, and a suspending agent, as well as sweeteners, flavors, aromatics, and antiseptics.

The injections for parenteral administration contain aseptic aqueous or non-aqueous solutions, suspensions, or emulsions. The diluent for use in the aqueous solutions may include, for example, distilled water for injection use and physiological saline. The diluent for use in the non-aqueous solutions may include, for example, propylene glycol, polyethylene glycol, plant oil (e.g., olive oil), alcohol (e.g., ethanol), and polysorbate 80 (official name). Such a composition may further contain additive agents, such as a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, and a solubilization assisting agent. These compositions are sterilized by filtration through a bacteria retaining filter, blending of a germicide, or irradiation. Furthermore, they may also be produced in the form of sterile solid compositions and dissolved or suspended in sterile water or a sterile solvent for injection use prior to their use.

The transmucosal agents, such as inhalers and transnasal agents, are used in the form of solid, liquid or semisolid and can be produced according to conventional known methods. For example, excipients (e.g., lactose and starch), pH adjusters, antiseptics, surface active agents, lubricants, stabilizers, thickeners, etc. may also be added as necessary. For administration, suitable devices for inhalation or insufflation can be used. For example, using known devices and sprayers, such as measuring inhalation devices, the compound can be administered independently or in the form of prescribed mixture powders. Furthermore, the compound combined with pharmaceutically acceptable carriers can also be administered in the form of solutions or suspensions. Dry powder inhalers and the like may be devices for single or multiple administrations, and dry powders or capsules containing powders can also be used. Still further, the devices may be in the form of a pressure aerosol spray or the like that uses a suitable ejection agent, such as chlorofluoroalkane or hydrofluoroalkane, or a suitable gas, such as carbon dioxide.

The drug for external use may include ointments, plasters, creams, jellies, patches, sprays, lotions, eye-drops, eye ointments, etc. The drug contains generally used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, etc. The ointment bases or lotion bases may include, for example, polyethylene glycol, carboxyvinal polymer, white Vaseline, bleached bee wax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, and sorbitan sesquioleate.

Examples

Although the present invention is described below specifically by way of Examples, the present invention is not limited by these Examples at all. Starting compounds being used in Examples include novel substances, and the methods for producing such starting compounds from known compounds are described by way of Preparations.

Preparation 1

The compounds in Preparations 1-1 to 1-25 shown in the following table were produced by using the corresponding starting compounds according to the method similar to that described in Example 1.

TABLE 2 Pr Structure 1-1 

1-2 

1-3 

1-4 

1-5 

1-6 

1-7 

1-8 

1-9 

1-10

1-11

1-12

1-13

1-14

1-15

1-16

1-17

1-18

1-19

1-20

1-21

1-22

1-23

1-24

1-25

TABLE 3 Pr Data 1-1 MS: 342 (M + H) + 1-2 MS: 342 (M + H) + 1-3 MS: 460 (M + H) + 1-4 MS: 370 (M + H) + 1-5 MS: 370 (M + H) + 1-6 MS: 358 (M + H) + 1-7 1H-NMR (400 MHz, d6-DMSO) δ: 1.32 (3H, t, J = 7.0 Hz), 1.43 (9H, s), 1.73-1.87 (2H, m), 1.90-2.08 (4H, m), 2.18-2.33 (2H, m), 4.08-4.18 (2H, m), 4.28 (2H, q, J = 7.0 Hz), 4.37-4.47 (1H, m), 6.52-6.57 (1H, m), 7.13-7.18 (1H, m), 8.56 (1H, s), 9.39 (1H, d, J = 7.6 Hz), 11.67 (1H, s). MS: 415 (M + H) + 1-8 1H-NMR (400 MHz, d6-DMSO) δ: 0.32 (3H, t, J = 7.1 Hz), 0.48-3.13 (14H, m), 4.26 (2H, q, J = 7.1 Hz), 4.68 (1H, s), 6.71-6.72 (1H, m), 7.23-7.24 (1H, m), 8.60 (1H, s), 9.34 (1H, s), 11.69 (1H, s). MS: 356 (M + H) + 1-9 1H-NMR (400 MHz, d6-DMSO) δ: 0.32 (3H, t, J = 7.1 Hz), 0.40-0.47 (2H, m), 1.95-2.17 (11H, m), 0.80-0.83 (1H, m), 4.26 (2H, q, J = 7.1 Hz), 4.73 (1H, d, J = 2.9 Hz), 6.76 (1H, dd, J = 2.4 Hz, 3.5 Hz), 7.22 (1H, dd, J = 2.6 Hz, 3.3 Hz), 8.60 (1H, s), 9.33 (1H, s), 11.68 (1H, s). MS: 356 (M + H) + 1-10 MS: 372 (M + H) + 1-11 MS: 471 (M + H) + 1-12 MS: 481 (M + H) + 1-13 MS: 405 (M + H) + 1-14 MS: 484 (M + H) + 1-15 MS: 484 (M + H) + 1-16 MS: 517 (M + H) + 1-17 MS: 445 (M + H) + 1-18 MS: 445 (M + H) + 1-19 MS: 300 (M + H) + 1-20 MS: 342 (M + H) + 1-21 MS: 354 (M + H) + 1-22 MS: 356 (M + H) + 1-23 MS: 342 (M + H) + 1-24 1H-NMR (400 MHz, d6-DMSO) δ: 1.35 (3H, t, J = 7.1 Hz), 1.68-1.77 (6H, m), 2.10-2.18 (9H, m), 4.26 (2H, q, J = 7.1 Hz), 6.75 (1H, d, J = 3.6 Hz), 7.22 (1H, d, J = 3.4 Hz), 8.60 (1H, s), 9.34 (1H, s), 11.67 (1H, s). MS: 340 (M + H) + 1-25 1H-NMR (400 MHz, d6-DMSO) δ: 1.32 (3H, t, J = 7.1 Hz), 1.61-2.07 (16H, m), 4.29 (2H, q, J = 7.1 Hz), 4.48 (1H, d, J = 3.5 Hz), 7.18 (1H, d, J = 3.2 Hz), 9.36 (1H, d, J = 8.0 Hz), 11.67 (1H, s). MS: 340 (M + H) +

Preparation 2

To glycinamide hydrochloride (34 mg) were added a solution of ethyl 3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-oxadiazole-5-carboxylate (60 mg) in 1-methyl-2-pyrrolidone (0.6 ml) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.092 ml), and the mixture was stirred at 70° C. for 1 hour. After being left to cool, the reaction solution was directly purified by preparative HPLC (10 mM NH₄HCO₃+NH₃ (pH=9.2):CH₃CN=90:10 to 20:80). The active fraction was concentrated and dried to hardness to obtain 3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyl-1,2,4-oxadiazole-5-carboxylate (23 mg) as a solid.

The compounds in Preparations 2-1 to 2-26 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 2.

TABLE 4 Pr Structure 2  

2-1 

2-2 

2-3 

2-4 

2-5 

2-6 

2-7 

2-8 

2-9 

2-10

2-11

2-12

2-13

2-14

2-15

2-16

2-17

2-18

2-19

2-20

2-21

2-22

2-23

2-24

2-25

2-26

TABLE 5 Ex MS data 2 MS: 278 (M + H) + 2-1 MS: 348 (M + H) + 2-2 MS: 334 (M + H) + 2-3 MS: 377 (M + H) + 2-4 MS: 361 (M + H) + 2-5 MS: 377 (M + H) + 2-6 MS: 357 (M + H) + 2-7 MS: 382 (M + H) + 2-8 MS: 348 (M + H) + 2-9 MS: 303 (M + H) + 2-10 MS: 332 (M + H) + 2-11 MS: 410 (M + H) + 2-12 MS: 368 (M + H) + 2-13 MS: 318 (M + H) + 2-14 MS: 346 (M + H) + 2-15 MS: 375 (M + H) + 2-16 MS: 415 (M + H) + 2-17 MS: 373 (M + H) + 2-18 MS: 322 (M + H) + 2-19 MS: 322 (M + H) + 2-20 MS: 375 (M + H) + 2-21 MS: 350 (M + H) + 2-22 MS: 334 (M + H) + 2-23 MS: 378 (M + H) + 2-24 MS: 378 (M + H) + 2-25 MS: 334 (M + H) + 2-26 MS: 347 (M + H) +

Preparation 3

Benzyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (55 mg), ethyl {[(4-amino-1-adamantyl)carbonyl]amino}acetate (54 mg) and triethylamine (80 μl) were dissolved in N-methyl-2-pyrrolidone (0.55 ml) and stirred at 180° C. for 1 hour using a microwave reaction system. To the reaction solution were added ethyl acetate and water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate), the obtained compound was dissolved in dioxane (1.1 ml) and methanol (1.1 ml), 10% palladium on carbon (50% wet) was added, and catalytic reduction was performed for 4 hours at ambient temperature at 1 atm. Methanol, dioxane, and 1M hydrochloric acid were added, and the precipitated solid was dissolved and filtered to remove the catalyst. The filtrate was concentrated under reduced pressure to obtain 4-({5-[(2-ethoxy-2-oxoethyl)carbamoyl]adamantan-2-yl}amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (18 mg).

TABLE 6 Pr Structure Data 3

MS: 441 (M + H)+

Preparation 4

To a ethanol (3 ml) was added acetyl chloride carefully at 4° C. The reaction solution was stirred at 4° C. for 30 minutes. To the reaction solution were added a solution of 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (50 mg) in chloroform (0.5 ml) and 2M hydrochloric acid/ethanol solution (0.5 ml) dropwise. The reaction solution was stirred under ambient temperature for 18 hours. The reaction solution was concentrated under reduced pressure to obtain ethyl 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidate trihydrochloride (75 mg).

TABLE 7 Pr Structure Data 4

MS: 355 (M - 3HCl + H)+

Preparation 5

The compounds in Preparations 5-1 to 5-32 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 3.

TABLE 8 Pr Structure 5-1 

5-2 

5-3 

5-4 

5-5 

5-6 

5-7 

5-8 

5-9 

5-10

5-9 

5-10

5-11

5-12

5-13

5-14

5-15

5-16

5-17

5-18

5-19

5-20

5-21

5-22

5-23

5-24

5-25

5-26

5-27

5-28

5-29

5-30

5-31

5-32

TABLE 9 Pr Data 5-1 MS: 272 (M + H)+ 5-2 MS: 272 (M + H)+ 5-3 1H-NMR (400 MHz, d6-DMSO)δ: 1.60-2.06 (14H, m), 4.24 (1H, d, J = 7.9 Hz), 6.46 (1H, dd, J = 1.3 Hz, 3.3 Hz), 7.16 (1H, dd, J = 2.4 Hz, 3.2 Hz), 8.52 (1H, s), 9.61 (1H, s), 11.59 (1H, s), 12.33 (1H, br)MS: 312 (M + H)+ 5-4 MS: 314 (M + H)+ 5-5 1H-NMR (400 MHz, d6-DMSO)δ: 1.67-1.75 (6H, m), 2.09-2.16 (9H, m), 6.71 (1H, s), 7.16 (1H, s), 8.56 (1H, s), 9.76 (1H, br), 11.49 (1H, s). MS: 312 (M + H)+ 5-6 MS: 326 (M + H)+ 5-7 MS: 410 (M + Na)+ 5-8 MS: 329 (M + H)+ 5-9 MS: 479 (M + H)+ 5-10 5-11 MS: 475 (M + Na)+ 5-12 5-13 MS: 409 (M + Na)+ 5-14 MS: 446 (M − H)− 5-15 MS: 377 (M + H)+ 5-16 MS: 209 (M − H)− 5-17 MS: 342 (M + H)+ 5-18 MS: 330 (M + H)+ 5-19 1H-NMR (400 MHz, d6-DMSO)δ: 1.43 (9H, s), 1.70-1.88 (2H, m), 1.88-2.09 (4H, m), 2.14-2.33 (2H, m), 4.05-4.20 (2H, m), 4.34-4.46 (1H, m), 6.48-6.58 (1H, m), 7.09-7.17 (1H, m), 8.52 (1H, s), 9.67 (1H, d, J = 6.2 Hz), 11.62 (1H, s), 12.45 (1H, br). MS: 387 (M + H)+ 5-20 MS: 463 (M + Na)+ 5-21 MS: 437 (M − H)− 5-22 MS: 371 (M + Na)+ 5-23 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-1.46 (2H, m), 1.96-2.15 (11H, m), 2.44-2.55 (1H, m), 3.82 (1H, s), 4.71 (1H, s), 6.72-6.75 (1H, m), 7.19 (1H, t, J = 2.9 Hz), 8.56 (1H, s), 9.71 (1H, br), 11.57 (1H, s). MS: 328 (M + H)+ 5-24 MS: 355 (M + Na)+ 5-25 MS: 314 (M + H)+ 5-26 MS: 437 (M − H)− 5-27 MS: 261 (M + H)+ 5-28 MS: 342 (M + H)+ 5-29 MS: 314 (M + H)+ 5-30 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.68 (6H, m), 1.98 (6H, s), 2.26 (2H, s), 4.66 (1H, s), 6.68 (1H, dd, J = 5.3 Hz, 11.4 Hz), 7.2 (1H, dd, J = 2.5 Hz, 3.0 Hz), 8.57 (1H, s), 9.70 (1H, br), 11.58 (1H, s). MS: 328 (M + H)+ 5-31 MS: 328 (M + H)+ 5-32 MS: 458 (M + H)+

Preparation 6

To a ethyl 7-[(trans-5-hydroxyadamantan-2-yl)amino]-3H-imidazo[4,5-b]pyridine-6-carboxylate (50 mg) was added 47% aqueous hydrobromic acid (0.75 ml), and the mixture was stirred at 120° C. for 1 hour using a microwave reaction system. After the reaction solution was cooled, the pH was adjusted to 5 with aqueous potassium carbonate, and the obtained solid was collected by filtration and washed with water to obtain 7-[(trans-5-bromoadamantan-2-yl)amino]-3H-imidazo[4,5-b]pyridine-6-carboxylic acid (44 mg).

The compounds in Preparations 6-1 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 6.

TABLE 10 Pr Structure Data 6  

MS: 391, 393 (M + H)+ 6-1

MS: 391, 393 (M + H)+

Preparation 7

A mixture of ethyl 7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-3H-imidazo[4,5-b]pyridine-6-carboxylate (400 mg), di-t-butyl dicarbonate (203 mg), triethylamine (130 μl), dioxane (4 ml) and water (4 ml) was stirred at ambient temperature for 1 hour. The mixture was diluted with ethyl acetate (5 ml) and water (20 ml). The resulting precipitate was collected by filtration (ethyl 7-{[(3-exo)-8-(tert-butoxycarbonyl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-3H-imidazo[4,5-b]pyridine-6-carboxylate, (200 mg)). The filtrate was diluted with ethyl acetate (50 ml) and extracted with ethyl acetate. The organic extracts were washed with brine, dried over sodium sulfate and concentrated. Recrystallization from ethyl acetate/n-hexane gave ethyl 7-{[(3-exo)-8-(tert-butoxycarbonyl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-3H-imidazo[4,5-b]pyridine-6-carboxylate (100 mg) as a white solid.

The compounds in Preparations 7-1 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 64.

TABLE 11 Pr Structure Data 7  

MS: 416 (M + H)+ 7-1

MS: 415 (M + H)+

Preparation 8

The compounds in Preparations 8-1 to 8-3 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 44.

TABLE 12 Pr Structure Data 8-1

MS: 326 (M + Na)+ 8-2

MS: 326 (M + Na)+ 8-3

MS: 326 (M + Na)+

Preparation 9

The compounds in Preparations 9-1 to 9-2 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 10.

TABLE 13 Pr Structure Data 9-1

MS: 319 (M + Na)+ 9-2

MS: 424 (M − H₂O + H)+

Preparation 10

The compounds in Preparations 10-1 to 10-18 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 4.

TABLE 14 Pr Structure 10-1

10-2

10-3

10-4

10-5

10-6

10-7

10-8

10-9

10-10

10-11

10-12

10-13

10-14

10-15

10-16

10-17

10-18

TABLE 15 Pr Data 10-1 MS: 332 (M + H)+ 10-2 MS: 246 (M + Na)+ 10-3 MS: 586 (M + H)+ 10-4 MS: 452 (M + H)+ 10-5 MS: 370 (M + Na)+ 10-6 MS: 368 (M + H)+ 10-7 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-1.45 (2H, m), 1.65-1.86 (8H, m), 1.94-1.97 (2H, m), 2.15-2.20 (2H, m), 3.08-3.11 (1H, m), 5.05-5.08 (1H, m), 6.55-6.57 (1H, m), 7.66-7.68 (1H, m), 8.19 (1H, s), 9.85 (1H, d, J = 6.8 Hz), 12.20 (1H, brs). MS: 367 (M + Na)+ 10-8 MS: 232 (M + Na)+ 10-9 MS: 427 (M + H)+ 10-10 MS: 415 (M + H)+ 10-11 MS: 233 (M + Na)+ 10-12 MS: 474 (M + Na)+ 10-13 MS: 462 (M + Na)+ 10-14 MS: 262 (M + Na)+ 10-15 MS: 447 (M + H)+ 10-16 10-17 MS: 232 (M + Na)+ 10-18 MS: 452 (M + H)+

Preparation 11

To a solution of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (350 mg) in N,N-dimethylformamide (4 ml) were added N,N-carbonyl diimidazole (289 mg) and glycinemethylester hydrochloride (447 mg) successively under ambient temperature. The mixture was stirred at ambient temperature for 2 hours. To the reaction solution was added water. The precipitated solid was filtered, washed with water, and dried to obtain 4-chloro-5-(1H-imidazol-1-ylcarbonyl)-1H-pyrrolo[2,3-b]pyridine (325 mg) as a white solid.

TABLE 16 Pr Structure Data 11

MS: 247 (M + H)+, 245 (M − H)−

Preparation 12

To a solution of 4-chloro-5-(1H-imidazol-1-ylcarbonyl)-1H-pyrrolo[2,3-b]pyridine (300 mg) in N,N-dimethylformamide (3 ml) were added N-ethyl-N-isopropylpropane-2-amine (0.64 ml) and glycine methylester hydrochloride (305 mg) at ambient temperature. The mixture was warmed immediately to 60° C. and stirred at 60° C. for 2 hours. After to the reaction solution was added water, the mixture was stirred for 1 hour. The precipitated solid was filtered, washed with water, and dried to obtain methyl N-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)carbonyl]glycinate (267 mg) as a white solid.

TABLE 17 Pr Structure Data 12

MS: 290 (M + Na)+

Preparation 13

To a solution of benzyl rel-[(1R,2S,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (1.3 g) in dichloroethane (13 ml) were added trimethyloxonium tetrafluoroborate (1.28 g), 2,6-di-t-butyl-4-methylpyridine (2.21 g). The reaction solution was refluxed for 3 hours. The reaction solution was concentrated under reduced pressure, ethyl acetate was added, and the insoluble matter was filtered. To the filtrate was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=19:1 to 7:3) to obtain benzyl rel-[(1R,2S,3S,5s)-5-methoxyadamantan-2-yl]carbamate (540 mg) as a colorless oily matter.

The compounds in Preparations 13-1 to 13-2 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 13.

TABLE 18 Pr Structure Data 13

MS: 338 (M + Na)+ 13-1

MS: 338 (M + Na)+ 13-2

MS: 352 (M + Na)+

Preparation 14

The compounds in Preparations 14-1 to 14-6 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Examples 12 to Examples 14.

TABLE 19 Pr Structure 14-1

14-2

14-3

14-4

14-5

14-6

TABLE 20 Pr Data 14-1 MS: 267 (M + H)+ 14-2 MS: 414 (M + H)+ 14-3 MS: 443 (M + H)+ 14-4 MS: 467 (M + H)+ 14-5 MS: 333 (M + Na)+ 14-6 MS: 481 (M + H)+

Preparation 15

To a solution of (3-exo,7-endo)-7-hydroxybicyclo[3.3.1]nonan-3-carboxylic acid (700 mg) in methanol (14 ml) was added concentrated sulfuric acid (2 ml) dropwise, and the reaction solution was refluxed for 1 hour. To the reaction solution was added water, the mixture was extracted with ethyl acetate. The organic layer was washed with water, saturated aqueous sodium hydrogencarbonate, and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain methyl-(3-exo,7-endo)-7-hydroxybicyclo[3.3.1]nonan-3-carboxylate (730 mg).

TABLE 21 Pr Structure Data 15

MS: 221 (M + Na)+

Preparation 16

The compounds in Preparations 16-1 to 16-3 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 28.

TABLE 22 Pr Structure 16-1

16-2

16-3

TABLE 23 Pr Data 16-1 1H-NMR (400 MHz, d6-DMSO)δ: 1.44 (9H, s), 1.77-2.39 (8H, m), 2.42 (3H, s), 4.09-4.20 (2H, m), 4.48-4.57 (1H, m), 6.61-6.66 (1H, m), 7.21-7.26 (1H, m), 8.57 (1H, s), 9.16 (1H, d, J = 7.5 Hz), 11.81 (1H, s). MS: 425 (M + H)+ 16-2 MS: 315 (M + Na)+ 16-3 MS: 425 (M + H)+

Preparation 17

The compound in Preparation 17 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Example 29.

TABLE 24 Pr Structure Data 17

MS: 301 (M + Na)+

Preparation 18

The compounds in Preparations 18-1 to 18-5 shown in the following table were produced using the corresponding starting compound according to the method similar to that described in Example 30.

TABLE 25 Pr Structure 18-1

18-2

18-3

18-4

18-5

TABLE 26 Pr Data 18-1 MS: 315 (M + Na)+ 18-2 MS: 287 (M + Na)+ 18-3 MS: 424 (M + H)+ 18-4 MS: 291 (M + Na)+ 18-5 MS: 468 (M + H)+

Preparation 19

To a solution of 4-chloro-N′-hydroxy-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidamide (100 mg) in N,N-dimethylformamide (1 ml) were added pyridine (58 μl) and 2-ethylhexyl chlorocarbonate (92 μl) at 4° C. The reaction solution was stirred at ambient temperature for 2 hours. To the reaction solution was added water. The precipitate was collected by filtration and dissolved in xylene (2 ml). The reaction solution was stirred at 160° C. for 3 hours. To the reaction solution was added water, and the precipitate was collected by filtration to obtain 3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-oxadiazol-5(4H)-one (63 mg) as a white solid.

TABLE 27 Pr Structure Data 19

MS: 235 (M − H)−

Preparation 20

To a solution of methyl N-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)carbonyl]glycinate (167 mg) in chloroform (5 ml) was added diphosphorus pentoxide (886 mg) under ambient temperature, and the mixture was refluxed for 18 hours. The reaction solution was cooled and added to saturated aqueous sodium hydrogencarbonate. The reaction solution was extracted with ethyl acetate. The organic layer was washed with water. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=15:1) to obtain 4-chloro-5-(5-methoxy-1,3-oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridine (45 mg) as a yellowish white solid.

TABLE 28 Pr Structure Data 20

MS: 250 (M + H)+

Preparation 21

To a solution of 4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (150 mg) in tetrahydrofuran (3 ml) was added 1.01M diisobutylaluminum hydride/toluene solution (1.93 ml) at −78° C. The reaction solution was stirred for 18 hours under ambient temperature. To the reaction solution was added 1M hydrochloric acid under ice cooling, and the mixture was stirred for 30 minutes. The mixture was extracted with chloroform and washed with water. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain 4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (100 mg) as a pale yellow amorphous substance.

The compound in Preparation 21-1 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Preparation 21.

TABLE 29 Pr Structure Data 21

MS: 312 (M + H)+ 21-1

MS: 312 (M + H)+

Preparation 22

To a mixture of 6-(benzylamino)-1-(5-hydroxyadamantan-2-yl)-7-nitro-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one (68 mg) and methanol (1 ml) were added ammonium formate (197 mg) and 50% wet 10% palladium on carbon (33 mg) at ambient temperature. The mixture was refluxed for 5 hours. After the mixture was cooled, the catalyst was removed by filtration. The mothr liquid was concentrated to obtain 6,7-diamino-1-(5-hydroxyadamantan-2-yl)-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one (54 mg).

The compounds in Preparations 22-1 to 22-3 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 22.

TABLE 30 Pr Structure 22

22-1

22-2

22-3

TABLE 31 Pr Data 22 MS: 316 (M + H)+ 22-1 MS: 332 (M + H)+ 22-2 MS: 320 (M + H)+ 22-3 MS: 332 (M + H)+

Preparation 23

To a suspension of ethyl 6-[(3,4-dimethoxybenzyl)amino]-4-[(cis-5-hydroxy adamantan-2-yl)amino]-5-nitronicotinate (2.73 g) in ethanol (40 ml) was added 10% palladium on carbon (50% wet) (550 mg). In hydrogen atmosphere, catalytic reduction was carried out at 80° C. for 5 hours. After the reaction solution was cooled to ambient temperature, the catalyst was filtered and washed with dioxane, and the solvent was evaporated under reduced pressure. To the residue were added ethyl orthoformate (17 ml) and concentrated hydrochloric acid (864 μl), and the mixture was stirred at ambient temperature for overnight. The reaction solution was neutralized with saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate and tetrahydrofuran. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain ethyl 3-(3,4-dimethoxybenzyl)-7-[(cis-5-hydroxyadamantan-2-yl) amino]-3H-imidazo[4,5-b]pyridine-6-carboxylate (2.17 g).

The compound in Preparation 23-1 shown in the following table were produced using the corresponding starting compound according to the method similar to that described in Preparation 23.

TABLE 32 Pr Structure Data 23

MS: 507 (M + H)+ 23-1

MS: 357 (M + H)+

Preparation 24

The compounds in Preparations 24-1 to 24-3 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 35.

TABLE 33 Pr Structure Data 24-1

MS: 182 (M + H)+ 24-2

MS: 299 (M + Na)+ 24-3

MS: 273 (M + Na)+

Preparation 25

To a reaction solution of N-Boc-nortropinone (1.38 g), benzylamine (0.803 ml) and acetic acid (0.35 ml) in dichloromethane (10 ml) and 1,2-dichloroethane (32 ml) was added sodium triacetoxyborohydride (1.95 g). And the mixture was stirred at ambient temperature for 2 hours. To the reaction mixture was added benzylamine (0.201 ml) and sodium triacetoxyborohydride (649 mg), and the mixture was stirred at 50° C. for 3.5 hours. Furthermore, to the reaction mixture was added sodium triacetoxyborohydride (649 mg) and the mixture was stirred at 50° C. for 3 hours. The reaction solvent was evaporated under reduced pressure. To the residue were added saturated aqueous sodium hydrogencarbonate and 1M aqueous sodium hydroxide to alkalify the residue. The residue was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogencarbonate, water, and saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain 3-(benzylamino)-8-azabicyclo[3.2.1]octane-8-carbamic acid t-butyl ester (1.78 g) as a white solid.

The compounds in Preparations 25-1 to 25-8 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 25.

TABLE 34 Pr Structure 25

25-1

25-2

25-3

25-4

25-5

25-6

25-7

25-8

TABLE 35 Pr Data 25 1H-NMR (400 MHz, CDCl₃)δ: 1.35-1.66 (3H, m), 1.45 (9H, s), 1.86-2.22 (6H, m), 3.00 (1H, dd, J = 6.0, 6.0 Hz), 3.78 (2H, s), 4.04-4.28 (2H, m), 7.20-7.38 (5H, m) 25-1 MS: 423, 425 (M + H)+ 25-2 MS: 383 (M + Na)+ 25-3 MS: 357 (M + H)+ 25-4 MS: 311 (M + H)+ 25-5 MS: 320, 322 (M + H)+ 25-6 MS: 327 (M + Na)+ 25-7 MS: 258 (M + H)+ 25-8 MS: 423, 425 (M + H)+

Preparation 26

The compounds in Preparations 26-1 to 26-2 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 50.

TABLE 36 Pr Structure Data 26-1

MS: 301 (M + Na)+ 26-2

MS: 317 (M + Na)+

Preparation 27

To a solution of rel-(1′R,3′S,5′S,7′s)-5′H-spiro[1,3-dioxolane-2,2′-tricyclo[3.3.1.1˜3,7˜]decane]-5′-carboxylic acid (100 mg) in toluene (1 ml) was added diphenylphosphate azide (99 μl) and triethylamine (64 μl). The mixture was stirred at 110° C. for 2 hours. After the reaction solution was cooled to ambient temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was dissolved in N,N-dimethylacetamide (1 ml), and potassium t-butoxide (49 mg) was added. The mixture was stirred at ambient temperature for overnight. To the reaction solution was added water, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate) to obtain t-butyl rel-(1′R,3′S,5′S,7′s)-5′H-spiro[1,3-dioxolane-2,2′-tricyclo[3.3.1.1˜3,7˜]decane]-5′-yl carbamate (40 mg).

The compounds in Preparations 27-1 to 27-3 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 27.

TABLE 37 Pr Structure Data 27

MS: 332 (M + Na)+ 27-1

MS: 455 (M + H)+ 27-2

MS: 436 (M + H)+ 27-3

MS: 374 (M + H)+

Preparation 28

To a concentrated sulfuric acid (175 ml) was added 70% nitric acid (20 ml) dropwise under ice cooling, and 2-adamantamine hydrochloride (25 g) was added slowly at 10° C. or less. The mixture was warmed to ambient temperature and stirred for 2 hours. The reaction solution was poured into ice water, and the mixture was neutralized with 6M aqueous sodium hydroxide and extracted with dichloromethane four times. The organic layers were combined, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain 4-aminoadamantan-1-ol (17.7 g).

TABLE 38 Pr Structure Data 28

MS: 168 (M + H)+

Preparation 29

A mixture of ethyl 4-{[3-exo(hydroxymethyl)bicyclo[2.2.1]heptyl-2-exo]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (54 mg), triisopropylsilyl chloride (52 μl), imidazole (17 mg), and N,N-dimethylformamide (0.3 ml) was stirred at ambient temperature for 2 hours. The reaction solution was diluted with ethyl acetate (20 ml) and poured into saturated aqueous sodium hydrogencarbonate (15 ml). The mixture was extracted with ethyl acetate (15 ml) two times, and the extract was washed with brine (20 ml), dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate) to obtain ethyl 4-{[3-exo(triisopropylsilyl)oxy]methyl}bicyclo[2.2.1]heptyl-2-exo]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (76 mg) as a pale brown solid.

TABLE 39 Pr Structure Data 29

MS: 486 (M + H)+

Preparation 30

To a solution of 4-chloro-2-methyl-1H-pyrrolo[2,3-b]pyridine (0.85 g) in N,N-dimethylformamide (8.5 ml) was added 60% oil-suspended NaH (245 mg) under nitrogen atmosphere while being cooled in an ice water bath. The reaction solution was stirred at ambient temperature for 1 hour and cooled again in the ice water bath. To the reaction solution was added triisopropylsilyl chloride (1.3 ml) slowly dropwise for 10 or more minutes. The reaction solution was stirred for 3 hours at ambient temperature and diluted with ethyl acetate (30 ml). The solution was washed with saturated aqueous sodium hydrogencarbonate (30 ml) and brine (20 ml). The solution was dehydrated with anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane) to obtain 4-chloro-2-methyl-1-(triisopropylsilyl)-pyrrolo[2,3-b]pyridine (1.45 g) as a colorless transparent liquid.

TABLE 40 Pr Structure Data 30

MS: 323 (M + H)+

Preparation 31

The compounds in Preparations 31-1 to 31-2 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 19.

TABLE 41 Pr Structure Data 31-1

MS: 272 (M + H)+ 31-2

MS: 287 (M + H)+

Preparation 32

A mixture of 4-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (4.73 g), potassium carbonate (6.4 g), methanol (45 ml), and water (15 ml) was stirred at 90° C. for 2 hours. After the mixture was cooled, the obtained needle crystals were filtered and washed with water to obtain 4-chloro-2-methyl-1H-pyrrolo[2,3-b]pyridine (1.85 g).

TABLE 42 Pr Structure Data 32

MS: 167 (M + H)+

Preparation 33

To a solution of benzyl rel-[(1R,2S,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (5.5 g) in methanol (55 ml) was added 10% palladium on carbon (50% wet) (1.1 g), and the mixture was stirred under hydrogen atmosphere at ambient temperature for 3 hours. After 10% palladium on carbon was removed with Celite, the filtrate was concentrated under reduced pressure to obtain rel-(1s,3R,4S,5S)-4-adamantamine-1-ol (3.8 g).

The compounds in Preparations 33-1 to 33-11 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 33.

TABLE 43 Pr Structure 33

33-1

33-2

33-3

33-4

33-5

33-6

33-7

33-8

33-9

33-10

33-11

TABLE 44 Pr Data Pr Data 33 MS: 168 (M + H)+ 33-1 MS: 281 (M + H)+ 33-2 MS: 168 (M + H)+ 33-3 MS: 234 (M + H)+ 33-4 MS: 182 (M + H)+ 33-5 MS: 182 (M + H)+ 33-6 MS: 170 (M + H)+ 33-7 MS: 170 (M + H)+ 33-8 MS: 196 (M + H)+ 33-9 MS: 281 (M + H)+ 33-10 MS: 170 (M + H)+ 33-11 MS: 234 (M + H)+

Preparation 34

The compounds in Preparations 34-1 to 34-3 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 21.

TABLE 45 Pr Structure Data 34-1

MS: 261 (M + Na)+ 34-2

MS: 171 (M + H)+ 34-3

MS: 323 (M + H)+

Preparation 35

To a solution of ethyl 5-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-3-carboxylate (350 mg) in ethanol (3.5 ml) was added 1M aqueous sodium hydroxide (1.79 ml), and the reaction solution was stirred at 50° C. for 3 hours. The reaction solution was cooled to 4° C., and 1M hydrochloric acid was added to acidify the solution. The mixture was extracted with a mixture of chloroform and methanol (4:1) and washed with water. The organic layer was dried over magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 4-chloro-5-(1,2,4-oxadiazole-5-yl)-1H-pyrrolo[2,3-b]pyridine (215 mg) as a white solid.

TABLE 46 Pr Structure Data 35

MS: 219 (M − H)+

Preparation 36

t-Butyl rel-(1′R,3′S,5′S,7′s)-5′H-spiro[1,3-dioxolane-2,2′-tricyclo[3.3.1.1˜3,7˜]decane]-5′-yl carbamate (420 mg) was dissolved in tetrahydrofuran (4.2 ml) and water (4.2 ml), para-tosylic acid monohydrate (516 mg) was added, and the mixture was stirred at 60° C. for 4 hours. The reaction solution was evaporated under reduced pressure, and saturated aqueous sodium hydrogencarbonate was added. The mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate) to obtain t-butyl (cis-4-oxoadamantan-1-yl)carbamate (120 mg).

The compound in Preparation 36-1 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Preparation 36.

TABLE 47 Pr Structure Data 36

MS: 288 (M + H)+ 36-1

MS: 220 (M + H)+

Preparation 37

To a reaction solution of 2-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-1H-isoindole-1,3(2H)-dione (1.4 g) in tetrahydrofuran (28 ml) and ethanol (28 ml) was added 80% aqueous hydrazine monohydrate (1.1 ml), and the mixture was refluxed for 3 hours. After the reaction solution was cooled to ambient temperature, insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure to reduce the amount of the solvent. To the residue was added dichloromethane, and the mixture was washed with 1M aqueous sodium hydroxide, dried over anhydrous magnesium sulfate, and evaporated under reduced pressure. To the residue was added methanol, the mixture was converted into hydrochloride by adding 4M hydrochloric acid/dioxane solution, concentrated under reduced pressure and dried to hardness to obtain (1R,2R,4S)-bicyclo[2.2.1]heptane-2-amine hydrochloride (0.6 g).

The compound in Preparation 37-1 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Preparation 37.

TABLE 48 Pr Structure Data 37

MS: 112 (M + H)+ 37-1

MS: 198 (M + H)+

Preparation 38

To a suspension of methyl (2-{[4-chloro-6-(methylamino)-5-vinylpyridine-3-yl]carbonyl}hydrazino)(oxo)acetate (450 mg) in tetrahydrofuran (7 ml) and dioxane (7 ml) was added diphosphorus pentasulfide (383 mg) under cooling in an ice bath. After the mixture was stirred at ambient temperature for 5 hours. To the reaction mixture was added tetrahydrofuran (10 ml) and diphosphorus pentasulfide (190 mg). After the mixture was stirred at ambient temperature for 2 hours, water was added to the reaction solution, and the pH was adjusted to approximately 10 with aqueous sodium hydroxide, and the solution was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chramatography (chloroform:methanol) to obtain methyl-5-(4-chloro-1H-pyrrolo[2,3,b]pyridine-5-yl)-1,3,4-thiadiazole-2-carboxylate (90 mg).

TABLE 49 Pr Structure Data 38

MS: 317 (M + H)+

Preparation 39

The compounds in Preparations 39-1 to 39-4 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 45.

TABLE 50 Pr Structure Data 39

MS: 304 (M + H)+, 326 (M + Na)+ 39-1

MS: 316 (M + Na)+ 39-2

MS: 330 (M + Na)+ 39-3

MS: 356 (M + Na)+ 39-4

MS: 356 (M + Na)+

Preparation 40

To a reaction solution of 4-Chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (2.26 g) in tetrahydrofuran (16 ml) was added sec-butyllithium (14.6 ml) dropwise in nitrogen atmosphere at −78° C. After the mixture was stirred at the same temperature for 30 minutes, a solution of benzyl chloroformate (2.1 ml) in tetrahydrofuran (16 ml) was added dropwise to the reaction mixture at −78° C. Furthermore, the reaction solution was stirred at −78° C. for 15 minutes, neutralized with saturated aqueous ammonium chloride (12 ml), and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was dissolved in tetrahydrofuran (17 ml), 1M tetrabutylammonium fluoride/tetrahydrofuran solution (16.9 ml) was added, and the mixture was stirred at ambient temperature for 3 hours. To the reaction solution were added ethyl acetate and water, the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate) to obtain benzyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (690 mg).

The compounds in Preparations 40-1 to 40-3 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 40.

TABLE 51 Pr Structure 40

40-1

40-2

40-3

TABLE 52 Pr Data 40 1H-NMR (d6-DMSO)δ: 5.40 (2H, s), 6.6 (1H, d, J = 1.8 Hz), 7.35-7.39 (3H, m), 7.41-7.45 (2H, m), 7.71 (1H, d, J = 3.5 Hz), 8.75 (1H, s), 12.42 (1H, br). MS: (+): 297 40-1 MS: 279 (M + Na)+ 40-2 MS: 247 (M + H)+ 40-3 MS: 285 (M − H)−

Preparation 41

Into a 100 ml metal sealed tube were put a stirring rod, ethyl 4-{[(3-exo)8-benzyl-8-azabicyclo[3.2.1]oct-3-yl]amino}-6-chloro-5-nicotinic acid ester (1.5 g), 28% aqueous ammonia (4.6 ml), and ethanol (7.5 ml). The tube was closed and stirred at 90° C. for 2 hours. After being cooled, the reaction solution was diluted with methanol (20 ml) and evaporated under reduced pressure. The residue was recrystallized from ethyl acetate-methanol to obtain ethyl 6-amino-4-{[(3-exo)8-benzyl-8-azabicyclo[3.2.1]oct-3-yl]amino}-5-nicotinic acid ester (1.3 g) as a yellow solid.

The compound in Preparation 41-1 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Preparation 41.

TABLE 53 Pr Structure Data 41

MS: 426 (M + H)+ 41-1

MS: 361 (M + H)+ 41-1

MS: 361 (M + H)+

Preparation 42

The compounds in Preparations 42-1 to 42-26 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Example 7.

TABLE 54 Pr Structure 42-1

42-2

42-3

42-4

42-5

42-6

42-7

42-8

42-9

42-10

42-11

42-12

42-13

42-14

42-15

42-16

42-17

42-18

42-19

42-20

42-21

42-22

42-23

42-24

42-25

42-26

TABLE 55 Pr Data 42-1 MS: 348 (M + H)+ 42-2 MS: 377 (M + H)+ 42-3 MS: 316 (M + Na)+ 42-4 MS: 370 (M + H)+ 42-5 MS: 384 (M + Na)+ 42-6 MS: 335 (M + H)+ 42-7 MS: 375 (M + H)+ 42-8 MS: 322 (M + H)+ 42-9 MS: 308 (M + H)+ 42-10 MS: 314 (M + Na)+ 42-11 MS: 384 (M + Na)+ 42-12 MS: 286 (M + Na)+ 42-13 MS: 384 (M + Na)+ 42-14 MS: 358 (M + Na)+ 42-15 MS: 358 (M + Na)+ 42-16 MS: 398 (M + Na)+ 42-17 MS: 404 (M + Na)+ 42-18 MS: 412 (M + Na)+ 42-19 MS: 398 (M + Na)+ 42-20 MS: 286 (M + Na)+ 42-21 MS: 418 (M + Na)+, 394 (M − H)− 42-22 MS: 300 (M + Na)+ 42-23 MS: 369 (M + Na)+ 42-24 MS: 286 (M + Na)+ 42-25 MS: 346 (M + H)+ 42-26 MS: 322 (M + H)+, 344 (M + Na)+, 320 (M − H)−

Preparation 43

The compound in Preparation 43 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Example 41.

TABLE 56 Pr Structure Data 43

MS: 264 (M + H)+

Preparation 44

To a solution of 4-aminoadamantan-1-ol (8.9 g) in tetrahydrofuran (89 ml) were added benzyloxycarbonyl chloride (7.6 ml) and 1M aqueous sodium hydroxide (53.4 ml) dropwise successively under ice cooling, and the mixture was stirred for 3 hours under ice cooling. The reaction solution was poured into aqueous potassium hydrogensulfate, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=1:1 to 1:3) to obtain benzyl rel-[(1R,2S,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (6.2 g) and benzyl rel-[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (5.3 g).

TABLE 57 Pr Structure Data 44

MS: 324 (M + Na)+ 324 (M + Na)+

Preparation 45

To a solution of (1R,2S,4S)-bicyclo[2.2.1]heptane-2-ol (1.0 g) in tetrahydrofuran (10 ml) were added phthalimide (1.4 g) and triphenylphosphine (2.6 g), and diethylazodicarboxylate (1.5 ml) dropwise under ice cooling. The mixture was warmed to ambient temperature and stirred for 24 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (n-hexane:ethyl acetate)=100:0 to 95:5) to obtain 2-[(1R,2R,4S)-bicyclo[2.2.1]kept-2-yl]-1H-isoindole-1,3(2H)-dione (1.4 g) as a colorless solid.

The compound in Preparation 45-1 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Preparation 45.

TABLE 58 Pr Structure Data 45

MS: 264 (M + Na)+ 45-1

MS: 350 (M + Na)+

Preparation 46

A mixture of ethyl 6-chloro-4-{[5-methoxyadamantan-2-yl]amino}-5-nicotinic acid ester (635 mg), benzylamine (253 μl), diisopropylethylamine (270 μl), and 2-propanol (3 ml) was subjected to microwave irradiation under nitrogen atmosphere and heated at 90° C. for 30 minutes. After being cooled, the reaction solution was diluted with ethyl acetate (20 ml) and poured into ½ saturated aqueous ammonia chloride (20 ml). The mixture was extracted with ethyl acetate (20 ml) two times, washed with brine (30 ml), dehydrated with anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate) to obtain ethyl 6-benzylamino-4-{[5-methoxyadamantan-2-yl]amino}-5-nicotinic acid ester (550 mg) as an orange solid.

The compounds in Preparations 46-1 to 46-2 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 46.

TABLE 59 Pr Structure Data 46

trans MS: 481 (M + H)+ 46-1

diastereomer of 46-2 cis or trans unknown MS: 481 (M + H)+ 46-2

diastereomer of 46-1 cis or trans unknown MS: 481 (M + H)+

Preparation 47

A solution of 4-chloro-2-methyl-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (525 mg) in tetrahydrofuran (10 ml) was cooled to −78° C. under nitrogen atmosphere, and to the reaction mixture was added 0.99M sec-butyllithium/cyclohexane solution (4.1 ml) dropwise. After the mixture was stirred at −78° C., ethyl chlorocarbonate (389 μl) was added dropwise. The reaction solution was stirred at −78° C. for 30 minutes, saturated aqueous ammonium chloride (20 ml) was added, and the temperature was returned to ambient temperature. The reaction solution was transferred into a separating funnel and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane) to obtain ethyl 4-chloro-2-methyl-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (645 mg) as a colorless viscous liquid.

The compound in Preparation 47-1 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Preparation 47.

TABLE 60 Pr Structure Data 47

MS: 417 (M + Na)+ 47-1

Preparation 48

A mixture of ethyl 4,6-dichloro-5-nitronicotinic acid ester (1 g), 2-adamantamine hydrochloride (708 mg), diisopropylethylamine (1.3 ml), and 2-propanol (4 ml) was subjected to microwave irradiation under nitrogen atmosphere, and heated at 90° C. for 10 minutes. After being cooled, the reaction solution was diluted with ethyl acetate (20 ml), and poured into ½ saturated aqueous ammonium chloride (20 ml). The mixture was extracted with ethyl acetate (20 ml) two times, washed with brine (30 ml), dehydrated with anhydrous magnesium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate) to obtain ethyl 4-(2-adamantylamino)-6-chloro-5-nicotinic acid ester (1.23 g) as an orange solid.

The compounds in Preparations 48-1 to 48-5 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 48.

TABLE 61 Pr Structure 48

48-1

cis-trans mix 48-2

trans 48-3

48-4

cis/trans mix 48-5

cis or trans unknown

TABLE 62 Pr Data 48 MS: 380 (M + H)+ 48-1 MS: 396 (M + H)+ 48-2 MS: 410 (M + H)+ 48-3 MS: 445 (M + H)+ 48-4 MS: 377 (M + H)+ 48-5 MS: 410 (M + H)+

Preparation 49

A mixture of ethyl 4,6-dichloro-5-nitronicotinic acid ester (333 mg), 4-amino-1-adamantanol (200 mg), diisopropylethylamine (219 μl), and isopropylalcohol (1 ml) was subjected to microwave irradiation under nitrogen atmosphere and heated at 90° C. for 10 minutes. After the mixture was cooled, benzylamine (157 μl) was added to the reaction solution, the mixture was subjected to microwave irradiation again and heated at 90° C. for 10 minutes. After being cooled, the reaction solution was diluted with ethyl acetate (20 ml), poured into ½ saturated aqueous ammonium chloride (20 ml), extracted with ethyl acetate (20 ml) two times, washed with brine (30 ml), dried over anhydrous magnesium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain ethyl 6-(benzylamino)-4-[(5-hydroxy-2-adamantyl)amino]-nicotinic acid ester (515 mg) as an orange solid.

The compounds in Preparations 49-1 to 49-5 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 49.

TABLE 63 Pr Structure 49

cis/trans mix 49-1

cis/trans mix 49-2

cis or trans unknown 49-3

cis 49-4

trans 49-5

cis

TABLE 64 Pr Data 49 MS: 467 (M + H)+ 49-1 MS: 469 (M + H)+ 49-2 MS: 476 (M + H)+ 49-3 MS: 467 (M + H)+ 49-4 49-5 MS: 527 (M + H)+

Preparation 50

The compound in Preparation 50 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Example 10.

TABLE 65 Pr Structure 50

Preparation 51

The compound in Preparation 51 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Example 28.

TABLE 66 Pr Structure Data 51

MS: 211 (M + H)+

Preparation 52

10% Palladium on carbon (50% wet) (40 mg) was added to a solution of benzyl 4-[(5-carbamoyladamantan-2-yl)amino]-1H-pyrrolo-[2,3-b]pyridine-5-carboxylate (183 mg) in methanol (5 ml) and 1,4-dioxane (5 ml), and hydrogenated under hydrogen atmosphere for 5 hours. Resulting precipitates were dissolved by tetrahydrofuran and filtered out the catalysts. The filtrates were evaporated in vacuo to give 4-[(5-carbamoyladamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (117 mg).

The compounds in Preparations 52-1 to 52-17 shown in the following table were produced using the corresponding starting compounds according to the method similar to that described in Preparation 52.

TABLE 67 Pr Structure 52-1

diastereomer of 52-14 cis or trans unknown 52-2

cis/trans mix 52-3

52-4

cis/trans mix 52-5

52-6

52-7

cis or trans unknown 52-8

cis or trans unknown 52-9

cis or trans unknown 52-10

cis/trans mix 52-11

52-12

diastereomer of 53-17 cis or trans unknown 52-13

cis or trans unknown 52-14

diastereomer of 53-1 cis or trans unknown 52-15

52-16

52-17

diastereomer of 53-12 cis or trans unknown

TABLE 68 Pr Data 52-1 MS: 355 (M + H)+ 52-2 MS: 370 (M + H)+ 52-3 MS: 168 (M + H)+. 52-4 MS: 267 (M + H)+ 52-5 MS: 316 (M + H)+ 52-6 MS: 313 (M − H)− 52-7 MS: 390, 392 (M + H)+ 52-8 MS: 230, 232 (M + H)+ 52-9 MS: 381 (M + H)+ 52-10 MS: 221 (M + H)+ 52-11 MS: 284 (M + H)+ 52-12 MS: 394 (M + H)+ 52-13 MS: 427 (M + H)+ 52-14 MS: 355 (M + H)+ 52-15 MS: 168 (M + H)+. 52-16 1H-NMR (400 MHz, CDCl₃)δ: 1.46 (9H, s), 1.61-2.29 (10H, m), 3.33 (1H, dd, J = 6.2, 6.2 Hz), 4.06-4.29 (2H, m) MS: 227 (M + H)+ 52-17 MS: 394 (M + H)+

Preparation 53

The compound in Preparation 53-1 to 53-4 shown in the following table was produced using the corresponding starting compound according to the method similar to that described in Example 16.

TABLE 69 Pr Structure 53-1

53-2

cis/trans mix 53-3

53-4

trans

TABLE 70 Pr Structure 53-1 MS: 143 (M − H)− 53-2 MS: 430 (M + Na)+ 53-3 MS: 176 (M − H)− 53-4 MS: 372, 374 (M + H)+

Example 1

To a solution of 5-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-methyl-1,3,4-oxadiazole-2-carboxamide (18 mg) in 1-methyl-2-pyrrolidone (0.18 ml) were added N,N-dibutyl-1-butaneamine (0.046 ml) and cis-(1S,3R,4R,5S)-4-aminoadamantan-1-ol (32.5 mg) under ambient temperature. The mixture was heated immediately to 150° C. and stirred for 2 hours. After the disappearance of the starting compound was ascertained, the residue was purified by silica gel column chromatography (chloroform:methanol=97:3 to 85:15) to obtain cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-methyl-1,3,4-oxadiazole-2-carboxamide (19.8 mg) as a white solid.

Example 2

To 1-[(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methaneamine (61 mg) were added a solution of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (39 mg) in 1-methyl-2-pyrrolidone (0.6 ml), triethylamine (0.056 ml), and sodium iodide (3 mg), and the mixture was stirred at 130° C. for 17 hours. After the reaction mixture was left to cool, to the reaction mixture were added N,N-dimethylformamide (0.3 ml) and water (0.1 ml), and the reaction mixture was dissolved. The reaction mixture was directly purified by preparative HPLC (10 mM-NH₄HCO₃+NH₃ (pH=9.2):CH₃CN=98:2 to 30:70). The active fraction was concentrated and dried to hardness to obtain 4-({[(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl}amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (33.5 mg) as a solid.

Example 3

To a suspension methyl 4-(2-oxo-3,6-dihydropyrazolo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-carboxy late (40 mg) in methanol (0.4 ml) and dioxane (0.4 ml) was added 1M aqueous sodium hydroxide (0.22 ml), and the suspension was refluxed for 2 hours. The reaction solution was cooled to ambient temperature, the pH was adjusted to 5 with 1M aqueous hydrochloric acid and pH 4 buffer solution, and the reaction solution was evaporated under reduced pressure. The obtained solid was collected by filtration and washed with water to obtain 4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-carboxylic acid (32 mg).

Example 4

4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-carboxylic acid (50 mg) was suspended in N,N-dimethyl formamide (1 ml). To the suspension were added aminoacetonitrile hydrochloride (17 mg), 1-hydroxybenzotriazole (28 mg), diisopropylethylamine (62 μl), and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (41 mg) successively, and the mixture was stirred overnight at ambient temperature. To the reaction solution were added ethyl acetate and water, and the organic layer was extracted. The organic layer was washed with saturated brine, dried over magnesium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain N-(cyanomethyl)-4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-carboxamide (23 mg).

Example 5

To a solution of 3-methylbenzoic acid (22.4 mg) in 1-methyl-2-pyrrolidone (0.6 ml) were added 4-[(3-exo-8-azabicyclo[3.2.1]oct-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (42.8 mg) and 1-hydroxybenzotriazole (22.3 mg). Furthermore, 1M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/1-methyl-2-pyrrolidone solution (0.225 ml) was added, and the mixture was stirred for 4 hours at 50° C. After being cooled, the reaction solution was directly purified by preparative HPLC system (10 mM-NH₄HCO₃+NH₃ (pH=9.2):CH₃CN=98:2 to 30:70). The active fraction was concentrated and dried to hardness to obtain 4-{[(3-exo)-8-(3-methylbenzoyl)-8-azabicyclo[3.2.1]oct-3-yl)amino]}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (34.8 mg) as a solid.

Example 6

To a solution of 2-aminoethanol (18.6 mg) in 1-methyl-2-pyrrolidone (0.6 ml) were added cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (41 mg) and 1-hydroxybenzotriazole (18.6 mg). Furthermore, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/1-methyl-2-pyrrolidone solution (0.188 ml) was added, and the mixture was stirred for 6 hours at 60° C. After being cooled, the reaction solution was directly purified by preparative HPLC (10 mM-NH₄HCO₃+NH₃ (pH=9.2):CH₃CN=98:2 to 30:70). The active fraction was concentrated and dried to hardness to obtain 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-N-(2-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (22.9 mg) as a solid.

Example 7

To a solution of ethyl 3-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-5-carboxylate (25 mg) in 1-methyl-2-pyrrolidone (0.25 ml) was added 2-piperazin-1-ylethanol (8.5 mg) under ambient temperature. The mixture was immediately warmed to 50° C. and stirred for 0.5 hour. After the disappearance of the starting compound was ascertained, the residue was purified by silica gel column chromatography (chloroform:methanol=96:4 to 87:13) to obtain cis-(1s,3R,4R,5S)-4-{[5-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1,2,4-oxadiazole-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (22.6 mg) as a yellowish white solid.

Example 8

To a solution of methylamine hydrochloride (4.7 mg) in 1-methyl-2-pyrrolidone (0.3 ml) were added ethyl cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-5-carboxylate (14.8 mg) and diisopropylamine (0.0183 ml), and the mixture was stirred for 6 hours at 90° C. After being cooled, the reaction solution was directly purified by preparative HPLC system (10 mM-NH₄HCO₃+NH₃ (pH=9.2):CH₃CN=90:10 to 20:80). The active fraction was concentrated and dried to hardness to obtain 5-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-methyl-1,2,4-oxadiazole-3-carboxamide (6.74 mg) as a solid.

Example 9

To a solution of cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-piperidine-4-yl-1,2,4-oxadiazole-3-carboxamide dihydrochloride (20 mg) in 1-methyl-2-pyrrolidone (0.25 ml) were added N-ethyl-N-isopropylpropan-2-amine (0.025 ml) and acetic anhydride (0.043 ml) under ambient temperature, and the mixture was stirred for 1 hour. The residue was purified by silica gel column chromatography (chloroform:methanol=99:1 to 89:11) to obtain cis-N-(1-acetylpiperidine-4-yl)-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-3-carboxamide (7.8 mg) as a yellowish white solid.

Example 10

To 1-(5-aminoadamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2 (1H)-one dihydrochloride (15 mg) were added dichloromethane-methanol and saturated aqueous sodium hydrogencarbonate, and the organic layer was extracted. The organic layer was dried over magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure. The residue was suspended in dichloromethane (7.5 ml), and triethylamine (13 μl) and propanoyl chloride (4 μl) were added. The mixture was stirred overnight at ambient temperature. The reaction solution was purified by NH silica gel column chromatography (chloroform:methanol) to obtain N-[4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-yl]propanamide (2 mg).

Example 11

To a solution of cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (30 mg) in N,N-dimethylformamide (0.21 ml) were added N,N′-carbonyl diimidazole (22.3 mg) and 2M dimethylamine/methanol solution (0.183 ml) successively under ambient temperature. The mixture was stirred at ambient temperature for 18 hours. Water was added to the reaction solution, and the reaction solution was filtered. The solid residue was washed with water and dried. The residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=10:1) to obtain methyl cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (18 mg) as a yellowish white solid.

Example 12

To a suspension of rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (25 mg) in N,N-dimethylformamide (0.4 ml) were added potassium carbonate (15.8 mg) and 1-chloroacetone (0.0073 ml), and the mixture was stirred at ambient temperature for 5 hours. The reaction solution was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 2-oxopropyl ester (20.8 mg) as a white solid.

Example 13

To a suspension of rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (45 mg), acetamide oxime (25.5 mg), and 1-hydroxybenzotriazole (27.9 mg) in N,N-dimethylformamide (1.08 ml) were added triethylamine (0.077 ml) and N-[3-(dimethylamino)propyl]-N′-ethylcarbodiimide hydrochloride (39.5 mg). The mixture was stirred for 2 hours at 60° C. The reaction solution was diluted with chloroform and ethanol, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain rel-(1Z)-N′-{[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)carbonyl]oxy}ethanimidamide (38.9 mg) as white powder.

Example 14

To a solution of cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (30 mg) in N,N-dimethylformamide (0.9 ml) were added N,N′-carbonyldiimidazole (83 mg), N-ethyl-N-isopropylpropane-2-amine (0.018 ml), and carbonic acid-guanidine (1:2) (82.5 mg) successively under ambient temperature. Furthermore, after 1-methyl-2-pyrrolidone (0.3 ml) was added, the mixture was immediately warmed to 60° C. and stirred for 5 hours. The mixture was evaporated under reduced pressure and dried. The residue was purified by basic thin-layer silica gel column chromatography (chloroform:methanol=6:1) to obtain cis-N-(diaminomethylene)-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (18.1 mg) as a yellowish white solid.

Example 15

To a solution of cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (80 mg) in 1-methyl-2-pyrrolidone (0.8 ml) were added (O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (HATU) (139 mg), N-ethyl-N-isopropylpropane-2-amine (0.17 ml), and hydrazine carboxamide hydrochloride (32.7 mg) successively under ambient temperature. The mixture was stirred for 3 hours at ambient temperature. To the reaction solution were added ethyl acetate and diisopropyl ether, and the mixture was filtered. The solid residue was washed with ethyl acetate-diisopropyl ether and dried to obtain cis-2-[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)carbonyl]hydrazinecarboxamide (90 mg) as a yellowish white solid.

Example 16

4-(2-Oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-carboxamide (70 mg) was suspended in N,N-dimethylformamide (1 ml), and 2,4,6-trichloro-1,3,5-triazine (37 mg) was added under ice cooling. The mixture was stirred at ambient temperature for 4 hours. To the reaction solution was added saturated aqueous sodium hydrogencarbonate, and the obtained solid was collected by filtration, washed with water and ethyl acetate to obtain 4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-carbonitrile (30 mg).

Example 17

To a solution of 5-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-3-carboxamide (30 mg) in tetrahydrofuran (1 ml) were added pyridine (37 μl) and trifluoroacetic anhydride (64 μl) under ice cooling, and the reaction solution was stirred under ambient temperature for 30 minutes. Water was added to the reaction solution, and the precipitate was collected by filtration and dissolved in tetrahydrofuran (1 ml). To the reaction solution was added 1M aqueous sodium hydroxide (0.114 ml) under ice cooling, and the reaction solution was stirred for 1 hour under ambient temperature. The reaction solution was extracted with chloroform and washed with water. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) to obtain 5-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-3-carbonitrile (5 mg) as a white solid.

Example 18

t-Butyl [4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-yl]carbamate (118 mg) was suspended in dioxane (1.2 ml). 4M hydrochloric acid/dioxane (0.7 ml) was added, and the mixture was stirred overnight at ambient temperature. To the reaction solution was added ethyl acetate, and the obtained solid was collected by filtration and washed with ethyl acetate to obtain 1-(5-adamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one dihydrochloride (108 mg).

Example 19

To 3-(3,4-dimethoxybenzyl)-N-(4-fluorobenzyl)-7-{(5-hydroxyadamantan-2-yl)amino}-3H-imidazo[4,5-b]pyridine-6-carboxamide (170 mg) was added trifluoroacetic acid (1.7 ml), and the mixture was stirred at ambient temperature for overnight. The reaction solution was neutralized with saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate and tetrahydrofuran. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain N-(4-fluorobenzyl)-7-{(5-hydroxyadamantan-2-yl)amino}-3H-imidazo[4,5-b]pyridine-6-carboxamide (31 mg).

Example 20

To a solution of 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-N-(tetrahydro-2H-pyran-2-yloxy)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (35 mg) in ethanol (0.525 ml) was added 2M hydrochloric acid/ethanol solution (0.205 ml) under ambient temperature. The reaction solution was stirred under ambient temperature for 2 hours. To the reaction solution was added ethyl acetate, and the precipitate was collected by filtration to obtain N-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride (18 mg) as a white solid.

Example 21

To a solution of 3-{[(triisopropylsilyl)oxy]methyl}bicyclo[2.2.1]hept-2-yl]-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (45 mg) in tetrahydrofuran (0.15 ml) was added 1M tetrabutylammoniumfluoride/tetrahydrofuran solution (297 μl), and the mixture was stirred overnight at ambient temperature. The reaction solution was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:methanol) to obtain 1-[3-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (14.8 mg) as a white solid. To a solution of rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbohydrazide in 1-methyl-2-pyrrolidone (1 ml) were added triethyl orthoformate (340 μl) and p-toluene sulfonic acid monohydrate (5.6 mg). After stirring at 120° C. for 30 minutes, triethyl orthoformate (340 μl) and p-toluene sulfonic acid monohydrate (5.6 mg) were added. After the mixture was stirred at 120° C. for 40 minutes, the reaction solution was extracted with 20% chloroform/methanol solution, and washed with saturated aqueous sodium bicarbonate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was evaporated under reduced pressure. The residue was purified by silica gel chromatography (chloroform:methanol) to obtain rel-(1s,3R,4R,5S)-4-{[1-(diethoxymethyl)-5-(1,3,4-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (28 mg) and rel-(1s,3R,4R,5S)-4-{[5-(1,3,4-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (70 mg).

Example 22

The cis-trans mixture of N-(cyanomethyl)-4-(2-oxo-3,6-dihydropyrazolo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamantan-1-carboxylate was separated by HPLC (aqueous (NH₄)HCO₃-aqueous ammonia (pH=9.2):acetonitrile) to obtain a fraction (8 mg) having a peak with a short retention time and another fraction (15 mg) having a peak with a long retention time.

Example 23

4-(Adamantan-1-ylamino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (17 mg) and triethylamine (15 μl) were dissolved in dioxane (0.5 ml). To the mixture was added diphenylphosphoryl azide (DPPA) (18 μl) at 120° C. under stirring. The mixture was stirred at the same temperature for 2 hours and cooled to ambient temperature. The obtained solid was collected by filtration and washed with acetonitrile to obtain (adamantan-1-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (11 mg).

Example 24

To a mixture of 5,6-diamino-4-{cis-5-hydroxyl-2-adamantyl]amino}-N-methylnicotinamide (9 mg) and triethyl orthoformate (0.15 ml) was added concentrated hydrochloric acid (5 μl), and the mixture was heated at 90° C. for 3 hours. After being cooled, the reaction solution was diluted with ethyl acetate (10 ml), and saturated aqueous sodium hydrogencarbonate (10 ml) was added. The organic layer was extracted, dried over magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain 7-{[cis-5-hydroxyadamantan-2-yl]amino}-N-methyl-3H-imidazo[4,5-b]pyridine-6-carboxyamide (0.5 mg) as a pale yellow solid.

Example 25

A mixture of acetic anhydride (897 μl) and formic acid (342 μl) was stirred at 60° C. for 2 hours. After the mixture was cooled, a solution of 4-(2-adamantylamino)-6-amino-5-nicotinamide (200 mg) in dichloromethane (1 ml) was added dropwise. The reaction mixture was stirred at ambient temperature for 1 hour and at 50° C. for 2 hours. After being cooled, the reaction mixture was evaporated under reduced pressure. To the residue were added ethanol (2 ml), tetrahydrofuran (1 ml), and water (1 ml). Then, iron powder (169 mg) and ammonium chloride (16 mg) were added to the mixture. The mixture was stirred at 120° C. for 6 hours. After being cooled, the mixture was evaporated under reduced pressure. To the residue was added saturated aqueous sodium hydroxide (10 ml), and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain 7-(2-adamantylamino)-3H-imidazo[4,5-b]pyridine-6-carboxyamide (110 mg) as a white solid.

Example 26

To a mixture of isopropyl 6-(benzylamino)-4-{[cis-5-hydroxyadamantan-2-yl]amino}-5-nicotinate (90 mg), ammonium formate (236 mg), and methanol was added 10% palladium on carbon (50% wet) (40 mg), and the mixture was stirred for 5 hours under refluxing. After being cooled, the reaction mixture was filtered to remove catalyst. The filtrate was concentrated under reduced pressure. To the residue were added triethyl orthoformate (0.6 ml) and concentrated hydrochloric acid (31 μl), and the mixture was stirred at ambient temperature for 3 hours. After the reaction mixture was diluted with ethyl acetate (20 ml), saturated aqueous sodium hydrogencarbonate (20 ml) was added. The organic layer was extracted, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain isopropyl-rel-7-{[(1R,2R,3S,5S)-5-hydroxyadamantan-2-yl]amino}-3H-imidazo[4,5-b]pyridine-6-carboxylate (45 mg) as a white solid.

Example 27

To a solution of 4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (100 mg) in methanol (3 ml) were added hydroxylamine hydrochloride (34 mg) and sodium hydrogencarbonate (82 mg), and the reaction solution was stirred at 90° C. for 18 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) to obtain N′-hydroxy-4-{[(2r,5s)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidamide (32 mg) as a white solid and to obtain N′-hydroxy-4-{[(2s,5r)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidamide (35 mg) as a white solid.

Example 28

A solution of rel-(1Z)-N′-{[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridin-5-yl)carbonyl]oxy}ethanimidamide (16.2 mg) in N,N-dimethylformamide (0.4 mL) was stirred at 160° C. for 3 hours, then stirred at 165° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with 10% sodium chloride aqueous solution, water (three times), and brine, dried over magnesium sulfate, filtered and evaporated in vacuo. The residue was purified by silica gel column chromatography (chlcroform:methanol, 15:1) to give rel-(1s,3R,4R,5S)-4-{[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]amino}adamantan-1-ol (6.0 mg) as a orange crystals.

Example 29

To a solution of rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbohydrazide in 1-methyl-2-pyrrolidone (1 ml) were added triethyl orthoformate (340 μl) and p-toluene sulfonic acid monohydrate (5.6 mg). After the mixture was stirred at 120° C. for 30 minutes, triethyl orthoformate (340 μl) and p-toluene sulfonic acid monohydrate (5.6 mg) were added. After the mixture was stirred at 120° C. for 40 minutes, the reaction solution was extracted with 20% chloroform/methanol solution and washed with saturated aqueous sodium bicarbonate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (chloroform:methanol) to obtain rel-(1s,3R,4R,5S)-4-{[1-(diethoxymethyl)-5-(1,3,4-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (28 mg) and to obtain rel-(1s,3R,4R,5S)-4-{[5-(1,3,4-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (70 mg).

Example 30

To a solution of N′-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboximidamide (45 mg) in dichloromethane (0.45 ml) were added pyridine (32 μl) and acetic anhydride (19 μl). The reaction solution was stirred under ambient temperature for 2 hours. To the reaction solution were further added pyridine (32 μl) and acetic anhydride (19 μl), and the reaction solution was stirred at 60° C. for 2 hours. To the reaction solution was further added pyridine (0.5 ml), and the mixture was stirred at 90° C. for 16 hours. The reaction solution was extracted with chloroform and washed with water. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) to obtain (1s,4r)-4-{[5-(5-methyl-1,2,4-oxadiazole-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (10 mg) as a white solid.

Example 31

To a solution of N′-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidamide (25 mg) in N,N-dimethylformamide (0.5 ml) were added pyridine (9 μl) and 2-ethylhexyl chlorocarbonate (14 μl) under ice cooling. The reaction solution was stirred at ambient temperature for 2 hours. To the reaction solution was added water. The mixture was extracted with chloroform and washed with water. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was dissolved in N,N-dimethylformamide (0.5 ml) and xylene (0.5 ml), and the reaction solution was stirred at 150° C. for 2 hours. After the reaction solution was cooled to ambient temperature, the precipitate was collected by filtration and washed with a small amount of ethyl acetate to obtain (1s,4r)-4-(3-aminopyrazolo[3,4-d]pyrrolo[2,3-b]pyridine-1(6H)-yl)adamantan-1-ol (8 mg) as a white solid.

Example 32

To a solution of 3-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-(2-methoxyethyl)-1,2,4-oxadiazole-5-carboxamide (35 mg) in 1-methyl-2-pyrrolidone (0.35 ml) were added N,N-dibutyl-1-butanamine (0.078 ml) and cis-(1S,3R,4R,5S)-4-aminoadamantan-1-ol (36 mg) under ambient temperature. The mixture was immediately heated to 190° C. and stirred for 1 hour. After the disappearance of the starting compound was ascertained, water was added to the reaction solution, and the solution was filtered. The solid residue was washed with water and dried. The solid residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=12:1) to obtain cis-N-{1-[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine-3-yl}-N′-(2-methoxyethyl)ethanediamide (18.1 mg) as a yellowish white solid.

Example 33

To a solution of 3-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-methyl-1,2,4-oxadiazole-5-carboxamide (14.2 mg) in 1-methyl-2-pyrrolidone (0.142 ml) were added N,N-dibutyl-1-butanamine (0.0487 ml) and cis-(1S,3R,4R,5S)-4-aminoadamantan-1-ol (25.7 mg). The mixture was stirred for 100 minutes using a microwave reaction system at 200° C. After being cooled, the reaction solution was directly purified by preparative HPLC system (10 mM NH₄HCO₃+NH₃ (pH=9.2):CH₃CN=95:5 to 20:80). The active fraction was concentrated to obtain cis-N-{1-[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine-3-yl}-N′-methylethanediamide (11.1 mg) as a solid.

Example 34

To a suspension of 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (60 mg) in toluene (0.6 ml) were added thiosemicarbazide (35.5 mg) and trifluoroacetic acid (0.15 ml), and the mixture was stirred at 70° C. for 6 hours. To the mixture were further added thiosemicarbazide (35.5 mg) and trifluoroacetic acid (0.15 ml), and the mixture was stirred at 90° C. for 51 hours. Furthermore, thiosemicarbazide (17.8 mg) was added, and the mixture was stirred at 90° C. for 48 hours. The reaction solution was alkalified with saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain (1s,4r)-4-{[5-(5-amino-1,3,4-thiadiazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (8.3 mg) as a white solid.

Example 35

To a solution of ethyl 5-[4-(2-oxo-3,6-dihydroimidazo[2,3-b]pyridine-1(2H)-yl)adamantan-1-yl]-1,2,4-oxadiazole-3-carboxylate (30 mg) in tetrahydrofuran (1 ml) was added lithium aluminum hydride (10 mg) under ice cooling, and the mixture was stirred for 1 hour at ambient temperature. To the reaction solution was added 1M aqueous sodium hydroxide. The mixture was stirred for 30 minutes at ambient temperature and extracted with chloroform. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain 1-{5-[3-(hydroxymethyl)-1,2,4-oxadiazole-5-yl]adamantan-2-yl}-3,6-dihydroimiazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (3 mg).

Example 36

To a solution of 4-{[(2r,5s)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (27 mg) in ethanol (0.5 ml) were added 10% palladium on carbon (30 mg) and 2M hydrochloric acid/ethanol solution (0.5 ml). The reaction solution was stirred for 3 hours under hydrogen atmosphere at 60° C. The catalyst was filtered with Celite, and the filtrate was concentrated under reduced pressure to obtain (1s,4r)-4-{[5-(aminomethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol trihydrochloride (37 mg) as a white solid.

Example 37

To a solution of 1-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)ethanone (20 mg) in tetrahydrofuran (2.5 ml) was added lithium aluminum hydride (19.4 mg) under ambient temperature. Furthermore, the mixture was stirred at ambient temperature for 2 hours. After the disappearance of the starting compound was ascertained, to the reaction solution were added water (19 μl), 2M aqueous sodium hydroxide (19 μl), and water (57 μl) successively. The precipitated solid was removed by Celite filtration and washed with tetrahydrofuran. The filtrate was concentrated under reduced pressure and purified by thin-layer silica gel column chromatography (chloroform:methanol=4:1) to obtain (1s,4r)-4-{[5-(1-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (9.1 mg).

Example 38

To a solution of 4-{[(3-exo)-8-(5-nitropyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (25 mg) in methanol (0.5 ml) were added ammonium formate (38.6 mg) and palladium on carbon (50% wet) (1.3 mg), and the mixture was heated for 5 hours under refluxing. After the mixture was cooled to ambient temperature, the insoluble matter was removed by Celite filtration and washed with methanol. The filtrate was evaporated under reduced pressure and purified by thin-layer silica gel column chromatography (chloroform:methanol=4:1) to obtain 4-{[(3-exo)-8-(5-aminopyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (12 mg).

Example 39

To a solution of N′-(5-bromoadamantan-2-yl)-4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbohydrazide (200 mg) in 1-methyl-2-pyrrolidone (1.5 ml) was added triethylamine (0.2 ml), and the mixture was stirred at 200° C. using a microwave reaction system for 2 hours. After the reaction solution was cooled, water was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol) to obtain 1-(5-bromoadamantan-2-yl)-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridine-3(2H)-one (91 mg).

Example 40

To a suspension of 4-{[(2R,5S)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (50 mg) in a mixture of toluene (1.5 ml) and N,N′-dimethylformamide (1.5 ml) were added sodium azide (105 mg) and triethylamine hydrochloride (223 mg), and the mixture was stirred for at 100° C. for 3 hours. To the reaction mixture was added sodium azide (210 mg) and triethylamine hydrochloride (446 mg), and the mixture was stirred at 100° C. for 3.5 hours. The reaction solution was diluted with a mixture solvent of dichloromethane:methanol (=10:1), and the organic layer was separated. Furthermore, the water layer was extracted with a mixture solvent of dichloromethane: methanol (=10:1) three times. The obtained organic layers were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (dichloromethane: methanol=10:1) to obtain rel-(1s,3R,4R,5S)-4-{[5-(2H-tetrazole-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (35 mg) as a solid.

Example 41

To 4-[(5-bromoadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (52 mg) were added ethylene cyanhydrin (250 μl) and triethylamine (56 μl), and the mixture was stirred for 20 minutes using a microwave reaction system at 150° C. The reaction solution was cooled and purified by silica gel column chromatography (chloroform:methanol). The obtained fraction was concentrated under reduced pressure, and water was added. The obtained solid was collected by filtration to obtain 4-{[5-(2-cyanoethoxy)adamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (16 mg).

Example 42

To a solution of 4-({5-[5-(trichloromethyl)-1,2,4-oxadiazole-3-yl]-1H-pyrrolo[2,3-b]pyridine-4-yl}amino)adamantan-1-ol (80 mg) in 1-methyl-2-pyrrolidinone (1.6 ml) was added ethylamine/methanol solution (2.0M) (1.7 ml) under ice cooling. The reaction solution was stirred for 5 hours under ambient temperature. To the reaction solution were added ethyl acetate, tetrahydrofuran, and water. The mixture was extracted with a mixture solvent of tetrahydrofuran and ethyl acetate, and washed with saturated brine. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel (NH silica gel) column chromatography (chloroform:methanol=100:0 to 91:9) to obtain 4-({5-[5-(ethylamino)-1,2,4-oxadiazole-3-yl]-1H-pyrrolo[2,3-b]pyridine-4-yl}amino)adamantan-1-ol (50 mg) as a yellow solid.

Example 43

4-[(5-Hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (100 mg) was dissolved in 45% aqueous HBr (0.5 ml), and the mixture was refluxed for 1.5 hours. The reaction solution was cooled, and the obtained solid was collected by filtration and washed with water. The obtained solid was dissolved in dichloromethane and methanol, and purified by silica gel column chromatography (chloroform:methanol) to obtain 4-[5-bromoadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (85 mg).

Example 44

(5-Hydroxyadamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (92 mg) was suspended in dichloromethane, and diethyl aminosulfur trifluoride (DAST) was added. The mixture was stirred at ambient temperature for 1 hour. The saturated aqueous sodium hydrogencarbonate and ethyl acetate were added. The obtained solid was collected by filtration and washed with diisopropyl ethylether to obtain (5-fluoroadamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (34 mg).

Example 45

To a solution of cis-(1s,3R,4R,5S)-4-{[5-(2H-tetrazole-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (55 mg) in 1-methyl-2-pyrrolidone (0.65 ml) were added N-ethyl-N-isopropylpropane-2-amine (0.11 ml) and iodomethane (0.015 ml) under ambient temperature, and the mixture was stirred at ambient temperature for 4 hours. The residue was purified by silica gel column chromatography (chloroform:methanol=99:1 to 90:10) to obtain cis-(1s,3R,4R,5S)-4-{[5-(2-methyl-2H-tetrazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (19.5 mg) as a major product (having a larger Rf value obtained by TLC (chloroform-methanol=10:1)) and to obtain cis-(1s,3R,4R,5S)-4-{[5-(1-methyl-1H-tetrazole-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (4.5 mg) as a minor product (having a smaller Rf value obtained by TLC (chloroform-methanol=10:1)), the major and minor products each being obtained as a yellowish white solid.

Example 46

To a solution of 2-chloronicotinonitrile (56.7 mg) and 4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (58.4 mg) in 1-methyl-2-pyrrolidone (0.6 ml) were added triethylamine (0.057 ml) and sodium iodide (3 mg), and the mixture was stirred for 10 hours at 130° C. After the reaction mixture was left to cool, 1-methyl-2-pyrrolidone (0.3 ml) was added to the reaction mixture, and the reaction mixture was dissolved. The mixture was directly purified by preparative HPLC system (10 mM NH₄HCO₃+NH₃ (pH=9.2):CH₃CN=98:2 to 60:40). The active fraction was concentrated and dried to hardness to obtain 4-{[(3-exo)-8-(3-cyanopyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (10.1 mg) as a solid.

Example 47

To a solution of 4-{[(3-exo)-8-(5-aminopyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (11 mg) in methanol/dichloromethane was added aqueous formalin (0.022 ml), and the mixture was stirred at ambient temperature for 0.5 hours. Sodium triacetoxyborohydride (30.9 mg) was further added, and the mixture was stirred for 16 hours at ambient temperature. To the reaction solution was added saturated aqueous sodium hydrogencarbonate, and the mixture was stirred for 30 minutes at ambient temperature and extracted with chloroform-methanol. The extract was concentrated, and the obtained yellow oily matter was purified by thin-layer silica gel column chromatography (chloroform:methanol=7:1) to obtain 4-{[(3-exo)-8-(5-(dimethylamino)pyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (5.2 mg) as a yellowish white solid.

Example 48

To a suspension of 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-ylamino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide dihydrochloride (25 mg) in 1,3-dimethyl-2-imidazolidinone (0.5 ml) was added triethylamine (0.029 ml). Furthermore, mesyl chloride (0.0059 ml) was added under ice cooling. After the mixture was stirred for 1 hour at ambient temperature, diluted aqueous sodium hydrogencarbonate was added, and the mixture was stirred. The precipitated white solid was collected by filtration, washed with water, and dried to obtain 4-{[(3-endo)-8-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (14.1 mg) as a white solid.

Example 49

To a solution of 1-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (12 mg) in N,N-dimethylacetamide (0.48 ml) and N,N-dimethylformamide (0.24 ml) were added N-ethyl-N-isopropylpropane-2-amine (0.015 ml) and 6-chloronicotinonitrile (11.7 mg). The mixture was immediately heated to 90° C. and stirred for 12 hours. After the disappearance of the starting compound was ascertained, the reaction solution was evaporated under reduced pressure and dried. The solid residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=8:1) to obtain 6-[(3-exo)-3-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)-8-azabicyclo[3.2.1]oct-8-yl]nicotinonitrile (5.2 mg) as a yellowish white solid.

Example 50

To a solution of ethyl 3-(4-{[(2r,5s)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-5-carboxylate (80 mg) in tetrahydrofuran (3.2 ml) was added 3M iodo(methyl)magnesium/diethy ether solution (0.315 ml) under ice cooling, and the reaction solution was stirred for 16 hours under ambient temperature. To the reaction solution was further added 3M iodo(methyl)magnesium/diethy ether solution (0.189 ml) under ice cooling. The reaction solution was stirred under ambient temperature for 16 hours. To the reaction solution was added water under ice cooling, and the mixture was stirred at the same temperature for 15 minutes. To the reaction solution were added chloroform and saturated aqueous ammonium chloride. The mixture was extracted with chloroform and washed with saturated brine. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) to obtain rel-(1s,3R,4R,5S)-4-({5-[5-(1-hydroxy-1-methylethyl)-1,2,4-oxadiazole-3-yl]-1H-pyrrolo[2,3-b]pyridine-4-yl}amino)adamantan-1-ol (15 mg) as a white solid.

Example 51

To a solution of 4-{[(3-exo)-8-(5-bromopyrimidine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (22.2 mg) in N,N-dimethylformamide (0.67 ml) and 1,3-dimethyl-2-imidazolidinone (0.67 ml) were added tetrakis(triphenylphosphine)palladium (O) (5.8 mg) and dicyanozinc (17.7 mg). Reaction was carried out at 160° C. using a microwave reaction system for 1 hour. To the reaction solution was added dichloromethane, and the mixture was filtered. The solid residue was washed with dichloromethane and dried. The solid residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=8:1) to obtain 4-{[(3-exo)-8-(5-cyanopyrimidine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (15 mg) as a yellowish white solid.

Example 52

To a solution of 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (30 mg) in tetrahydrofuran (0.6 ml) was added diisobutylaluminum hydride (0.99M toluene solution) (0.49 ml) at 5° C. The mixture was stirred for 2 hours at 5° C. and further stirred for 3 hours at ambient temperature. To the reaction solution was added 6M aqueous hydrochloric acid (0.09 ml) at 5° C. The mixture was stirred for 0.5 hour at ambient temperature. Solid sodium hydroxide (23.3 mg) and magnesium sulfate were added, and the mixture was stirred for 0.5 hour at ambient temperature. The insoluble matter was removed by Celite filtration and washed with tetrahydrofuran. The filtrate was evaporated under reduced pressure and purified by thin-layer silica gel column chromatography (chloroform:methanol=9:1) to obtain 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboaldehyde (18 mg) as a yellowish white solid.

Example 53

To a solution of 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboaldehyde (20 mg) in ethanol (0.6 ml) were added pyridine (0.052 ml) and O-methylhydroxyamine hydrochloride (32.1 mg), and the mixture was heated for 6 hours under refluxing. After being cooled to ambient temperature, the reaction solution was evaporated under reduced pressure, dried, and purified by thin-layer silica gel column chromatography (chloroform:methanol=10:1) to obtain 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboaldehyde O-methyloxime (11 mg) as a yellowish white solid.

Example 54

To acetic acid (0.8 ml) were added pyrrolidine (0.013 ml) and para-formaldehyde (5.72 mg), and the mixture was stirred for 5 minutes at 60° C. To the reaction solution was added cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (40.0 mg) at 60° C., and the mixture was stirred at 60° C. for 2 hours. The reaction solution was evaporated under reduced pressure, and toluene and N-ethyl-N-isopropylpropane-2-amine were added, and the mixture was subjected to azeotropy. The solid residue was purified by NH thin-layer silica gel column chromatography (chloroform:methanol=10:1) to obtain cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-3-(pyrrolidine-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (10.8 mg) as a yellowish white solid.

Example 55

To a solution of 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboaldehyde (40 mg) in tetrahydrofuran (1 ml) was added methyl (triphenylphosphoranylidene)acetate (56 mg), and the reaction solution was stirred at 80° C. for 16 hours. To the reaction solution was further added methyl (triphenylphosphoranylidene)acetate (43 mg), and the reaction solution was stirred at 90° C. for 3 hours. To the reaction solution was further added methyl (triphenylphosphoranylidene)acetate (129 mg), and the reaction solution was stirred at 90° C. for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) to obtain methyl (2E)-3-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)acrylate (7 mg) as a yellow solid.

Example 56

To a solution of cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (50 mg) in N,N-dimethylformamide (0.6 ml) was added 1-chloro-2,5-pyrrolidinedione (18.4 mg) at ambient temperature. After the mixture was stirred at ambient temperature for 2 hours, water was added to the reaction solution, and the solution was filtered. The solid residue was washed with water and dried. The solid residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=4:1) to obtain cis-3-chloro-4-{[(1R,2R,3S,5s)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (5 mg) as a yellowish white solid.

Example 57

To a solution of N′-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidamide (30 mg) in acetic acid (0.5 ml) was added acetic anhydride (11 μl), and the reaction solution was stirred for 30 minutes under ambient temperature. To the reaction solution was added 10% palladium on carbon (10 mg), and the mixture was stirred under hydrogen atmosphere at 50° C. for 3 hours. After the reaction solution was cooled to ambient temperature, the catalyst was filtered off with Celite. The filtrate was concentrated under reduced pressure, and the residue was washed with acetonitrile under stirring. The precipitate was collected by filtration to obtain 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidamide acetate (20 mg) as a yellow solid.

Example 58

To a solution of cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (30 mg) in 1-methyl-2-pyrrolidone (0.18 ml) was added pyridine hydrochloride (10.6 mg) at ambient temperature. Reaction was carried out at 200° C. for 1 hour using a microwave reaction system. To the reaction solution was added saturated aqueous sodium hydrogencarbonate, and the mixture was extracted with ethyl acetate and washed with water. The extract was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=10:1) to obtain cis-(1s,3R,4R,5S)-4-(1H-pyrrolo[2,3-b]pyridine-4-ylamino)adamantan-1-ol (14.1 mg) as a yellowish white solid.

Example 59

To a solution of cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (30 mg) in N,N-dimethylformamide (0.1 ml) was added N,N′-carbonyldiimidazole (29.7 mg), and the mixture was stirred for 0.5 hours at 60° C. To the reaction mixture was added methanesulfonamide (17.4 mg) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.027 ml). After being further stirred at 60° C. for 3 hours, the reaction solution was concentrated under reduced pressure. The residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=4:1) to obtain cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-N-(methylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (7.8 mg) as a yellowish white solid.

Example 60

To a solution of cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (75 mg) in tetrahydrofuran (0.5 ml) and methanol (0.375 ml) was added 1,1-dimethoxy-N,N-dimethylmethaneamine (1.54 ml) at ambient temperature. After being stirred for 1 hour under heating and refluxing, the mixture was cooled to ambient temperature and stirred for 1 hour. The precipitated solid was collected by filtration, washed and dried to obtain cis-N-[(dimethylamino)methylene]-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (70 mg) as a white solid.

Example 61

A solution of cis-2-[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)carbonyl]hydrazine carboxamide (30 mg) in a mixture of xylene (0.45 ml) and acetic acid (0.45 ml) was stirred at 120° C. for 3 hours. Furthermore, 1-methyl-2-pyrrolidone (0.45 ml) was added, and the mixture was stirred at 150° C. for 4 hours. The reaction solution was concentrated under reduced pressure and dried. The residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=10:1) to obtain cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one (5.6 mg) as a product (having a higher Rf value obtained by TLC (chloroform-methanol=10:1)) and to obtain cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,3,4-oxadiazole-2(3H)-one (8.9 mg) as another product (having a lower Rf value obtained by TLC (chloroform-methanol=10:1)), these products each being obtained as a yellowish white solid.

Example 62

To a solution of ethyl 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidate trihydrochloride (75 mg) in ethanol (1 ml) was added 1,2-ethanediamine (0.11 ml), the reaction solution was stirred at 120° C. for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by NH-silica gel column chromatography (chloroform:methanol=100:0 to 95:5) to obtain (1s,4r)-4-{[5-(4,5-dihydro-1H-imidazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (17 mg) as a white solid.

Example 63

To a solution of ethyl 4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidate trihydrochloride (150 mg) in ethanol (1.5 ml) were added 2-aminoethanol (78 μl) and triethylamine (0.225 ml), and the reaction solution was stirred at 110° C. for 2 hours. The reaction solution was cooled to ambient temperature and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10). The obtained solid was washed with ethyl acetate under stirring and collected by filtration to obtain (1s,4r)-4-{[5-(4,5-dihydro-1,3-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (5 mg) as a white solid.

Example 64

4-[(5-Hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (200 mg) and Raney nickel were added to ethanol (5 ml), and the reaction solution was stirred under hydrogen atmosphere at 60° C. for 8 hours. The catalyst was filtered off with Celite. The filtrate was concentrated under reduced pressure. The residue was dissolved in dioxane (3 ml), and 1M aqueous sodium hydroxide (0.65 ml) was added. To the reaction solution was added di-t-butyl dicarbonate (0.22 ml) under ambient temperature, and the mixture was stirred for 16 hours. The reaction solution was extracted with chloroform and washed with water. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) to obtain t-butyl ({4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-yl}methyl)carbamate (40 mg) as a pale yellow solid.

The compounds shown in the following Table 71 were produced according to the above-mentioned production methods, the methods obvious to those skilled in the art, or modified methods of these. The tables 71 and 72 show the structures and physicochemical data of the compounds described in these Examples and also show the methods for producing the compounds.

TABLE 71 Ex Structure  1

cis  2

 3

cis/trans mix  4

cis/trans mix  5

 6

cis  7

cis  8

cis  9

cis  10

cis/trans mix  11

cis  12

cis  13

cis  14

cis  15

cis  16

diastereomer of 365 cis or trans unknown  17

cis  18

cis/trans mix  19

cis  20

cis  21

 22

diastereomer of 382 cis or trans unknown  23

 24

cis  25

 26

cis  27

cis  28

cis  29

cis  30

cis  31

cis  32

cis  33

cis  34

cis  35

cis/trans mix  36

cis  37

cis  38

 39

cis/trans mix  40

cis  41

cis  42

cis  43

trans  44

cis  45

cis  46

 47

 48

 49

 50

cis  51

 52

cis  53

cis  54

cis  55

cis  56

cis  57

cis  58

cis  59

cis  60

cis  61

cis  62

cis  63

cis  64

cis/trans mix  65

 66

cis/trans mix  67

diastereomer of 68 cis or trans unknown  68

diastereomer of 67 cis or trans unknown  69

cis  70

 71

 72

trans  73

cis  74

trans  75

trans  76

trans  77

cis/trans mix  78

cis  79

cis  80

cis  81

cis  82

trans  83

cis  84

diastereomer of 85 cis or trans unknown  85

diastereomer of 84 cis or trans unknown  86

cis  87

cis  88

cis/trans mix  89

cis/trans mix  90

cis  91

 92

 93

 94

 95

 96

cis  97

cis/trans mix  98

cis  99

100

101

cis 102

trans 103

cis/trans mix 104

trans 105

cis 106

trans 107

cis 108

cis 109

cis 110

cis 111

trans 112

cis/trans mix 113

114

115

cis 116

cis 117

118

119

cis 120

121

trans 122

cis 123

cis/trans mix 124

cis/trans mix 125

trans 126

cis 127

cis 128

cis 129

cis/trans mix 130

trans 131

racemate 132

racemate 133

134

cis 135

cis 136

cis 137

cis 138

cis 139

140

141

142

143

144

cis/trans mix 145

cis 146

147

cis/trans mix 148

cis 149

cis 150

trans 151

cis/trans mix 152

cis/trans mix 153

diastereomer of 154 cis or trans unknown 154

diastereomer of 153 cis or trans unknown 155

cis/trans mix 156

cis/trans mix 157

cis/trans mix 158

cis/trans mix 159

cis/trans mix 160

cis/trans mix 161

trans 162

cis 163

cis 164

cis 165

cis 166

cis 167

cis 168

cis 169

cis 170

171

172

173

cis 174

cis 175

cis 176

cis 177

cis 178

cis 179

cis 180

cis 181

cis 182

cis 183

cis 184

185

186

187

188

cis/trans mix 189

190

cis/trans mix 191

diastereomer of 192 cis or trans unknown 192

diastereomer of 191 cis or trans unknown 193

cis 194

trans 195

196

cis/trans mix 197

cis 198

cis/trans mix 199

diastereomer of 200 cis or trans unknown 200

diastereomer of 199 cis or trans unknown 201

cis 202

203

cis 204

cis 205

cis 206

cis 207

cis 208

209

210

cis 211

cis 212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

cis 241

cis 242

cis 243

cis 244

cis 245

cis 246

cis 247

cis 248

cis 249

cis 250

cis 251

cis 252

cis 253

254

cis 255

cis 256

cis 257

cis 258

cis 259

cis 260

cis 261

cis 262

cis 263

cis 264

cis 265

cis 266

cis 267

cis 268

cis 269

cis 270

cis 271

cis 272

cis 273

cis 274

cis 275

cis 276

cis 277

cis 278

cis 279

cis 280

cis 281

cis 282

cis/trans mix 283

cis 284

cis 285

cis 286

cis 287

cis 288

cis 289

cis 290

cis 291

cis 292

trans 293

cis 294

cis 295

cis 296

cis 297

cis 298

cis 299

cis 300

cis 301

cis 302

cis 303

cis 304

cis 305

cis 306

cis 307

cis 308

cis 309

cis 310

cis 311

cis 312

cis 313

cis 314

cis 315

cis 316

cis 317

cis 318

cis 319

cis 320

cis 321

cis 322

cis 323

cis 324

cis 325

cis 326

cis 327

cis 328

cis 329

cis 330

cis 331

cis 332

cis 333

cis 334

cis 335

cis 336

cis 337

cis 338

cis 339

cis 340

cis 341

cis 342

cis 343

344

cis 345

cis 346

cis 347

cis 348

cis 349

350

diastereomer of 351 cis or trans unknown 351

diastereomer of 350 cis or trans unknown 352

cis/trans mix 353

cis 354

cis 355

cis 356

cis 357

cis 358

cis 359

cis 360

cis 361

cis 362

cis 363

cis 364

cis/trans mix 365

diastereomer of 16 cis or trans unknwon 366

cis 367

cis/trans mix 368

cis/trans mix 369

cis/trans mix 370

cis 371

cis/trans mix 372

cis 373

374

375

diastereomer of 376 cis or trans unknown 376

diastereomer of 375 cis or trans unknown 377

cis/trans mix 378

379

cis 380

trans 381

cis/trans mix 382

diastereomer of 22 cis or trans unknown 383

diastereomer of 384 cis or trans unknown 384

diastereomer of 383 cis or trans unknwon 385

diastereomer of 386 cis or trans unknown 386

diastereomer of 385 cis or trans unknown 387

diastereomer of 388 cis or trans unknown 388

diastereomer of 387 cis or trans unknwon 389

trans 390

cis 391

392

cis/trans mix 393

394

cis/trans mix 395

396

cis 397

trans 398

cis/trans mix 399

diastereomer of 400 cis or trans unknown 400

diastereomer of 399 cis or trans unknwon 401

diastereomer of 402 cis or trans unknwon 402

diastereomer of 401 cis or trans unknown 403

cis/trans mix 404

diastereomer of 405 cis or trans unknown 405

diastereomer of 404 cis or trans unknown 406

cis or trans unknown 407

trans 408

409

410

411

412

cis/trans mix 413

cis/trans mix 414

diastereomer of 415 cis or trans unknown 415

diastereomer of 414 cis or trans unknown 416

cis/trans mix 417

418

cis 419

cis 420

cis 421

cis 422

cis 423

trans 424

diastereomer of 425 cis or trans unknown 425

diastereomer of 424 cis or trans unknown 426

cis or trans unknown 427

trans 428

cis 429

cis/trans mix 430

cis 431

cis 432

cis 433

cis 434

cis 435

cis 436

cis 437

cis 438

cis 439

cis 440

cis 441

442

trans 443

cis 444

cis 445

cis 446

cis 447

cis 448

cis 449

cis 450

cis or trans unknown 451

cis 452

cis 453

cis/trans mix 454

cis/trans mix 455

cis/trans mix 456

cis 457

cis 458

459

cis 460

cis 461

cis 462

cis 463

cis 464

cis 465

cis 466

cis 467

cis 468

cis 469

cis 470

cis 471

cis 472

cis 473

cis 474

cis 475

cis 476

cis 477

cis 478

479

cis 480

cis 481

cis 482

cis 483

484

cis 485

diastereomer of 486 cis or trans unknown 486

diastereomer of 485 cis or trans unknown 487

cis/trans mix 488

diastereomer of 490 cis or trans unknown 489

490

diastereomer of 488 cis or trans unknown 491

492

cis/trans mix 493

diastereomer of 494 cis or trans unknown 494

diastereomer of 493 cis or trans unknown 495

trans 496

cis/trans mix 497

diastereomer of 498 cis or trans unknown 498

diastereomer of 497 cis or trans unknown 499

trans 500

trans 501

cis 502

trans 503

trans 504

cis 505

cis 506

cis 507

cis 508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

diastereomer of 534 cis or trans unknown 531

cis/trans mix 532

diastereomer of 533 cis or trans unknown 533

diastereomer of 532 cis or trans unknown 534

diastereomer of 530 cis or trans unknown 535

cis/trans mix 536

537

538

539

540

541

542

543

544

545

546

cis 547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

cis 566

cis 567

trans 568

cis 569

cis 570

cis 571

cis 572

cis 573

cis 574

cis 575

cis 576

trans 577

trans 578

cis 579

cis

TABLE 72 Ref. Ex Ex Data 1 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-2.38 (10H, m), 2.85 (3H, d, J = 4.8 Hz), 4.23 (1H, m), 4.53 (1H, s), 6.58 (1H, m), 7.27 (1H, m), 8.58 (1H, s), 8.78 (1H, m), 9.25 (1H, m), 11.79 (1H, s). MS: 409 (M + H)+ 2 — MS: 313 (M + H)+ 3 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.52-2.46 (11H, m), 2.63-2.72 (2H, m), 4.49-4.53 (1H, m), 6.31-6.35 (1H, m), 7.42-7.45 (1H, m), 7.89-7.90 (1H, m), 10.75-10.77 (1H, m), 11.55-11.58 (1H, m), 12.10 (1H, br). MS: 353 (M + H)+ 4 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-2.13 (8H, m), 2.18-2.47 (3H, m), 2.65-2.76 (2H, m), 4.02-4.13 (2H, m), 4.50-4.55 (1H, m), 6.34-6.39 (1H, m), 7.44-7.46 (1H, m), 7.90 (1H, s), 8.14-8.39 (1H, m), 10.77-10.78 (1H, m), 11.58 (1H, s). MS: 391 (M + H)+ 5 — MS: 404 (M + H)+ 6 — MS: 371 (M + H)+ 7 — MS: 508 (M + H)+ 8 — MS: 409 (M + H)+ 9 — MS: 542 (M + Na)+ 10 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.38-2.77 (18H, m), 4.38-4.54 (1H, m), 6.29-6.35 (1H, m), 7.25-7.37 (1H, m), 7.42-7.45 (1H, m), 7.89-7.90 (1H, m), 10.75 (1H, br), 11.57 (1H, s). MS: 380 (M + H)+ 11 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.29 (9H, m), 3.83 (3H, s), 4.10 (1H, m), 4.56 (1H, s), 6.50 (1H, m), 7.18 (1H, m), 8.55 (1H, s), 9.27 (1H, m), 11.68 (1H, s). MS: 342 (M + H)+ 12 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.54 (2H, m), 1.58-1.73 (4H, m), 1.73-1.86 (4H, m), 2.05-2.12 (1H, m), 2.17 (3H, s), 2.21-2.29 (2H, m), 4.08-4.16 (1H, m), 4.56 (1H, s), 4.99 (2H, s), 6.48-6.55 (1H, m), 7.18-7.24 (1H, m), 8.63 (1H, s), 9.12 (1H, d, J = 7.8 Hz), 11.74 (1H, s). MS: 384 (M + H)+ 13 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.53 (2H, m), 1.57-1.74 (4H, m), 1.74-1.90 (4H, m), 1.80 (3H, s), 2.04-2.12 (1H, m), 2.20-2.29 (2H, m), 4.06-4.14 (1H, m), 4.56 (1H, s), 6.45 (2H, brs), 6.47-6.52 (1H, m), 7.14-7.19 (1H, m), 8.76 (1H, s), 9.41 (1H, d, J = 8.0 Hz), 11.64 (1H, s). MS: 384 (M + H)+ 14 — MS: 369 (M + H)+ 15 — MS: 383 (M − H)− 16 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.57-1.63 (2H, m), 1.95-2.09 (3H, m), 2.17-2.24 (2H, m), 3.31-3.71 (6H, m), 4.62 (1H, s), 6.38-6.40 (1H, m), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.80 (1H, s), 11.58 (1H, s). MS: 334 (M + H)+ 17 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-1.56 (2H, m), 1.63-1.74 (4H, m), 1.83-1.91 (4H, m), 2.09-2.13 (1H, m), 2.30-2.34 (2H, m), 4.22-4.25 (1H, m), 4.58 (1H, s), 6.62 (1H, d, J = 3.6 Hz), 7.31 (1H, d, J = 3.6 Hz), 8.50 (1H, d, J = 7.6 Hz), 8.66 (1H, s), 12.00 (1H, brs). MS: 399 (M + Na)+ 18 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.48 (10H, m), 2.72-2.85 (2H, m), 4.61 (1H, s), 6.44-6.61 (1H, m), 7.64-7.71 (1H, m), 8.02-8.35 (4H, m), 11.59-11.64 (1H, m), 12.51-12.53 (1H, m). MS: 324 (M + H)+ 19 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-1.48 (2H, m), 1.59-1.74 (6H, m), 1.79-1.85 (2H, m), 2.02-2.07 (1H, m), 2.16-2.20 (2H, m), 4.45-4.48 (3H, m), 4.97 (1H, d, J = 7.4 Hz), 7.13-7.19 (2H, m), 7.36-7.40 (2H, m), 8.06 (1H, s), 8.48 (1H, s), 8.89 (1H, t, J = 5.9 Hz), 9.62. MS: 436 (M + H)+ 20 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.50-1.56 (2H, m), 1.62-1.72 (4H, m), 1.77-1.88 (4H, m), 2.08-2.11 (1H, m), 2.24-2.28 (2H, m), 3.56 (1H, m), 4.15-4.20 (1H, m), 6.67-6.69 (1H, m), 7.36-7.38 (1H, m), 8.28 (1H, s), 9.40 (1H, br), 10.36-10.41 (1H, m), 11.55 (1H, s), 12.53 (1H, brs), 14.29 (1H, br). MS: 343 (M − HCl + H)+ 21 — 1H-NMR (400 MHz, d6-DMSO)δ: 0.86-1.37 (3H, m), 1.58-1.69 (2H, m), 2.20-2.24 (1H, m), 2.41-2.51 (2H, m), 2.77-2.80 (1H, m), 2.90 (1H, s), 3.03-3.05 (1H, m), 4.29-4.35 (2H, m), 6.63 (1H, s), 7.43 (1H, s), 7.87 (1H, s), 10.7 (1H, s), 11.6 (1H, s). MS: 299 (M + H)+ 22 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.68-1.93 (6H, m), 2.02-2.13 (3H, m), 2.40-2.47 (2H, m), 2.71-2.75 (2H, m), 4.04 (2H, d, J = 5.5 Hz), 4.50 (1H, s), 6.34-6.36 (1H, m), 7.45 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 8.16 (1H, t, J = 5.6 Hz), 10.77 (1H, s), 11.59 (1H, s). MS: 391 (M + H)+ 23 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.71-1.89 (6H, m), 2.21-2.25 (3H, m), 2.53-2.56 (6H, m), 6.63 (1H, s), 7.46 (1H, t, J = 3.2 Hz), 7.90 (1H, s), 10.77 (1H, s), 11.61 (1H, s). MS: 309 (M + H)+ 24 — MS: 342 (M + H)+ 25 — MS: 312 (M + H)+ 26 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.33 (6H, d, J = 6.2 Hz), 1.46-1.86 (10H, m), 2.06 (1H, brs), 2.22 (2H, brs), 4.54 (1H, s), 5.05 (1H, d, J = 8.8 Hz), 5.18-5.15 (1H, m), 8.12 (1H, s), 8.63 (1H, s), 9.16 (1H, d, J = 8.8 Hz), 13.0 (1H, brs). MS: 371 (M + H)+ 27 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.41-1.45 (2H, m), 1.59-1.62 (2H, m), 1.65-1.70 (2H, m), 1.74-1.79 (2H, m), 1.88-1.92 (2H, m), 2.05-2.09 (1H, m), 2.18-2.21 (2H, m), 4.02-4.05 (1H, m), 4.32 (1H, s), 5.82 (2H, brs), 6.41-6.42 (1H, m), 7.09-7.11 (1H, m), 8.13 (1H, s), 8.96 (1H, d, J = 8.1 Hz), 9.50 (1H, s), 11.23 (1H, brs). MS: 342 (M + H)+ 28 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.57 (2H, m), 1.57-1.78 (4H, m), 1.78-1.97 (4H, m), 2.05-2.14 (1H, m), 2.26-2.34 (2H, m), 2.44 (3H, s), 4.17-4.24 (1H, m), 4.53 (1H, s), 6.56-6.61 (1H, m), 7.24-7.28 (1H, m), 8.58 (1H, s), 9.10 (1H, d, J = 7.8 Hz), 11.82 (1H, brs). MS: 366 (M + H)+ 29 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.32 (13H, m), 4.20-4.22 (1H, m), 4.55 (1H, s), 6.55-6.57 (1H, m), 7.25-7.27 (1H, m), 8.49 (1H, s), 8.79 (1H, d, J = 8.0 Hz), 9.27 (1H, s), 11.73 (1H, brs). MS: 374 (M + Na)+ 30 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-1.52 (2H, m), 1.62-1.64 (2H, m), 1.68-1.73 (2H, m), 1.81-1.91 (4H, m), 2.09-2.11 (1H, m), 2.28-2.31 (2H, m), 2.67 (3H, s), 4.19-4.22 (1H, m), 4.53 (1H, s), 6.53-6.54 (1H, m), 7.22-7.24 (1H, m), 7.88 (1H, d, J = 7.8 Hz), 8.69 (1H, s), 11.61 (1H, brs). MS: 366 (M + H)+ 31 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.49 (2H, m), 1.62-1.64 (2H, m), 1.74-1.79 (2H, m), 1.98-2.03 (4H, m), 2.15-2.18 (1H, m), 3.00-3.03 (2H, m), 4.45 (1H, brs), 4.61 (1H, brs), 5.77 (2H, s), 6.35-6.37 (1H, m), 7.33-7.35 (1H, m), 8.14 (1H, s), 11.44 (1H, brs). MS: 324 (M + H)+ 32 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.60 (13H, m), 3.27 (3H, s), 3.37-3.49 (4H, m), 4.44 (1H, m), 4.77 (1H, s), 6.66 (1H, m), 7.46 (1H, m), 8.71 (1H, s), 8.98 (1H, m), 10.92 (1H, s), 12.08 (1H, s). MS: 453 (M + H)+ 33 — MS: 409 (M + H)+ 34 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.42-1.51 (2H, m), 1.58-1.75 (4H, m), 1.76-1.95 (4H, m), 2.05-2.13 (1H, m), 2.25-2.32 (2H, m), 4.11-4.19 (1H, m), 4.50 (1H, brs), 6.49-6.54 (1H, m), 7.17-7.22 (1H, m), 7.24 (2H, s), 8.06 (1H, s), 9.70 (1H, d, J = 7.6 Hz), 11.57 (1H, s). MS: 383 (M + H)+ 35 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.49 (10H, m), 2.72-2.80 (2H, m), 4.49-4.56 (2H, m), 4.60-4.67 (1H, m), 5.64-5.71 (1H, m), 6.34-6.39 (1H, m), 7.42-7.47 (1H, m), 7.89-7.92 (1H, m), 8.62 (1H, s), 10.77-10.83 (1H, m), 11.55-11.61 (1H, m). MS: 407 (M + H)+ 36 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.32-1.87 (12H, m), 2.09 (1H, m), 2.08 (2H, m), 4.18-4.22 (1H, m), 4.68 (1H, m), 6.70-6.71 (1H, m), 7.09 (1H, s), 7.25 (1H, s), 7.37-7.39 (1H, m), 8.32 (1H, s), 10.32 (1H, m), 12.68 (1H, brs). MS: 313 (M − 3HCl + H)+ 37 — MS: 328 (M + H)+ 38 — MS: 378 (M + H)+ 39 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.54-1.63 (2H, m), 1.86-2.56 (10H, m), 2.77-2.85 (1H, m), 4.91 (1H, s), 6.64-6.66 (1H, m), 7.36-7.38 (1H, m), 8.50 (1H, s), 10.82 (1H, s), 11.93-11.95 (1H, m). MS: 387, 389 (M + H)+ 40 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.50-1.53 (2H, m), 1.64-2.01 (8H, m), 2.11 (1H, s), 2.32 (2H, s), 4.21 (1H, d, J = 7.5 Hz), 4.56 (2H, s), 6.58 (1H, s), 7.26 (1H, s), 8.61 (1H, s), 9.86 (1H, brs), 11.77 (1H, s). MS: 350 (M − H)− 41 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.54-1.60 (2H, m), 1.68-1.77 (4H, m), 1.78-1.86 (2H, m), 1.90-1.98 (2H, m), 2.12-2.16 (1H, m), 2.25-2.30 (2H, m), 2.68 (2H, t, J = 6.0 Hz), 3.57 (2H, t, J = 6.0 Hz), 4.08 (1H, d, J = 7.8 Hz), 6.46 (1H, dd, J = 2.0, 3.6 Hz), 7.04 (1H, br), 7.13 (1H, dd, J = 2.6, 3.6 Hz), 7.80 (1H, br), 8.38 (1H, s), 10.17 (1H, d, J = 8.2 Hz), 11.47 (1H, s). MS: 380 (M + H)+ 42 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.21 (3H, t, J = 7.2 Hz), 1.41-2.34 (13H, m), 3.33-3.42 (2H, m), 4.12-4.18 (1H, m), 4.50 (1H, s), 6.48-6.51 (1H, m), 7.17-7.21 (1H, m), 8.02 (1H, brd, J = 7.6 Hz), 8.42 (1H, brt, J = 5.6 Hz), 8.58 (1H, s), 11.51 (1H, brs). MS: 395 (M + H)+ 43 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.58-1.69 (2H, m), 1.86-1.96 (2H, m), 2.04-2.11 (1H, m), 2.14-2.23 (2H, m), 2.34-2.44 (4H, m), 2.61-2.71 (2H, m), 4.38-4.42 (1H, m), 6.63-6.67 (1H, m), 7.25 (1H, s), 7.35 (1H, br), 8.05 (1H, br), 10.58 (1H, s), 10.58 (1H, s), 11.94 (1H, s). MS: 389, 391 (M + H)+ 44 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.72-2.04 (9H, m), 2.29-2.91 (4H, m), 4.42-4.45 (1H, m), 6.37 (1H, d, J = 3.5 Hz), 7.44 (1H, d, J = 3.5 Hz), 7.90 (1H, s), 10.80 (1H, br, s), 11.58 (1H, s). MS: 327 (M + H)+ 45 — MS: 366 (M + H)+ 46 — MS: 388 (M + H)+ 47 — MS: 406 (M + H)+ 48 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.84-1.97 (2H, m), 1.97-2.17 (4H, m), 2.19-2.34 (2H, m), 2.96 (3H, s), 4.12-4.24 (2H, m), 4.30-4.40 (1H, m), 6.44-6.51 (1H, m), 7.04 (1H, br), 7.08-7.15 (1H, m), 7.81 (1H, br), 8.38 (1H, s), 10.22 (1H, d, J = 7.6 Hz), 11.47 (1H, s). MS: 364 (M + H)+ 49 — MS: 386 (M + H)+ 50 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.53 (2H, m), 1.62-1.65 (2H, m), 1.64 (6H, s), 1.69-1.74 (2H, m), 1.81-1.93 (4H, m), 2.08-2.12 (1H, m), 2.29-2.32 (2H, m), 4.19-4.23 (1H, m), 4.53 (1H, s), 6.07 (1H, s), 6.53-6.55 (1H, m), 7.22-7.24 (1H, m), 7.87-7.90 (1H, m), 8.72 (1H, s), 11.62 (1H, brs). MS: 410 (M + H)+ 51 — MS: 389 (M + H)+ 52 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.47 (9H, m), 3.17 (1H, m), 4.10 (1H, m), 4.58 (1H, s), 6.51 (1H, m), 7.21 (1H, m), 8.22 (1H, s), 9.79 (1H, s), 9.90 (1H, m), 11.84 (1H, s). MS: 312 (M + H)+ 53 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-2.33 (8H, m), 3.90 (3H, s), 4.15 (1H, m), 4.51 (1H, s), 6.48 (1H, m), 7.17 (1H, m), 7.90 (1H, s), 8.43 (1H, s), 8.46 (1H, m), 11.50 (1H, s). MS: 341 (M + H)+ 54 — MS: 410 (M + H)+ 55 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.37-1.48 (2H, m), 1.57-1.91 (8H, m), 2.04-2.08 (1H, m), 2.24-2.33 (2H, m), 3.71 (3H, s), 3.99-4.02 (1H, m), 4.50 (1H, s), 5.85-5.87 (1H, m), 6.34-6.38 (1H, m), 6.43-6.46 (1H, m), 7.14-7.17 (1H, m), 7.93-7.98 (1H, m), 8.20 (1H, s), 11.49 (1H, brs). MS: 368 (M + H)+ 56 — MS: 361 (M + H)+ 57 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-1.45 (2H, m), 1.59-1.61 (2H, m), 1.64-1.70 (2H, m), 1.73-1.79 (2H, m), 1.85-1.91 (5H, m), 2.05-2.08 (1H, m), 2.20-2.23 (2H, m), 4.01-4.04 (1H, m), 4.42-4.52 (1H, m), 6.44 (1H, d, J = 3.6 Hz), 7.12 (1H, d, J = 3.6 Hz), 8.15 (1H, s), 10.05 (1H, br), 11.38 (1H, brs). MS: 326 (M − AcOH + H)+ 58 — MS: 284 (M + H)+ 59 — MS: 427 (M + Na)+, 403 (M − H)− 60 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.27 (7H, m), 3.12 (3H, s), 3.18 (3H, s), 4.07 (1H, m), 4.46 (1H, s), 6.44 (1H, m), 7.09 (1H, m), 8.58 (1H, s), 9.08 (1H, s), 10.56 (1H, m), 11.45 (1H, s). MS: 382.3 (M + H)+ 61 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.69 (13H, m), 4.19 (1H, m), 4.53 (1H, s), 6.54 (1H, m), 7.25 (1H, m), 8.43 (1H, s), 8.75 (1H, m), 11.68 (1H, s). MS: 367.3 (M + H), 365.0 (M − H)− 62 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-1.45 (2H, m), 1.59-1.70 (4H, m), 1.75-1.81 (2H, m), 1.90-1.95 (2H, m), 2.06-2.09 (1H, m), 2.20-2.23 (2H, m), 3.35 (2H, m), 3.89 (2H, t, J = 9.6 Hz), 4.04-4.08 (1H, m), 4.43 (1H, br), 6.44 (1H, d, J = 3.6 Hz), 6.87 (1H, brs), 7.10 (1H, d, J = 3.5 Hz), 8.21 (1H, s), 10.97 (1H, d, J = 7.8 Hz), 11.34 (1H, brs). MS: 352 (M + H)+ 63 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.48 (2H, m), 1.60-1.63 (2H, m), 1.66-1.72 (2H, m), 1.77-1.83 (2H, m), 1.87-1.92 (2H, m), 2.06-2.10 (1H, m), 2.22-2.26 (2H, m), 4.05 (2H, t, J = 9.0 Hz), 4.09-4.13 (1H, m), 4.32 (2H, t, J = 9.0 Hz), 4.47 (1H, s), 6.47-6.49 (1H, m), 7.15-7.17 (1H, m), 8.34 (1H, s), 9.98 (1H, d, J = 7.8 Hz), 11.49 (1H, brs). MS: 353 (M + H)+ 64 — 1H-NMR (400 MHz, d6-DMSO)δ: 1.02-1.05 (4H, m), 1.37-1.41 (9H, m), 1.53-1.67 (5H, m), 1.74-1.85 (2H, m), 2.01-2.23 (5H, m), 4.11-4.18 (2H, m), 6.29-6.36 (1H, m), 7.09-7.13 (1H, m), 7.28-7.32 (1H, m), 7.64-7.65 (1H, m), 11.11 (1H, brs). MS: 413 (M + H)+ 65 1 MS: 431 (M + H)+ 66 1 MS: 341 (M + H)+ 67 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.81-2.02 (8H, m), 2.09-2.62 (5H, m), 4.15-4.20 (1H, m), 6.43-6.46 (1H, m), 7.09 (1H, br), 7.14-7.16 (1H, m), 7.86 (1H, br), 8.40 (1H, s), 10.25 (1H, d, J = 8.2 Hz), 11.50 (1H, s). MS: 336 (M + H)+ 68 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.54-1.60 (2H, m), 1.86-1.97 (3H, m), 1.99-2.03 (2H, m), 2.08-2.15 (4H, m), 2.27-2.35 (2H, m), 4.27 (1H, d, J = 7.6 Hz), 6.50-6.52 (1H, m), 6.99 (1H, br), 7.14 (1H, t), 7.81 (1H, s), 8.38 (1H, s), 10.17 (1H, d, J = 8.3 Hz), 11.48 (1H, s). MS: 336 (M + H)+ 69 1 MS: 534 (M + H)+, 532 (M − H)− 70 1 MS: 376 (M + H)+ 71 1 MS: 402 (M + H)+ 72 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-1.43 (2H, m), 1.62-1.72 (4H, m), 1.79-1.89 (4H, m), 2.02-2.09 (1H, m), 2.11-2.17 (2H, m), 2.75 (3H, d, J = 4.3 Hz), 4.09-4.16 (1H, m), 4.49 (1H, brs), 6.39-6.41 (1H, m), 7.11-7.15 (1H, m), 8.18-8.25 (1H, m), 8.30 (1H, s), 9.87 (1H, d, J = 8.3 Hz), 11.42 (1H, brs). MS: 341 (M + H)+ 73 1 MS: 341 (M + H)+ 74 1 MS: 355 (M + H)+ 75 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-2.27 (9H, m), 2.76 (3H, d, J = 4.4 Hz), 4.23 (1H, m), 6.48 (1H, m), 7.14 (1H, m), 8.25 (1H, m), 8.32 (1H, s), 9.87 (1H, m), 11.45 (1H, s). MS: 343 (M + H)+ 76 1 MS: 355 (M + H)+ 77 1 MS: 440 (M + H)+ 78 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-2.36 (8H, m), 1.63 (6H, s), 4.22 (1H, m), 4.54 (1H, s), 5.90 (1H, s), 6.55 (1H, m), 7.25 (1H, m), 8.50 (1H, s), 8.80 (1H, m), 11.72 (1H, s). MS: 410 (M + H)+ 79 1 MS: 382 (M + H)+, 380 (M − H)− 80 1 MS: 417 (M + Na)+, 395 (M + H)+ 81 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.48 (2H, m), 1.60-1.68 (4H, m), 1.76-1.85 (4H, m), 2.06-2.08 (1H, m), 2.29-2.31 (2H, m), 4.13-4.15 (1H, m), 4.53-4.54 (1H, m), 5.99 (1H, d, J = 7.0 Hz), 6.68 (1H, d, J = 3.6 Hz), 7.28 (1H, d, J = 3.6 Hz), 8.11 (1H, s), 11.86 (1H, brs). MS: 331 (M + Na)+ 82 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-1.43 (2H, m), 1.64-1.69 (4H, m), 1.83-1.88 (4H, m), 2.05-2.07 (1H, m), 2.21-2.23 (2H, m), 4.25-4.27 (1H, m), 4.52 (1H, brs), 6.04 (1H, d, J = 7.2 Hz), 6.68 (1H, d, J = 3.5 Hz), 7.28 (1H, d, J = 3.4 Hz), 8.10 (1H, s), 11.85 (1H, brs). MS: 309 (M + H)+ 83 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.50-1.55 (2H, m), 1.62-1.73 (4H, m), 1.79-1.89 (4H, m), 2.08-2.12 (1H, m), 2.28-2.32 (2H, m), 4.24-4.28 (1H, m), 6.68-6.71 (1H, m), 7.39-7.41 (1H, m), 8.42 (1H, s), 8.44-8.48 (1H, m), 12.48 (1H, brs). MS: 368 (M + H)+ 84 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.50-1.57 (2H, m), 1.81-1.87 (2H, m), 1.92-2.00 (5H, m), 2.04-2.09 (2H, m), 2.18-2.24 (2H, m), 3.62 (3H, s), 4.30-4.33 (1H, m), 6.16 (1H, d, J = 7.1 Hz), 6.72 (1H, d, J = 3.4 Hz), 7.28 (1H, d, J = 3.3 Hz), 8.11 (1H, s), 11.85 (1H, brs). MS: 373 (M + Na)+ 85 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.70-1.75 (2H, m), 1.78-1.91 (5H, m), 1.94-2.02 (2H, m), 2.04-2.12 (2H, m), 2.19-2.26 (2H, m), 3.60 (3H, s), 4.25-4.28 (1H, m), 6.19 (1H, d, J = 7.1 Hz), 6.70-6.72 (1H, m), 7.27-7.29 (1H, m), 8.10 (1H, s), 11.85 (1H, brs). MS: 373 (M + Na)+ 86 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.53 (2H, m), 1.63-1.74 (4H, m), 1.81-1.91 (4H, m), 2.08-2.11 (1H, m), 2.21 (3H, s), 2.29-2.36 (4H, m), 2.39-2.42 (2H, m), 3.49-3.53 (2H, m), 3.66-3.70 (2H, m), 4.19-4.23 (1H, m), 4.49 (1H, s), 6.57-6.59 (1H, m), 7.27-7.29 (1H, m), 8.64 (1H, s), 8.83-8.86 (1H, m), 11.86 (1H, brs). MS: 478 (M + H)+ 87 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-1.52 (2H, m), 1.61-1.81 (8H, m), 2.05-2.08 (1H, m), 2.20-2.24 (2H, m), 4.09-4.12 (1H, m), 4.53 (1H, s), 6.63-6.65 (1H, m), 6.82-6.86 (1H, m), 7.30-7.32 (1H, m), 8.65 (1H, s), 10.52-10.56 (1H, m), 11.80 (1H, brs). MS: 352 (M + H)+ 88 1 1H-NMR (400 MHz, d6-DMSO)δ: 0.85-0.93 (1H, m), 1.34, 1.40 (9H, s), 1.47-1.53 (1H, m), 1.67-1.79 (1H, m), 1.85-1.92 (3H, m), 1.99-2.06 (3H, m), 2.13-2.34 (4H, m), 4.21-4.25, 4.30-4.34 (1H, m), 6.37-6.41, 6.54-6.56 (1H, m), 6.51-6.63, 6.57-6.59 (1H, m), 7.28-7.29 (1H, m), 8.06-8.32 (2H, m), 8.63, 8.64 (1H, s), 8.87-8.89, 8.99-9.01 (1H, m), 11.88 (1H, brs). MS: 516 (M + Na)+ 89 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.31-1.36 (1H, m), 1.47-1.53 (3H, m), 1.59-1.64 (1H, m), 1.67-1.80 (2H, m), 1.89-2.00 (3H, m), 2.06-2.11 (1H, m), 2.16-2.20 (2H, m), 3.02-3.09 (2H, m), 4.27-4.44 (2H, m), 6.52-6.54, 6.61-6.63 (1H, m), 7.26-7.29 (1H, m), 8.10-8.31 (2H, m), 8.63 (1H, s), 8.92-8.95, 9.04-9.07 (1H, m), 11.86 (1H, brs). MS: 431 (M + Na)+ 90 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.53 (2H, m), 1.62-1.73 (4H, m), 1.81-1.92 (4H, m), 2.09-2.12 (1H, m), 2.29-2.32 (2H, m), 3.46 (3H, s), 4.20-4.24 (1H, m), 4.54 (1H, s), 4.86 (2H, s), 6.54-6.56 (1H, m), 7.24-7.25 (1H, m), 7.84-7.86 (1H, m), 8.72 (1H, s), 11.65 (1H, s). MS: 396 (M + H)+ 91 1 1H-NMR (400 MHz, d6-DMSO)δ: 0.74-0.88 (1H, m), 1.13-1.75 (7H, m), 2.10-2.30 (2H, m), 4.27-4.44 (1H, m), 6.55 (1H, brs), 6.56 (1H, d, J = 3.4 Hz), 7.11 (1H, m), 7.65 (1H, d, J = 3.4 Hz), 8.35 (1H, s), 9.86 (1H, d, J = 7.9 Hz), 11.43 (1H, brs). MS: 271 (M + H)+ 92 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.75-2.33 (5H, m), 2.97-3.36 (5H, m), 3.73-3.88 (1H, m), 4.38-4.64 (1H, m), 6.63 (1H, d, J = 3.4 Hz), 7.17 (1H, brs), 7.23 (1H, d, J = 3.4 Hz), 7.92 (1H, brs), 8.44 (1H, s), 10.25 (1H, d, J = 7.8 Hz), 11.68 (1H, s). MS: 286 (M + H)+ 93 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.29-2.02 (5H, m), 2.41 (1H, dd, J = 3.8, 13.8 Hz), 2.65-2.83 (4H, m), 4.05-4.20 (1H, m), 4.36 (1H, t, J = 5.1 Hz), 6.51-6.58 (1H, m), 6.88-7.94 (3H, m), 8.37 (1H, s), 9.99 (1H, d, J = 7.9 Hz), 11.46 (1H, brs). MS: 286 (M + H)+ 94 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.12-1.65 (7H, m), 1.82-1.97 (1H, m), 2.25-2.34 (2H, m), 3.85-3.96 (1H, m), 6.57 (1H, d, J = 3.3 Hz), 7.12 (1H, d, J = 2.4 Hz), 6.78-7.92 (2H, brs), 8.35 (1H, s), 9.57 (1H, d, J = 7.1 Hz), 11.5 (1H, brs). MS: 271 (M + H)+ 95 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.17-1.64 (10H, m) 2.0-2.07 (1H, m), 2.18-2.22 (1H, m), 2.38-2.40 (1H, m), 3.18-3.23 (1H, m), 4.14 (1H, t, J = 7.8 Hz), 4.25 (2H, q, J = 7.0 Hz), 4.46 (1H, t, J = 4.8 Hz), 7.17 (1H, s), 6.70 (1H, s), 8.51 (1H, s), 8.78 (1H, d, J = 8.0 Hz), 11.7 (1H, s). MS: 330 (M + H)+ 96 1 1HNMR (400 MHz, d6-DMSO)δ: 1.38-1.86 (10H, m), 2.07 (1H, brs), 2.19 (2H, brs), 2.29 (3H, s), 3.97 (1H, d, J = 8.0 Hz), 4.49 (1H, s), 6.14 (1H, s), 6.98 (1H, brs), 7.78 (1H, brs), 8.28 (1H, s), 9.99 (1H, d, J = 8.0 Hz), 11.3 (1H, s). MS: 341 (M + H)+ 97 1 1HNMR (400 MHz, CDCl3)δ: 1.35-2.67 (13H, m), 3.75 (1H, brs), 4.05-4.20 (1H, m), 5.00-5.12 (1H, brs), 6.45-6.48 (1H, m), 7.15-7.16 (1H, m), 7.95 (1H, d, J = 4.7 Hz), 10.0 (1H, brs).. MS: 302 (M + H)+ 98 1 1HNMR (400 MHz, d6-DMSO)δ: 1.40-2.30 (13H, m), 3.92-3.96 (1H, m), 4.44 (1H, s), 5.27-5.29 (1H, m), 6.51 (1H, dd, J = 2.0, 3.2 Hz), 7.21 (1H, dd, J = 2.8, 3.2 Hz), 7.88 (1H, d, J = 4.8 Hz), 11.3 (1H, s). MS: 302 (M + H)+ 99 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.13-1.40 (3H, m), 1.48-1.63 (3H, m), 1.93-2.00 (1H, m), 2.14-2.18 (1H, m), 2.35-2.38 (1H, m), 3.12-3.20 (1H, m), 3.41-3.47 (1H, m), 4.04-4.10 (1H, m), 4.38-4.41 (1H, m), 6.61-6.65 (1H, m), 6.81-7.03 (1H, br), 7.09-7.13 (1H, m), 7.61-7.86 (1H, br), 8.33 (1H, s), 9.64 (1H, d, J = 8.0 Hz), 11.45 (1H, brs). MS: 301 (M + H)+. 100 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.38-2.28 (12H, m), 2.87-2.98 (1H, m), 3.63 (3H, s), 4.45-4.57 (1H, m), 6.42-6.45 (1H, m), 6.80-7.13 (1H, br), 7.18-7.22 (1H, m), 7.51-7.93 (1H, br), 8.34 (1H, s), 9.44 (1H, d, J = 8.0 Hz), 11.49 (1H, brs). MS: 357 (M + H)+. 101 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.33 (3H, t, J = 8.0 Hz), 1.47-1.51 (2H, m), 1.61-1.72 (4H, m), 1.78-1.85 (4H, m), 2.07-2.10 (1H, m), 2.23-2.27 (2H, m), 4.09-4.12 (1H, m), 4.30 (2H, q, J = 8.0 Hz), 4.56 (1H, brs), 6.48-6.50 (1H, m), 7.17-7.19 (1H, m), 8.56 (1H, s), 9.28 (1H, d, J = 7.6 Hz), 11.69 (1H, brs). MS: 356 (M + H)+. 102 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.32 (3H, t, J = 6.8 Hz), 1.43-1.50 (2H, m), 1.65-1.73 (4H, m), 1.78-1.90 (4H, m), 2.06-2.10 (1H, m), 2.16-2.21 (2H, m), 4.19-4.23 (1H, m), 4.29 (2H, q, J = 6.8 Hz), 4.54 (1H, brs), 6.45-6.46 (1H, m), 7.18-7.20 (1H, m), 8.56 (1H, s), 9.26 (1H, d, J = 8.0 Hz), 11.68 (1H, brs). MS: 356 (M + H)+. 103 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.38-1.48 (2H, m), 1.59-1.70 (4H, m), 1.73-1.86 (4H, m), 2.03-2.09 (1H, m), 2.11-2.16 (1H, m), 2.18-2.23 (1H, m), 3.258 (1.5H, s), 3.263 (1.5H, s), 3.53 (1.5H, s), 3.54 (1.5H, s), 4.00-4.05 (0.5H, m), 4.10-4.15 (0.5H, m), 4.50 (0.5H, brs), 4.52 (0.5H, brs), 6.42-6.45 (0.5H, m), 6.46-6.48 (0.5H, m), 7.16-7.19 (1H, m), 7.89 (0.5H, d, J = 8.4 Hz), 7.94 (0.5H, d, J = 8.4 Hz), 8.15-8.16 (1H, m), 11.52 (1H, brs). MS: 371 (M + H)+. 104 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.24 (13H, m), 4.31-4.33 (1H, m), 4.52 (1H, s), 6.52-6.53 (1H, m), 7.25-7.27 (1H, m), 8.49 (1H, s), 8.76 (1H, d, J = 8.0 Hz), 9.25 (1H, s), 11.72 (1H, s). MS: 352 (M + H)+ 105 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-2.17 (13H, m), 3.07-3.08 (2H, m), 4.31-4.32 (1H, m), 4.40-4.42 (1H, m), 6.50-6.51 (1H, m), 7.24-7.25 (1H, m), 8.49 (1H, s), 8.84 (1H, d, J = 8.0 Hz), 9.25 (1H, s), 11.71 (1H, s). MS: 366.3 (M + H)+ 106 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.13-2.19 (13H, m), 2.97-3.00 (2H, m), 3.82-3.83 (1H, m), 4.31-4.40 (1H, m), 6.57-6.58 (1H, m), 7.26-7.27 (1H, m), 8.48 (1H, s), 8.78 (1H, d, J = 8.0 Hz), 9.24-9.25 (1H, m), 11.70 (1H, s). MS: 366 (M + H)+ 107 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-2.31 (13H, m), 4.17-4.18 (1H, m), 4.58 (1H, brs), 6.56 (1H, d, J = 3.4 Hz), 7.22 (1H, d, J = 2.7 Hz, 7.50-7.57 (5H, m), 8.06 (1H, s), 10.58 (1H, d, J = 7.9 Hz), 11.82 (1H, brs). MS: 388 (M + H)+. 108 1 1H-NMR (400 MHz, d6-DMSO)δ: 0.88-2.26 (13H, m), 4.10-4.11 (1H, m), 4.58 (1H, brs), 4.60 (2H, s), 4.82 (2H, s), 6.51-6.52 (1H, s), 7.17-7.18 (1H, s), 7.30-7.38 (5H, m), 10.52 (1H, d, J = 7.9 Hz), 11.76 (1H, brs). MS: 432 (M + H)+ 109 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-2.25 (13H, m), 3.36 (3H, s), 4.10-4.12 (1H, m), 4.57 (1H, s), 4.69 (2H, s), 6.51-6.52 (1H, m), 7.16-7.18 (1H, m), 8.49 (1H, s), 10.51 (1H, d, J = 8.0 Hz), 11.76 (1H, brs). MS: 356 (M + H)+ 110 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.25 (14H, m), 4.10 (1H, d, J = 7.9 Hz), 5.48 (2H, s), 6.51-6.53 (1H, m), 6.92-6.99 (3H, m), 7.18 (1H, brs), 7.28-7.30 (2H, m), 8.65 (1H, s), 10.44 (1H, d, J = 7.9 Hz), 11.8 (1H, s). MS: 418 (M + H)+ 111 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.19 (13H, m), 4.21-4.23 (1H, m), 4.51 (1H, s), 4.59 (2H, s), 4.80 (2H, s), 6.46-6.48 (1H, m), 7.17-7.18 (1H, m), 7.29-7.37 (6H, m), 10.45 (1H, d, J = 8.0 Hz), 11.73 (1H, s). MS: 432 (M + H)+ 112 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.23-2.33 (13H, m), 2.99-3.11 (2H, m), 4.21 (1H, brs), 4.40-4.41 (1H, m), 4.59 (2H, s), 4.79 (2H, s), 6.51 (1H, brs), 7.16-7.37 (6H, m), 8.51 (1H, s), 10.50 (1H, d, J = 8.0 Hz), 11.72 (1H, s). MS: 446 (M + H)+ 113 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-2.33 (13H, m), 3.53-3.75 (2H, m), 4.16-4.17 (1H, m), 4.40 (1H, s), 4.87 (1H, s), 6.19-6.20 (1H, m), 6.82 (1H, s), 7.21-7.22 (1H, m), 9.80 (1H, d, J = 8.0 Hz), 11.64 (1H, s). MS: 398 (M + H)+ 114 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-1.52 (2H, m), 1.62 (6H, s), 1.64-2.31 (11H, m), 4.19-4.20 (1H, m), 4.54 (1H, s), 6.27 (1H, s), 6.53 (1H, brs), 7.20-7.22 (1H, m), 8.30 (1H, s), 9.80 (1H, d, J = 8.0 Hz), 11.64 (1H, brs). MS: 426 (M + H)+ 115 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.32 (13H, m), 2.82 (3H, d, J = 4.8 Hz), 4.27-4.28 (1H, m), 4.52 (1H, s), 6.55-6.57 (1H, m), 7.22-7.23 (1H, m), 8.83 (1H, m), 9.31-9.32 (1H, m), 9.82-9.83 (1H, m), 11.76 (1H, s). MS: 424.9 (M − H)− 116 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.27-2.77 (24H, m), 3.75-3.77 (1H, m), 4.24-4.25 (1H, m), 4.53 (1H, s), 6.55-6.56 (1H, m), 7.23-7.24 (1H, m), 8.38 (1H, s), 9.24 (1H, d, J = 8.0 Hz), 9.80 (1H, d, J = 7.6 Hz), 11.77 (1H, brs). MS: 508 (M + H)+ 117 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.55-1.61 (2H, m), 1.71-1.75 (2H, m), 1.81-2.05 (10H, m), 4.16-4.21 (1H, m), 6.40-6.43 (1H, m), 6.81-7.06 (1H, br), 7.10-7.13 (1H, m), 7.53-7.91 (1H, br), 8.37 (1H, s), 10.17 (1H, d, J = 8.0 Hz), 11.44 (1H, brs). MS: 311 (M + H)+. 118 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.64-1.74 (6H, m), 2.02-2.15 (9H, m), 6.66-6.69 (1H, m), 6.96-7.13 (1H, br), 7.15-7.18 (1H, m), 7.66-7.93 (1H, br), 8.33 (1H, s), 9.70 (1H, brs), 11.45 (1H, brs). MS: 311 (M + H)+. 119 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.37-1.43 (2H, m), 1.91-2.10 (11H, m), 3.77-3.81 (1H, m), 4.68-4.70 (1H, m), 6.67-6.70 (1H, m), 6.92-7.14 (1H, br), 7.16-7.19 (1H, m), 7.66-7.91 (1H, br), 8.33 (1H, s), 9.68 (1H, brs), 11.45 (1H, brs). MS: 349 (M + Na)+. 120 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.66 (6H, m), 1.88-1.95 (6H, m), 2.21-2.26 (2H, m), 4.63 (1H, brs), 6.63-6.66 (1H, m), 6.93-7.15 (1H, br), 7.17-7.20 (1H, m), 7.70-7.91 (1H, br), 8.34 (1H, s), 9.70 (1H, brs), 11.46 (1H, brs). MS: 349 (M + Na)+. 121 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.38-1.44 (2H, m), 1.63-1.71 (4H, m), 1.80-1.87 (4H, m), 2.02-2.07 (1H, m), 2.12-2.16 (2H, m), 4.11-4.15 (1H, m), 4.50 (1H, brs), 6.39-6.41 (1H, m), 6.90-7.05 (1H, br), 7.11-7.14 (1H, m), 7.70-7.83 (1H, br), 8.37 (1H, s), 10.09 (1H, d, J = 8.0 Hz), 11.45 (1H, brs). MS: 327 (M + H)+ 122 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.50 (2H, m), 1.58-1.71 (4H, m), 1.76-1.86 (4H, m), 2.06-2.10 (1H, m), 2.21-2.25 (2H, m), 4.05-4.10 (1H, m), 4.54 (1H, brs), 6.51-6.53 (1H, m), 7.08-7.26 (2H, m), 7.88-8.03 (1H, br), 8.42 (1H, s), 10.43-10.51 (1H, m), 11.80 (1H, s). MS: 327 (M + H)+. 123 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.41-1.48 (0.8H, m), 1.49-1.56 (1.2H, m), 1.65-1.97 (8H, m), 2.08-2.16 (1H, m), 2.17-2.23 (0.8H, m), 2.23-2.28 (1.2H, m), 4.05-4.11 (0.6H, m), 4.15-4.20 (0.4H, m), 6.44-6.48 (1H, m), 6.87-7.11 (1H, br), 7.11-7.15 (1H, m), 7.66-7.91 (1H, br), 8.37 (0.4H, s), 8.38 (0.6H, s), 10.12 (0.4H, d, J = 8.4 Hz), 10.14 (0.6H, d, J = 8.4 Hz), 11.45 (1H, brs). MS: 341 (M + H)+. 124 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.51 (1H, m), 1.68-1.96 (8H, m), 2.01-2.31 (3H, m), 2.33-2.40 (1H, m), 4.06-4.12 (0.5H, m), 4.21-4.28 (0.5H, m), 6.45-6.53 (1H, m), 6.88-7.20 (2H, m), 7.65-7.95 (1H, br), 8.38 (0.5H, s), 8.39 (0.5H, s), 10.10 (0.5H, d, J = 8.4 Hz), 10.18 (0.5H, d, J = 8.4 Hz), 11.48 (1H, brs). MS: 329 (M + H)+. 125 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.41-1.48 (2H, m), 1.69-1.78 (4H, m), 1.82-1.98 (4H, m), 2.08-2.13 (1H, m), 2.17-2.23 (2H, m), 3.15 (3H, s), 4.15-4.20 (1H, m), 6.44-6.47 (1H, m), 6.86-7.10 (1H, br), 7.11-7.15 (1H, m), 7.62-7.91 (1H, br), 8.37 (1H, s), 10.12 (1H, d, J = 8.4 Hz), 11.45 (1H, brs). MS: 341 (M + H)+. 126 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-1.56 (2H, m), 1.64-1.75 (4H, m), 1.77-1.95 (4H, m), 2.10-2.15 (1H, m), 2.23-2.28 (2H, m), 3.12 (3H, s), 4.05-4.11 (1H, m), 6.44-6.48 (1H, m), 6.89-7.10 (1H, br), 7.11-7.15 (1H, m), 7.61-7.93 (1H, br), 8.38 (1H, s), 10.14 (1H, d), 11.45 (1H, brs). MS: 341 (M + H)+. 127 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.68-1.76 (4H, m), 1.79-1.89 (4H, m), 2.01-2.09 (2H, m), 2.19-2.25 (1H, m), 2.32-2.38 (2H, m), 4.06-4.12 (1H, m), 6.45-.6.49 (1H, m), 6.91-7.18 (2H, m), 7.65-7.92 (1H, br), 8.39 (1H, s), 10.18 (1H, d, J = 8.4 Hz), 11.48 (1H, brs). MS: 351 (M + Na)+. 128 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.06 (3H, t, J = 8.0 Hz), 1.53-1.59 (2H, m), 1.68-1.75 (4H, m), 1.80-1.94 (4H, m), 2.10-2.14 (1H, m), 2.24-2.28 (2H, m), 3.42 (2H, q, J = 8.0 Hz), 4.08-4.13 (1H, m), 6.51-6.53 (1H, m), 7.12-7.31 (2H, m), 7.83-8.03 (1H, br), 8.42 (1H, s), 10.43 (1H, d, J = 8.0 Hz), 11.74 (1H, brs). MS: 355 (M + H)+. 129 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.53-2.20 (13H, m), 3.58-3.64 (3H, m), 4.19-4.29 (1H, m), 6.54-6.58 (1H, m), 7.19-7.47 (2H, m), 7.96-8.16 (1H, br), 8.46 (1H, s), 10.65-10.72 (1H, m), 11.98 (1H, brs). MS: 369 (M + H)+. 130 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.49 (2H, m), 1.82-1.94 (6H, m), 2.12-2.29 (5H, m), 4.22-4.26 (1H, m), 6.47-.6.50 (1H, m), 6.86-7.17 (2H, m), 7.66-7.93 (1H, br), 8.38 (1H, s), 10.10 (1H, d, J = 8.0 Hz), 11.47 (1H, brs). MS: 329 (M + H)+. 131 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.32-1.39 (1H, m), 1.63-1.90 (8H, m), 1.98-2.14 (2H, m), 2.30-2.37 (1H, m), 3.76-3.80 (1H, m), 4.18-4.23 (1H, m), 4.96-5.00 (1H, m), 6.34-.6.38 (1H, m), 6.61-7.09 (2H, m), 7.21-7.72 (1H, br), 8.23 (1H, s), 10.03 (1H, d, J = 8.0 Hz), 11.33 (1H, brs). MS: 327 (M + H)+. 132 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.83 (7H, m), 1.87-2.09 (4H, m), 2.19-2.25 (1H, m), 3.88-3.92 (1H, m), 4.53-4.58 (1H, m), 4.97-5.00 (1H, m), 6.75-6.78 (1H, m), 6.80-7.14 (2H, m), 7.59-7.89 (1H, br), 8.35 (1H, s), 10.17 (1H, d, J = 8.0 Hz), 11.39 (1H, brs). MS: 327 (M + H)+. 133 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.17-1.57 (7H, m), 1.87-1.91 (1H, m), 2.27-2.30 (2H, m), 3.90 (1H, m), 6.57-6.58 (1H, m), 6.88-7.15 (1H, brs), 7.11-7.13 (1H, m), 7.60-7.90 (1H, brs), 8.35 (1H, s), 9.57 (1H, d, J = 3.6 Hz), 11.45 (1H, s). MS: 271 (M + H)+ 134 1 1H-NMR (400 MHz, d6-DMSO)δ: 0.12-0.15 (2H, m), 0.40-0.44 (2H, m), 0.89-0.92 (2H, m), 1.49-1.72 (8H, m), 1.81-1.91 (4H, m), 2.10 (1H, s), 2.30 (1H, s), 4.12 (1H, s), 4.21 (1H, d, J = 7.5 Hz), 4.54 (1H, s), 6.53-6.57 (2H, brs), 6.55 (1H, s), 7.24 (1H, m), 7.89 (1H, d, J = 7.7 Hz), 8.72 (1H, s), 11.63 (1H, s). MS: 435 (M + H)+ 135 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.91 (15H, m), 2.10 (1H, s), 2.30 (2H, s), 2.70 (2H, d, J = 5.7 Hz), 3.58-3.63 (1H, m), 3.72-3.77 (1H, m), 3.88-3.91 (1H, m), 4.12 (2H, s), 4.21 (1H, d, J = 7.6 Hz), 4.54 (1H, s), 6.54 (1H, d, J = 1.7 Hz), 7.23-7.24 (1H, m), 7.89 (1H, d, J = 7.6 Hz), 8.72 (1H, s), 11.62 (1H, s). MS: 465 (M + H)+, 487 (M + Na)+ 136 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.24-1.33 (2H, m), 1.48-1.51 (2H, m), 1.64-1.72 (4H, m), 1.79-1.91 (6H, m), 2.10 (1H, s), 2.30 (2H, s), 2.66 (1H, brs), 2.72-2.77 (1H, m), 3.26-3.33 (2H, m), 3.81-3.85 (2H, m), 4.13 (2H, s), 4.21 (1H, d, J = 7.5 Hz), 4.54 (1H, s), 6.54-6.55 (1H, m), 7.23-7.24 (1H, m), 7.90 (1H, d, J = 7.8 Hz), 8.71 (1H, s), 11.63 (1H, s). MS: 465 (M + H)+ 137 1 1H-NMR (400 MHz, d6-DMSO)δ: 0.90 (1H, m), 1.48-1.51 (2H, m), 1.63 (2H, s), 1.69-1.72 (2H, m), 1.82-1.91 (4H, m), 2.10 (1H, s), 2.30 (2H, s), 2.79-2.82 (2H, m), 3.25 (3H, s), 3.41-3.44 (2H, m), 4.11 (2H, s), 4.20 (1H, d, J = 7.5 Hz), 4.54 (1H, s), 6.54 (1H, m), 7.23-7.24 (1H, m), 7.89 (1H, d, J = 7.8 Hz), 8.71 (1H, s), 11.63 (1H, s). MS: 439 (M + H)+, 461 (M + Na)+ 138 1 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.52 (2H, m), 1.63 (2H, s), 1.69-1.72 (2H, m), 1.82-1.92 (4H, m), 2.10 (1H, s), 2.30 (2H, s), 2.70-2.73 (2H, m), 3.49-3.50 (2H, m), 4.12 (2H, s), 4.22 (1H, d, J = 7.5 Hz), 4.55 (2H, s), 6.55 (1H, s), 7.24 (1H, s), 7.89 (2H, d, J = 7.8 Hz), 8.72 (1H, s), 11.63 (1H, s). MS: 425 (M + H)+, 447 (M + Na)+ 139 2 MS: 343 (M + H)+ 140 2 MS: 343 (M + H)+ 141 2 MS: 364 (M + H)+ 142 2 MS: 300 (M + H)+ 143 2 MS: 388 (M + H)+ 144 3 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-2.46 (11H, m), 2.64-2.82 (2H, m), 4.47-4.69 (1H, m), 6.33-6.39 (1H, m), 7.41-7.50 (1H, m), 7.89-7.94 (1H, m), 10.77-10.83 (1H, m), 11.59 (1H, s). MS: 421 (M + H)+ 145 3 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-1.46 (2H, m), 1.58-1.68 (4H, m), 1.72-1.78 (2H, m), 1.83-1.89 (2H, m), 2.04-2.09 (1H, m), 2.29-2.33 (2H, m), 3.99-4.03 (1H, m), 4.52 (1H, brs), 5.74-5.77 (1H, m), 6.26 (1H, d, J = 15.7 Hz), 6.43-6.45 (1H, m), 7.16-7.18 (1H, m), 7.87 (1H, d, J = 15.7 Hz), 8.16 (1H, s), 11.47 (1H, brs), 12.12 (1H, br). MS: 354 (M + H)+ 146 3 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.62 (4H, m), 1.69-1.78 (2H, m), 1.90-1.99 (2H, m), 2.09-2.14 (2H, m), 2.19-2.26 (2H, m), 2.77-2.88 (1H, m), 4.47-4.59 (1H, m), 6.43-6.47 (1H, m), 6.85-7.10 (1H, br), 7.20-7.23 (1H, m), 7.57-7.90 (1H, br), 8.34 (1H, s), 9.45 (1H, d, J = 8.0 Hz), 11.49 (1H, brs), 12.12 (1H, brs). MS: 343 (M + H)+. 147 3 MS: 328 (M + H)+ 148 3 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.55 (2H, m), 1.58-1.75 (4H, m), 1.77-1.93 (4H, m), 2.05-2.13 (1H, m), 2.22-2.29 (2H, m), 4.09-4.16 (1H, m), 4.60 (1H, s), 6.61 (1H, d, J = 3.5 Hz), 7.27 (1H, d, J = 3.5 Hz), 8.63 (1H, s), 11.83-12.00 (1H, m), 12.08 (1H, brs), 13.43 (1H, br). MS: 396 (M + H)+ 149 3 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.50 (2H, m), 1.61-1.71 (4H, m), 1.77-1.86 (4H, m), 2.06-2.10 (1H, m), 2.23-2.27 (2H, m), 4.06-4.11 (1H, m), 4.54 (1H, brs), 6.46-6.50 (1H, m), 7.15-7.18 (1H, m), 8.52 (1H, s), 9.50 (1H, brs), 11.61 (1H, brs), 12.36 (1H, brs). MS: 350 (M + Na)+. 150 3 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.49 (2H, m), 1.65-1.73 (4H, m), 1.78-1.91 (4H, m), 2.05-2.10 (1H, m), 2.16-2.21 (2H, m), 4.18-4.24 (1H, m), 4.54 (1H, brs), 6.47-6.50 (1H, m), 7.20-7.22 (1H, m), 8.54 (1H, s), 9.65 (1H, d, J = 8.0 Hz), 11.76 (1H, brs), 12.69 (1H, brs). MS: 328 (M + H)+. 151 3 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.15 (13H, m), 4.12-4.20 (1H, m), 6.42-6.46 (1H, m), 6.87-7.15 (2H, m), 7.63-7.91 (1H, br), 8.37 (1H, s), 10.14-10.23 (1H, m), 11.45 (1H, brs), 12.13 (1H, brs). MS: 355 (M + H)+. 152 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.50-2.75 (15H, m), 3.21-3.72 (2H, m), 4.48-4.54 (1H, m), 6.33-6.39 (1H, m), 7.43-7.46 (1H, m), 7.75-8.01 (2H, m), 10.76-10.78 (1H, m), 11.58 (1H, s). MS: 405 (M + H)+ 153 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.69-1.77 (2H, m), 1.83-1.92 (4H, m), 2.03-2.12 (3H, m), 2.39-2.48 (2H, m), 2.70-2.75 (2H, m), 3.59 (2H, d, J = 5.6 Hz), 4.49 (1H, s), 6.34-6.36 (1H, m), 6.99 (1H, s), 7.12 (1H, s), 7.42-7.45 (2H, m), 7.90 (1H, s), 10.76 (1H, s), 11.57 (1H, s). MS: 409 (M + H)+ 154 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.50-1.57 (2H, m), 1.83-1.89 (2H, m), 1.95-2.03 (3H, m), 2.20-2.28 (2H, m), 2.38-2.46 (2H, m), 2.63-2.70 (2H, m), 3.63 (2H, d, J = 5.8 Hz), 4.54 (1H, s), 6.39-6.40 (1H, m), 6.95-7.25 (3H, m), 7.45 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.77 (1H, br), 11.57 (1H, s). MS: 409 (M + H)+ 155 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.57-2.73 (13H, m), 3.20-3.28 (3H, m), 4.36-4.39 (2H, m), 4.51-4.59 (1H, m), 6.30-6.38 (1H, m), 7.41-7.46 (1H, m), 7.89-7.90 (1H, m), 10.72-10.87 (1H, m), 11.53-11.61 (1H, m). MS: 405 (M + H)+ 156 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.20-1.56 (2H, m), 1.80-2.16 (7H, m), 2.31-2.45 (2H, m), 2.65-2.78 (2H, m), 3.54-3.60 (2H, m), 4.45-4.54 (1H, m), 6.27-6.37 (1H, m), 7.43-7.46 (1H, m), 7.83-7.94 (2H, m), 10.78 (1H, s), 11.58 (1H, s). MS: 391 (M + H)+ 157 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-2.70 (17H, m), 3.71-3.84 (1H, m), 4.46-4.56 (1H, m), 6.29-6.39 (1H, m), 7.42-7.44 (1H, m), 7.89-7.91 (1H, m), 10.77-10.81 (1H, m), 11.55-11.59 (1H, m). MS: 417 (M + H)+ 158 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-2.87 (13H, m), 4.41-4.72 (1H, m), 6.28-6.42 (1H, m), 7.40-7.48 (1H, m), 7.86-7.93 (1H, m), 8.01-8.11 (1H, m), 8.20-8.32 (1H, m), 10.71-10.82 (1H, m), 11.54-11.63 (1H, m). MS: 420 (M + H)+ 159 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.22 (9H, m), 2.36-2.44 (2H, m), 2.63-2.74 (2H, m), 3.06-3.18 (2H, m), 3.36-3.44 (2H, m), 4.46-4.54 (1H, m), 4.61-4.68 (1H, m), 6.35-6.38 (1H, m), 7.24-7.55 (2H, m), 7.90 (1H, s), 10.74-10.76 (1H, m), 11.57 (1H, s). MS: 396 (M + H)+ 160 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.35-1.99 (9H, m), 1.50-2.45 (11H, m), 2.63-2.74 (2H, m), 2.92-3.14 (4H, m), 4.46-4.53 (1H, m), 6.32-6.39 (1H, m), 6.78-9.86 (1H, m), 7.32-7.60 (2H, m), 7.90 (1H, s), 10.73-10.79 (1H, m), 11.57 (1H, s). MS: 495 (M + H)+ 161 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.59-1.65 (2H, m), 1.85-1.95 (2H, m), 2.05-2.11 (1H, m), 2.13-2.21 (2H, m), 2.35-2.47 (6H, m), 5.16 (1H, d, J = 8.7 Hz), 7.13 (1H, br), 7.91 (1H, br), 8.08 (1H, s), 8.47 (1H, s), 9.98 (1H, d, J = 8.7 Hz), 12.81 (1H, br). MS: 390, 392 (M + H)+ 162 4 MS: 479 (M + H)+ 163 4 MS: 465 (M + H)+ 164 4 MS: 508 (M + H)+ 165 4 MS: 492 (M + H)+ 166 4 MS: 508 (M + H)+ 167 4 MS: 488 (M + H)+ 168 4 MS: 513 (M + H)+ 169 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.78-1.89 (4H, m), 2.04-2.11 (1H, m), 2.22-2.25 (4H, m), 2.30-2.35 (2H, m), 2.51-2.56 (2H, m), 5.05 (1H, d, J = 8.7 Hz), 7.20 (1H, br), 7.95 (1H, br), 8.07 (1H, s), 8.49 (1H, s), 10.17 (1H, d, J = 8.7 Hz), 12.81 (1H, br). MS: 390, 392 (M + H)+ 170 4 MS: 353 (M + H)+ 171 4 MS: 390 (M + H)+ 172 4 MS: 434 (M + H)+ 173 4 MS: 417 (M + H)+ 174 4 MS: 369 (M + H)+ 175 4 MS: 369 (M + H)+ 176 4 MS: 355 (M + H)+ 177 4 MS: 433 (M + H)+ 178 4 MS: 423 (M + H)+ 179 4 MS: 433 (M + H)+ 180 4 MS: 419 (M + H)+ 181 4 MS: 558 (M + Na)+ 182 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-2.34 (12H, m), 3.09 (3H, s), 4.08 (2H, s), 4.44 (1H, s), 4.50 (1H, m), 5.00 (1H, m), 8.04 (1H, s), 9.11 (1H, s), 10.18 (1H, m), 11.11 (1H, m), 12.80 (1H, s). MS: 424 (M + H)+ 183 4 MS: 434 (M + H)+. MS: 432 (M − H)− 184 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.43 (9H, s), 1.68-1.84 (2H, m), 1.84-2.13 (4H, m), 2.13-2.31 (2H, m), 4.04-4.17 (2H, m), 4.30-4.39 (1H, m), 6.44-6.49 (1H, m), 7.01 (1H, br), 7.06-7.12 (1H, m), 7.77 (1H, br), 8.37 (1H, s), 10.24 (1H, d, J = 7.6 Hz), 11.43 (1H, s). MS: 386 (M + H)+ 185 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.76-2.40 (8H, m), 3.95 (1H, d, J = 18.8 Hz), 4.05 (1H, d, J = 18.8 Hz), 4.13-4.24 (1H, m), 4.29-4.41 (1H, m), 4.44-4.55 (1H, m), 6.39-6.47 (1H, m), 7.04 (1H, br), 7.08-7.15 (1H, m), 7.80 (1H, br), 8.38 (1H, s), 10.28 (1H, d, J = 7.6 Hz), 11.46 (1H, s). MS: 353 (M + H)+ 186 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.72-2.52 (8H, m), 3.94-4.09 (1H, m), 4.37-4.48 (1H, m), 4.58-4.73 (1H, m), 6.45-6.51 (1H, m), 7.02 (1H, br), 7.07-7.14 (1H, m), 7.42-7.56 (5H, m), 7.79 (1H, br), 8.37 (1H, s), 10.29 (1H, d, J = 7.7 Hz), 11.45 (1H, s). MS: 390 (M + H)+ 187 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.30-1.50 (11H, m), 1.67-2.22 (6H, m), 4.12 (2H, brs), 5.40-5.55 (1H, m), 7.10 (1H, brs), 7.82 (1H, brs), 8.10 (1H, s), 8.43 (1H, s), 9.28 (1H, d, J = 8.6 Hz), 12.8 (1H, brs). MS: 387 (M + H)+ 188 4 1H-NMR (400 MHz, d6-DMSO)δ: 0.96-2.19 (13H, m), 4.09-4.19 (1H, m), 6.42-6.43 (1H, m), 6.55-6.57 (1H, m), 7.11-7.14 (1H, m), 7.63-7.65 (1H, m), 7.86-7.89 (1H, m), 7.86-7.89 (1H, m), 8.20 (1H, s), 8.37 (1H, d, J = 2.8 Hz), 10.11-10.23 (1H, m), 11.47 (1H, s), 12.16 (1H, s).. MS: 393 (M + H)+ 189 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.42-1.60 (4H, m), 1.70-1.83 (4H, m), 2.05-2.11 (2H, m), 2.19-2.26 (2H, m), 2.76-2.87 (1H, m), 4.54-4.66 (1H, m), 6.53-6.56 (1H, m), 6.71 (1H, brs), 6.88-7.10 (1H, br), 7.19-7.22 (1H, m), 7.35 (1H, brs), 7.60-7.85 (1H, br), 8.34 (1H, s), 9.45 (1H, d, J = 8.0 Hz), 11.46 (1H, brs). MS: 364 (M + Na)+. 190 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.13 (13H, m), 4.10-4.21 (1H, m), 6.43-6.46 (1H, m), 6.73-6.78 (1H, m), 6.92-7.14 (3H, m), 7.61-7.95 (1H, br), 8.37-8.39 (1H, m), 10.11-10.18 (1H, m), 11.46 (1H, brs). MS: 354 (M + H)+ 191 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-1.53 (2H, m), 1.78-1.96 (7H, m), 2.00-2.10 (4H, m), 4.16-4.21 (1H, m), 6.44-6.46 (1H, m), 6.76 (1H, brs), 6.88-7.13 (3H, m), 7.62-7.90 (1H, br), 8.37 (1H, s), 10.17 (1H, d, J = 8.0 Hz), 11.45 (1H, brs). MS: 376 (M + Na)+. 192 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.69-1.98 (11H, m), 2.10-2.15 (2H, m), 4.10-4.15 (1H, m), 6.43-6.46 (1H, m), 6.75 (1H, brs), 6.90-7.09 (2H, m), 7.11-7.15 (1H, m), 7.66-7.93 (1H, br), 8.37 (1H, s), 10.13 (1H, d, J = 8.0 Hz), 11.46 (1H, brs). MS: 354.2 (M + H)+. 193 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-1.86 (10H, m), 2.05 (1H, brs), 2.19 (2H, brs), 4.48 (1H, s), 4.94 (1H, d, J = 8.7 Hz), 7.09 (1H, brs), 7.83 (1H, brs), 8.04 (1H, s), 8.45 (1H, s), 9.97 (1H, d, J = 8.7 Hz), 12.8 (1H, brs). MS: 328 (M + H)+ 194 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-1.89 (10H, m), 2.11 (1H, brs), 2.18 (2H, brs), 3.15 (3H, s), 5.04 (1H, d, J = 8.8 Hz), 7.10 (1H, brs), 7.82 (1H, brs), 8.06 (1H, s), 8.46 (1H, s), 9.98 (1H, d, J = 8.8 Hz), 12.7 (1H, brs). MS: 342 (M + H)+ 195 4 1HNMR (400 MHz, d6-DMSO)δ: 1.40-1.65 (2H, m), 1.80-2.15 (6H, m), 3.90-4.10 (2H, m), 4.20 (1H, brs), 4.55 (1H, brs), 5.45-5.55 (1H, m), 7.18 (1H, brs), 7.81 (1H, brs), 8.11 (1H, s), 8.25 (1H, s), 9.25 (1H, d, J = 9.1 Hz), 12.8 (1H, brs). MS: 376 (M + Na)+ 196 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.2-2.1 (14H, m), 2.73 (1H, s), 2.89 (1H, s), 3.7-4.6 (4H, m), 6.4-6.5 (1H, m), 7.1-7.5 (1H, m), 7.9-8.0 (1H, m), 8.3-8.4 (1H, m), 10.1-10.2 (1H, m), 11.46 (1H, s). MS: 497.2 (M + H)+. 197 4 MS: 385 (M + H)+ 198 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.52-2.23 (13H, m), 3.23-3.34 (3H, m), 4.12-4.47 (3H, m), 6.47-6.58 (1H, m), 6.94-7.14 (2H, m), 7.81 (1H, brs), 8.34-8.47 (1H, m), 10.12-10.27 (1H, m, J = 11.44 Hz), 11.44 (1H, s). MS: 393 (M + H)+. 199 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.56-2.31 (14H, m), 2.77 (3H, d, J = 4.4 Hz), 4.16-4.18 (1H, m), 6.43 (1H, s), 7.14-7.16 (1H, s), 8.31-8.40 (1H, s), 9.96-9.98 (1H, s), 11.48 (1H, s). MS: 350 (M + H)+ 200 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-2.34 (14H, m), 2.74 (3H, d, J = 4.0 Hz), 4.2-4.3 (1H, m), 6.50-6.52 (1H, m), 7.13-7.15 (1H, m), 8.25-8.26 (1H, m), 9.92-9.95 (1H, m), 11.46 (1H, s). MS: 350 (M + H)+ 201 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-1.54 (2H, m), 1.62-1.74 (4H, m), 1.81-1.92 (4H, m), 2.08-2.11 (1H, m), 2.28-2.31 (2H, m), 3.36-3.44 (2H, m), 3.48-3.76 (6H, m), 4.04, 4.12 (2H, s), 4.20-4.24 (1H, m), 4.40, 4.50 (1H, s), 6.58-6.61 (1H, m), 7.27-7.30 (1H, m), 8.65 (1H, s), 8.83-8.86 (1H, m), 11.90 (1H, brs). MS: 531 (M + H)+ 202 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.57-2.20 (8H, m), 2.42 (3H, s), 4.05-4.06 (2H, m), 4.26-4.27 (1H, m), 4.58 (2H, s), 6.66-6.67 (1H, m), 7.31-7.32 (1H, m), 8.43 (1H, d, J = 8.0 Hz), 8.57 (1H, s), 11.88 (1H, brs). MS: 392.2 (M + H)+ 203 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.31-1.50 (4H, m), 1.54-1.72 (8H, m), 1.72-1.89 (4H, m), 2.03-2.11 (1H, m), 2.16-2.25 (2H, m), 2.75-2.87 (4H, m), 3.98-4.06 (1H, m), 4.53 (1H, s), 6.41-6.47 (1H, m), 7.10-7.15 (1H, m), 8.27 (1H, s), 9.09 (1H, brs), 9.52 (1H, d, J = 6.8 Hz), 11.46 (1H, brs). MS: 410 (M + H)+ 204 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.38-1.81 (16H, m), 2.02-2.10 (1H, m), 2.14-2.22 (2H, m), 3.45-3.56 (4H, m), 3.93-4.01 (1H, m), 4.50 (1H, s), 6.44-6.48 (1H, m), 6.97 (1H, d, J = 8.4 Hz), 7.16-7.21 (1H, m), 7.80 (1H, s), 11.46 (1H, brs). MS: 395 (M + H)+ 205 4 1H-NMR (400 MHz, d6-DMSO)δ: 0.93-1.88 (20H, m), 2.01-2.09 (1H, m), 2.12-2.22 (2H, m), 3.85-4.03 (2H, m), 4.48 (1H, s), 4.59 (2H, s), 6.42-6.47 (1H, m), 7.11 (1H, d, J = 8.0 Hz), 7.13-7.18 (1H, m), 7.94 (1H, s), 11.40 (1H, brs). MS: 424 (M + H)+ 206 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.04-1.92 (20H, m), 2.03-2.12 (1H, m), 2.15-2.27 (2H, m), 2.65-2.77 (1H, m), 3.98-4.08 (1H, m), 4.51 (1H, s), 4.90-5.01 (1H, m), 6.40-6.47 (1H, m), 7.10-7.16 (1H, m), 8.27 (1H, s), 9.47 (1H, d, J = 8.1 Hz), 9.66-9.74 (1H, m), 11.47 (1H, s). MS: 424 (M + H)+ 207 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.42-1.49 (2H, m), 1.58-1.72 (4H, m), 1.75-1.88 (4H, m), 1.92 (3H, s), 2.04-2.10 (1H, m), 2.18-2.25 (2H, m), 4.03-4.08 (1H, m), 4.52 (1H, s), 6.44-6.48 (1H, m), 7.14-7.17 (1H, m), 8.42 (1H, s), 9.65 (1H, d, J = 8.0 Hz), 9.76 (1H, s), 9.99 (1H, brs), 11.52 (1H, brs). MS: 384 (M + H)+ 208 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.88-2.47 (8H, m), 2.42 (3H, s), 3.98 (1H, d, J = 18.9 Hz), 4.08 (1H, d, J = 18.9 Hz), 4.20-4.26 (1H, m), 4.48-4.57 (2H, m), 6.56-6.61 (1H, m), 7.23-7.28 (1H, m), 8.58 (1H, s), 9.17 (1H, d, J = 7.6 Hz), 11.83 (1H, s). MS: 392 (M + H)+ 209 4 1H-NMR (400 MHz, d6-DMSO)δ: 1.81-1.94 (4H, m), 2.11 (1H, m), 2.46-2.51 (3H, m), 4.13 (2H, s), 4.39 (1H, s), 4.71 (1H, s), 4.97 (1H, m), 6.26 (1H, s), 7.36-7.44 (1H, m), 7.94 (1H, s), 11.02 (1H, brs), 11.65 (1H, s). MS: 373 (M + Na)+ 210 4 MS: 439 (M + H)+ 211 4 MS: 493 (M + H)+ 212 4 MS: 404 (M + H)+ 213 4 MS: 404 (M + H)+ 214 4 MS: 415 (M + H)+ 215 4 MS: 415 (M + H)+ 216 4 MS: 415 (M + H)+ 217 4 MS: 408 (M + H)+ 218 4 MS: 420 (M + H)+ 219 4 MS: 420 (M + H)+ 220 4 MS: 432 (M + H)+ 221 4 MS: 448 (M + H)+ 222 4 MS: 328 (M + H)+ 223 4 MS: 342 (M + H)+ 224 4 MS: 344 (M + H)+ 225 4 MS: 354 (M + H)+ 226 4 MS: 356 (M + H)+ 227 4 MS: 358 (M + H)+ 228 4 MS: 370 (M + H)+ 229 4 MS: 371 (M + H)+ 230 4 MS: 391 (M + H)+ 231 4 MS: 391 (M + H)+ 232 4 MS: 391 (M + H)+ 233 4 MS: 396 (M + H)+ 234 4 MS: 397 (M + H)+ 235 4 MS: 405 (M + H)+ 236 4 MS: 422 (M + H)+ 237 4 MS: 434 (M + H)+ 238 4 MS: 468 (M + H)+ 239 4 MS: 483 (M + H)+ 240 4 MS: 385 (M + H)+ 241 4 MS: 398 (M + H)+ 242 4 MS: 413 (M + H)+ 243 4 MS: 384 (M + H)+ 244 4 MS: 399 (M + H)+ 245 4 MS: 425 (M + H)+ 246 4 MS: 424 (M + H)+ 247 4 MS: 450 (M + H)+ 248 4 MS: 411 (M + H)+ 249 4 MS: 415 (M + H)+ 250 4 MS: 425 (M + H)+ 251 4 MS: 411 (M + H)+ 252 4 MS: 438 (M + H)+ 253 4 1H-NMR (400 MHz, d6-DMSO)δ: 0.81 (3H, s), 0.91 (3H, s), 0.99 (3H, s), 0.87-1.31 (3H, m), 1.34-1.52 (3H, m), 2.33-2.49 (1H, m), 4.13-4.28 (1H, m), 6.42 (1H, d, J = 2.6 Hz), 6.72-7.94 (3H, m), 8.36 (1H, s), 10.09 (1H, d, J = 8.4 Hz), 11.46 (1H, brs). MS: 313 (M + H)+ 254 4 MS: 440 (M + H)+ 255 4 MS: 398 (M + H)+ 256 4 MS: 435 (M + H)+ 257 4 MS: 435 (M + H)+ 258 4 MS: 435 (M + H)+ 259 4 MS: 442 (M + H)+ 260 4 MS: 407 (M + H)+ 261 4 MS: 403 (M + H)+ 262 4 MS: 410 (M + H)+ 263 4 MS: 411 (M + H)+ 264 4 MS: 447 (M + H)+ 265 4 MS: 432 (M + H)+ 266 4 MS: 447 (M + H)+ 267 4 MS: 432 (M + H)+ 268 7 MS: 469 (M + H)+ 269 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.35 (10H, m), 3.39 (2H, m), 3.76-4.13 (5H, m), 4.23 (1H, m), 4.54 (1H, s), 6.56 (1H, m), 7.26 (1H, m), 7.74 (1H, m), 8.80 (1H, s), 9.41 (1H, m), 11.69 (1H, s). MS: 479 (M + H)+ 270 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.48 (14H, m), 3.41 (2H, m), 4.23 (1H, m), 4.55 (1H, s), 6.57 (1H, m), 7.26 (1H, m), 7.72 (1H, m), 8.78 (1H, s), 9.30 (1H, m), 11.69 (1H, s). MS: 466 (M + H)+ 271 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-2.32 (12H, m), 3.45 (2H, m), 3.85 (2H, m), 4.01 (1H, m), 4.23 (1H, m), 4.56 (1H, s), 4.87 (1H, m), 6.56 (1H, m), 7.26 (1H, m), 7.72 (1H, m), 8.71 (1H, s), 11.71 (1H, s). MS: 479 (M + H)+ 272 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.47 (14H, m), 3.67-3.78 (4H, m), 4.24 (1H, m), 4.56 (1H, s), 6.56 (1H, m), 7.25 (1H, m), 7.71 (1H, m), 8.71 (1H, s), 11.71 (1H, s). MS: 478 (M + H)+ 273 7 MS: 550 (M + H)+ 274 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.38 (13H, m), 3.55 (4H, m), 3.99 (1H, m), 4.23 (1H, m), 4.51 (1H, s), 4.82 (2H, m), 6.60 (1H, m), 7.27 (1H, m), 8.17 (1H, m), 8.65 (1H, m), 8.84 (1H, m), 11.88 (1H, s). MS: 469 (M + H)+ 275 7 MS: 469 (M + H)+ 276 7 MS: 556 (M + H)+ 277 7 MS: 505 (M + Na)+ 278 7 MS: 491 (M + Na)+ 279 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.42 (9H, s), 1.44-2.38 (7H, m), 2.85 (2H, m), 3.89-4.05 (4H, m), 4.22 (1H, m), 4.38 (1H, s), 6.60 (1H, m), 7.27 (1H, m), 8.31 (1H, m), 8.73 (1H, m), 8.89 (1H, m), 11.87 (1H, s). MS: 600 (M + Na)+ 280 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.51 (2H, m), 1.61-1.64 (2H, m), 1.67-1.73 (2H, m), 1.81-1.87 (2H, m), 1.93-1.99 (2H, m), 2.08-2.12 (1H, m), 2.32-2.36 (2H, m), 4.19-4.23 (1H, m), 4.46 (1H, s), 6.60 (1H, d, J = 3.6 Hz), 7.28 (1H, d, J = 3.6 Hz), 8.17-8.21 (2H, m), 8.64 (1H, s), 8.88 (1H, d, J = 7.5 Hz), 11.88 (1H, brs). MS: 395 (M + H)+ 281 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-1.53 (2H, m), 1.62-1.65 (2H, m), 1.67-1.74 (2H, m), 1.81-1.92 (4H, m), 2.08-2.12 (1H, m), 2.28-2.32 (2H, m), 3.06 (3H, s), 3.11 (3H, s), 4.19-4.23 (1H, m), 4.50 (1H, s), 6.59 (1H, d, J = 3.6 Hz), 7.28 (1H, d, J = 3.6 Hz), 8.65 (1H, s), 8.88 (1H, d, J = 7.6 Hz), 11.89 (1H, brs). MS: 423 (M + H)+ 282 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.5-2.2 (14H, m), 2.98 (3H, s), 3.00 (3H, s), 4.11-4.18 (1H, m), 6.44-6.48 (1H, m), 7.11-7.12 (1H, m), 7.39-7.56 (1H, m), 7.70-7.73 (1H, m), 8.31 (1H, s), 8.37-8.38 (1H, m), 10.16-10.18 (1H, m), 11.46 (1H, brs). MS: 382.3 (M + H)+. 283 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.54 (2H, m), 1.61-1.65 (2H, m), 1.68-1.74 (2H, m), 1.82-1.93 (4H, m), 2.08-2.12 (1H, m), 2.29-2.33 (2H, m), 3.56-3.63 (4H, m), 3.68-3.70 (4H, m), 4.20-4.24 (1H, m), 4.52 (1H, s), 6.59 (1H, d, J = 3.6 Hz), 7.29 (1H, d, J = 3.6 Hz), 8.64 (1H, s), 8.84 (1H, d, J = 7.8 Hz), 11.89 (1H, brs). MS: 487 (M + Na)+ 284 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-1.53 (2H, m), 1.62-1.65 (2H, m), 1.68-1.73 (2H, m), 1.81-1.92 (4H, m), 2.08-2.12 (1H, m), 2.28-2.33 (2H, m), 2.68-2.72 (2H, m), 2.75-2.79 (2H, m), 3.40-3.43 (2H, m), 3.59-3.62 (2H, m), 4.19-4.22 (1H, m), 4.51 (1H, brs), 6.57-6.60 (1H, m), 7.27-7.29 (1H, m), 8.64 (1H, s), 8.83-8.86 (1H, m), 11.89 (1H, brs). MS: 464 (M + H)+ 285 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.54 (2H, m), 1.63-1.65 (2H, m), 1.69-1.74 (2H, m), 1.82-1.92 (4H, m), 2.09-2.12 (1H, m), 2.30-2.33 (2H, m), 2.86 (3H, s), 4.22-4.25 (1H, m), 4.55 (1H, brs), 6.57 (1H, d, J = 3.6 Hz), 7.27 (1H, d, J = 3.6 Hz), 7.71-7.74 (1H, m), 8.78 (1H, s), 9.38 (1H, brs), 11.68 (1H, brs). MS: 409 (M + H)+ 286 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.51 (2H, m), 1.61-1.64 (2H, m), 1.67-1.73 (2H, m), 1.81-1.87 (2H, m), 1.93-1.99 (2H, m), 2.08-2.12 (1H, m), 2.32-2.36 (2H, m), 4.19-4.23 (1H, m), 4.46 (1H, s), 6.60 (1H, d, J = 3.6 Hz), 7.28 (1H, d, J = 3.6 Hz), 8.17-8.21 (2H, m), 8.64 (1H, s), 8.88 (1H, d, J = 7.5 Hz), 11.88 (1H, brs). MS: 395 (M + H)+ 287 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.53 (2H, m), 1.63-1.80 (8H, m), 1.82-1.99 (6H, m), 2.09-2.12 (1H, m), 2.17 (3H, s), 2.30-2.33 (2H, m), 2.76-2.81 (2H, m), 3.73-3.79 (1H, m), 4.22-4.25 (1H, m), 4.53 (1H, s), 6.56-6.57 (1H, m), 7.25-7.27 (1H, m), 7.74-7.76 (1H, m), 8.80 (1H, s), 9.33-9.36 (1H, m), 11.68 (1H, brs). MS: 492 (M + H)+ 288 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-1.55 (2H, m), 1.63-1.66 (2H, m), 1.69-1.75 (2H, m), 1.82-1.93 (4H, m), 2.09-2.12 (1H, m), 2.30-2.33 (2H, m), 3.67-3.73 (6H, m), 3.83-3.86 (2H, m), 4.22-4.26 (1H, m), 4.52 (1H, s), 6.55-6.57 (1H, m), 7.24-7.26 (1H, m), 7.70-7.73 (1H, m), 8.72 (1H, s), 11.68 (1H, brs). MS: 465 (M + H)+ 289 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-1.54 (2H, m), 1.63-1.65 (2H, m), 1.69-1.75 (2H, m), 1.82-1.93 (4H, m), 2.09-2.12 (1H, m), 2.30-2.33 (2H, m), 3.10 (3H, s), 3.25 (3H, s), 4.22-4.26 (1H, m), 4.52 (1H, s), 6.55-6.57 (1H, m), 7.24-7.26 (1H, m), 7.71-7.73 (1H, m), 8.72 (1H, s), 11.67 (1H, brs). MS: 423 (M + H)+ 290 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.41-1.42 (9H, m), 1.48-1.57 (4H, m), 1.63-1.74 (4H, m), 1.78-1.92 (6H, m), 2.09-2.12 (1H, m), 2.30-2.32 (2H, m), 2.79-2.90 (1H, m), 3.33-3.39 (2H, m), 3.93-4.02 (2H, m), 4.22-4.26 (1H, m), 4.53 (1H, s), 6.56-6.58 (1H, m), 7.25-7.27 (1H, m), 7.73-7.76 (1H, m), 8.79 (1H, s), 9.37-9.40 (1H, m), 11.68 (1H, brs). MS: 578 (M + H)+ 291 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.54 (2H, m), 1.63-1.65 (2H, m), 1.69-1.74 (2H, m), 1.82-2.00 (6H, m), 2.09-2.12 (1H, m), 2.30-2.33 (2H, m), 3.33-3.62 (2H, m), 3.79-4.01 (2H, m), 4.22-4.25 (1H, m), 4.54, 4.55 (1H, m), 4.72-4.73 (1H, m), 5.00-5.01, 5.55-5.56 (1H, m), 6.55-6.57 (1H, m), 7.25-7.26 (1H, m), 7.71-7.74 (1H, m), 8.73, 8.74 (1H, s), 11.72 (1H, m). MS: 477 (M + H)+ 292 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.52 (2H, m), 1.67-1.75 (4H, m), 1.87-1.93 (4H, m), 2.08-2.12 (1H, m), 2.23-2.26 (2H, m), 2.85 (3H, d, J = 4.7 Hz), 3.17 (1H, s), 4.33-4.37 (1H, m), 6.53-6.55 (1H, m), 7.27-7.29 (1H, m), 7.74-7.77 (1H, m), 8.78 (1H, s), 9.37-9.41 (1H, m), 11.72 (1H, brs). MS: 409 (M + H)+ 293 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.31 (13H, m), 3.28 (3H, s), 3.47-3.52 (4H, m), 4.22-4.23 (1H, m), 4.52 (1H, brs), 6.55-6.57 (1H, m), 7.25-7.26 (1H, m), 7.71-7.73 (1H, m), 8.78 (1H, s), 9.42 (1H, brs), 11.66 (1H, brs). MS: 453 (M + H)+ 294 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.08 (3H, d, J = 6.0 Hz), 1.49-2.32 (13H, m), 3.16-3.27 (2H, m), 3.84-3.86 (1H, m), 4.23-4.24 (1H, m), 4.52 (1H, s), 4.82 (1H, d, J = 4.8 Hz), 6.55-6.57 (1H, m), 7.25-7.27 (1H, m), 7.72-7.74 (1H, m), 8.78 (1H, s), 9.26-9.27 (1H, m), 11.66 (1H, brs).. MS: 453 (M + H)+ 295 7 1H-NMR (400 MHz, d6-DMSO)δ: 1.02-2.31 (18H, m), 3.20-3.24 (4H, m), 3.83-3.84 (2H, m), 4.23-4.24 (1H, m), 4.52 (1H, brs), 6.56-6.57 (1H, m), 7.24-7.26 (1H, m), 7.72-7.74 (1H, m), 8.78 (1H, s), 9.45-9.46 (1H, m), 11.66 (1H, brs). MS: 493 (M + H)+ 296 8 MS: 439 (M + H)+ 297 8 MS: 453 (M + H)+ 298 8 MS: 453 (M + H)+ 299 8 MS: 466 (M + H)+ 300 8 MS: 452 (M + H)+ 301 8 MS: 463 (M + H)+ 302 8 MS: 479 (M + H)+ 303 8 MS: 488 (M + H)+ 304 8 MS: 460 (M + H)+ 305 8 MS: 465 (M + H)+ 306 8 MS: 479 (M + H)+ 307 8 MS: 506 (M + H)+ 308 8 MS: 506 (M + H)+ 309 8 MS: 478 (M + H)+ 310 8 MS: 477 (M + H)+ 311 8 MS: 493 (M + H)+ 312 8 MS: 479 (M + H)+ 313 8 MS: 492 (M + H)+ 314 8 MS: 479 (M + H)+ 315 8 MS: 493 (M + H)+ 316 8 MS: 506 (M + H)+ 317 8 MS: 508 (M + H)+ 318 8 MS: 541 (M + H)+ 319 8 MS: 546 (M + H)+ 320 8 MS: 434 (M + H)+ 321 8 MS: 499 (M + H)+ 322 8 MS: 423 (M + H)+ 323 8 MS: 352 (M + H)+ 324 8 MS: 452 (M + H)+ 325 8 MS: 467 (M + H)+ 326 8 MS: 483 (M + H)+ 327 8 MS: 475 (M + H)+ 328 8 MS: 486 (M + H)+ 329 8 MS: 486 (M + H)+ 330 8 MS: 486 (M + H)+ 331 8 MS: 492 (M + H)+ 332 8 MS: 493 (M + H)+ 333 8 MS: 506 (M + H)+ 334 8 MS: 509 (M + H)+ 335 8 MS: 477 (M + H)+ 336 8 MS: 556 (M + H)+ 337 8 MS: 513 (M + H)+ 338 8 MS: 527 (M + H)+ 339 8 MS: 508 (M + H)+ 340 8 MS: 479 (M + H)+ 341 8 MS: 504 (M + H)+ 342 8 MS: 449 (M + H)+ 343 8 1H-NMR (400 MHz, d6-DMSO)δ: 1.92-2.32 (8H, m), 2.49 (3H, s), 3.58-4.57 (5H, m), 6.76-6.77 (1H, m), 7.39-7.40 (1H, m), 8.69 (1H, s), 8.79-9.05 (3H, m), 12.20 (1H, brs). MS: 325 (M + H)+ 344 10 MS: 542 (M + H)+ 345 10 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-2.39 (9H, m), 2.79 (6H, s), 2.81 (2H, m), 3.57 (2H, m), 3.99 (1H, m), 4.21 (1H, m), 4.40 (1H, s), 6.59 (1H, m), 7.27 (1H, m), 8.64 (1H, s), 8.76 (1H, m), 8.90 (1H, m), 11.89 (1H, s). MS: 571 (M + Na)+ 346 10 MS: 585 (M + H)+ 347 10 MS: 535 (M + H)+ 348 13 1H-NMR (400 MHz, d6-DMSO)δ: 1.30 (3H, t, J = 7.1 Hz), 1.45-1.54 (2H, m), 1.58-1.75 (4H, m), 1.77-1.89 (4H, m), 2.06-2.12 (1H, m), 2.23-2.29 (2H, m), 4.09-4.15 (1H, m), 4.30 (2H, q, J = 7.1 Hz), 4.58 (1H, s), 6.49-9.53 (1H, m), 7.10 (2H, brs), 7.17-7.21 (1H, m), 8.90 (1H, s), 9.33 (1H, d, J = 7.8 Hz), 11.72 (1H, brs). MS: 442 (M + H)+ 349 13 1H-NMR (400 MHz, d6-DMSO)δ: 1.43 (9H, s), 1.71-1.85 (2H, m), 1.80 (3H, s), 1.90-2.09 (4H, m), 2.17-2.32 (2H, m), 4.08-4.17 (2H, m), 4.38-4.46 (1H, m), 6.45 (2H, brs), 6.50-6.56 (1H, m), 7.12-7.17 (1H, m), 8.77 (1H, s), 9.51 (1H, d, J = 7.6 Hz), 11.64 (1H, s). MS: 443 (M + H)+ 350 14 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-1.55 (2H, m), 1.79-1.82 (2H, m), 1.86-1.99 (5H, m), 2.02-3.15 (4H, m), 4.09 (2H, d, J = 5.5 Hz), 4.17-4.23 (1H, m), 6.44-6.47 (1H, m), 7.00 (1H, br), 7.11-7.14 (1H, m), 7.78 (1H, br), 8.28 (1H, t, J = 5.4 Hz), 8.38 (1H, s), 10.18 (1H, d, J = 8.2 Hz), 11.46 (1H, s). MS: 393 (M + H)+ 351 14 1H-NMR (400 MHz, d6-DMSO)δ: 1.71-2.03 (11H, m), 2.13-2.17 (2H, m), 4.06 (2H, d, J = 5.5 Hz), 4.12-4.16 (1H, m), 6.43-6.46 (1H, m), 6.99 (1H, br), 7.11-7.15 (1H, m), 7.77 (1H, br), 8.21 (1H, d, J = 5.5 Hz), 8.37 (1H, s), 10.18 (1H, d), 11.46 (1H, s). MS: 393 (M + H)+ 352 14 1H-NMR (400 MHz, d6-DMSO)δ: 1.37-1.39 (9H, m), 1.43-1.48 (2H, m), 1.68-2.03 (8H, m), 2.05-2.19 (3H, m), 4.04-4.17 (1H, m), 6.36-6.56 (2H, m), 6.87-7.16 (2H, m), 7.76 (1H, br), 8.36-8.38 (1H, m), 10.11-10.15 (1H, m), 11.44 (1H, m). MS: 426 (M + H)+ 353 14 1H-NMR (400 MHz, d6-DMSO)δ: 1.14-2.21 (13H, m), 4.02-4.04 (1H, m), 4.36 (2H, brs), 4.48 (1H, s), 6.43-6.33 (1H, m), 7.12-7.13 (1H, m), 8.28 (1H, s), 9.48 (1H, s), 9.67 (1H, d, J = 8.0 Hz), 11.42 (1H, brs). MS: 342 (M + H)+ 354 14 MS: 366 (M + H)+ 355 14 MS: 418 (M + H)+ 356 14 MS: 418 (M + H)+ 357 14 MS: 418 (M + H)+ 358 14 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.22 (8H, m), 3.70 (3H, s), 4.04 (1H, m), 4.53 (1H, s), 6.45 (1H, m), 7.15 (1H, m), 8.16 (1H, s), 9.41 (1H, s), 11.41 (1H, s), 11.51 (1H, s). MS: 357 (M + H)+ 359 14 MS: 355 (M + H)+, 353 (M − H)− 360 14 1H-NMR (400 MHz, d6-DMSO)δ: 1.09-2.23 (16H, m), 3.28 (2H, m), 4.48 (1H, s), 4.96 (1H, m), 8.05 (1H, s), 8.31 (1H, m), 8.40 (1H, s), 9.73 (1H, m), 12.73 (1H, s). MS: 356 (M + H)+ 361 14 1H-NMR (400 MHz, d6-DMSO)δ: 1.22-2.34 (13H, m), 4.29 (2H, m), 4.51 (1H, s), 5.01 (1H, m), 8.08 (1H, s), 8.43 (1H, s), 8.99 (1H, m), 9.65 (1H, m), 12.86 (1H, s). MS: 367 (M + H)+ 362 14 MS: 377 (M − H)− 363 15 MS: 408 (M + Na)+, 384 (M − H)− 364 16 1H-NMR (400 MHz, d6-DMSO)δ: 0.80-2.84 (13H, m), 4.60-4.69 (1H, m), 7.43-7.47 (1H, m), 7.90-7.92 (1H, m), 8.91-8.94 (1H, m), 10.78-10.85 (1H, m), 11.55-11.65 (1H, m). MS: 402 (M + H)+ 365 16 1H-NMR (400 MHz, d6-DMSO)δ: 1.90-1.97 (4H, m), 2.03-2.12 (5H, m), 2.62-2.67 (2H, m), 2.74-2.79 (2H, m), 4.54 (1H, s), 6.34-6.35 (1H, m), 7.45 (1H, t, J = 3.1 Hz), 7.91 (1H, s), 10.86 (1H, s), 11.61 (1H, s). MS: 334 (M + H)+ 366 17 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-1.83 (10H, m), 2.07 (1H, brs), 2.29 (2H, brs), 4.57 (1H, s), 4.67-4.77 (1H, m), 5.95-6.02 (1H, m), 8.245 (1H, s), 8.249 (1H, s), 13.1 (1H, brs). MS: 332 (M + Na)+ 367 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.52-1.61 (2H, m), 1.72-1.92 (3H, m), 1.99-2.13 (4H, m), 2.22-2.41 (3H, m), 2.64-2.74 (2H, m), 2.80-2.93 (2H, m), 3.26-3.38 (2H, m), 4.57-4.64 (1H, m), 6.52-6.59 (1H, m), 7.58-7.63 (1H, m), 7.82-7.91 (2H, m), 7.96. MS: 395 (M + H)+ 368 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.50-1.59 (2H, m), 1.72-1.99 (6H, m), 2.05-2.17 (2H, m), 2.24-2.36 (2H, m), 4.21-4.30 (1H, m), 6.52-6.66 (1H, m), 7.31-7.39 (1H, m), 7.62 (1H, br), 7.70-7.71 (1H, m), 8.00-8.39 (4H, m), 8.53-8.56 (1H, m), 9.10 (1H, s), 11.08 (1H, br), 12.44 (1H, br), 14.38 (1H, br). MS: 326 (M + H)+ 369 18 MS: 340 (M + H)+ 370 18 MS: 478 (M + H)+ 371 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-1.57 (1H, m), 1.71-1.79 (2H, m), 1.83-1.90 (2H, m), 1.96-2.02 (2H, m), 2.06-2.20 (4H, m), 2.33-2.46 (2H, m), 4.38-4.42 (1H, m), 6.60-6.62, 6.73-6.75 (1H, m), 7.41-7.45 (1H, m), 8.11-8.29 (3H, m), 8.44, 8.56 (1H, brs), 8.80 (1H, s), 9.31-9.34, 9.45-9.50 (1H, m), 12.45 (1H, brs). MS: 394 (M − 3HCl + H)+ 372 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.52-1.57 (2H, m), 1.65-1.75 (4H, m), 1.84-1.92 (6H, m), 1.97-2.02 (2H, m), 2.10-2.14 (1H, m), 2.32-2.36 (2H, m), 2.99-3.09 (2H, m), 3.30-3.36 (2H, m), 4.09-4.16 (1H, m), 4.32-4.35 (1H, m), 6.72-6.75 (1H, m), 7.40-7.42 (1H, m), 8.29-8.41 (1H, m), 8.56-8.65 (1H, m), 8.74-8.79 (1H, m), 8.82 (1H, s), 9.66-9.68 (1H, m), 12.37 (1H, brs). MS: 478 (M − 2HCl + H)+ 373 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.93-2.24 (6H, m), 2.46-2.61 (2H, m), 3.95-4.09 (2H, m), 4.42-4.54 (1H, m), 6.68-6.76 (1H, m), 7.34-7.41 (1H, m), 7.78 (1H, brs), 8.51 (1H, brs), 8.63 (1H, s), 9.11-9.51 (2H, m), 11.25 (1H, d, J = 7.3 Hz), 12.69 (1H, s), 14.76 (1H, br). MS: 286 (M + H − 2HCl)+ 374 18 1H-NMR (400 MHz, d6-DMSO)δ: 2.02-2.20 (4H, m), 2.24-2.36 (2H, m), 2.43-2.61 (2H, m), 2.47 (3H, s), 4.01-4.11 (2H, m), 4.53-4.62 (1H, m), 6.67-6.73 (1H, m), 7.37-7.42 (1H, m), 8.74 (1H, s), 9.00-9.10 (1H, m), 9.18-9.29 (1H, m), 9.45 (1H, d, J = 7.6 Hz), 12.34 (1H, brs). MS: 325 (M + H − 2HCl)+ 375 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.34-2.15 (15H, m), 4.02-4.11 (1H, m), 6.43 (1H, d, J = 2.9 Hz), 6.56 (1H, d, J = 2.9 Hz), 7.11-7.12 (1H, m), 7.63-7.65 (1H, m), 8.37 (1H, s), 10.11 (1H, d, J = 8.0 Hz), 11.43 (1H, brs). MS: 326 (M + H)+. 376 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.38-2.08 (15H, m), 4.09-4.11 (1H, m), 6.39 (1H, d, J = 3.5 Hz), 6.56 (1H, d, J = 3.5 Hz), 7.11-7.12 (1H, m), 7.64-7.65 (1H, m), 8.35 (1H, s), 10.09 (1H, d, J = 8.2 Hz), 11.44 (1H, brs). MS: 326 (M + H)+. 377 18 1H-NMR (400 MHz, d6-DMSO)δ: 1.15-2.51 (15H, m), 4.28-4.33 (1H, m), 6.53-6.59 (1H, m), 6.75-6.79 (1H, m), 7.32-7.34 (1H, m), 8.06-8.12 (3H, m), 8.24-8.25 (1H, m), 12.09-12.14 (1H, m). MS: 308 (M + H)+ 378 19 MS: 286 (M + H)+ 379 19 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.51 (2H, m), 1.63 (1H, brs), 1.68-1.71 (2H, m), 1.80-1.89 (4H, m), 2.09 (1H, brs), 2.25 (1H, brs), 4.10-4.13 (1H, m), 4.56 (1H, m), 4.75 (2H, d, J = 5.6 Hz), 4.87 (1H, t, J = 5.6 Hz), 6.50-6.52 (1H, m), 7.11-7.18 (1H, m), 8.47 (1H, s), 10.50 (1H, d, J = 8.0 Hz), 11.77 (1H, brs). MS: 342 (M + H)+ 380 19 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.19 (13H, m), 4.21-4.23 (1H, m), 4.51 (1H, s), 4.74-4.76 (2H, d, J = 6.0 Hz), 4.83 (1H, t, J = 6.9 Hz), 6.46-6.48 (1H, m), 7.17-7.19 (1H, m), 8.47 (1H, s), 10.46 (1H, d, J = 8.0 Hz), 11.74 (1H, s). MS: 342 (M + H)+ 381 19 1H-NMR (400 MHz, d6-DMSO)δ: 1.23-2.32 (13H, m), 3.00-3.07 (2H, m), 4.21 (1H, brs), 4.43 (1H, brs), 4.75 (2H, brs), 6.46-6.49 (1H, m), 6.55 (1H, s), 7.16-7.17 (1H, m), 8.46 (1H, s), 10.54 (1H, d, J = 8.0 Hz), 11.75 (1H, brs). MS: 356 (M + H)+ 382 22 MS: 391 (M + H)+ 383 22 1H-NMR (400 MHz, d6-DMSO)δ: 1.77-1.87 (2H, m), 1.92-2.08 (6H, m), 2.10-2.15 (1H, m), 2.65-2.73 (4H, m), 3.21 (3H, s), 4.36 (2H, s), 4.51 (1H, s), 6.35-6.38 (1H, m), 7.45 (1H, t, J = 2.9 Hz), 7.91 (1H, s), 10.84 (1H, s), 11.60 (1H, s). MS: 405 (M + H)+ 384 22 1H-NMR (400 MHz, d6-DMSO)δ: 1.59-1.67 (2H, m), 1.82-2.07 (3H, m), 2.16-2.30 (4H, m), 2.35-2.43 (2H, m), 2.69-2.73 (2H, m), 3.28 (3H, s), 4.39 (2H, s), 4.59 (1H, s), 6.31-6.35 (1H, m), 7.43 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.77 (1H, br), 11.56 (1H, s). MS: 406 (M + H)+ 385 22 MS: 340 (M + H)+ 386 22 MS: 340 (M + H)+ 387 22 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-1.53 (4H, m), 1.58-1.64 (2H, m), 1.70-1.75 (2H, m), 1.93-1.96 (1H, m), 2.05-2.11 (2H, m), 2.16-2.20 (2H, m), 3.06-3.08 (2H, m), 4.27-4.30 (1H, m), 4.41-4.45 (1H, m), 6.52-6.54 (1H, m), 7.26-7.28 (1H, m), 8.11-8.12 (1H, m), 8.29-8.31 (1H, m), 8.63 (1H, s), 9.03-9.06 (1H, m), 11.86 (1H, brs). MS: 409 (M + H)+ 388 22 1H-NMR (400 MHz, d6-DMSO)δ: 1.31-1.35 (2H, m), 1.47-1.49 (2H, m), 1.75-1.80 (2H, m), 1.85-2.00 (5H, m), 2.16-2.19 (2H, m), 3.01-3.03 (2H, m), 4.33-4.41 (2H, m), 6.61-6.63 (1H, m), 7.27-7.28 (1H, m), 8.14-8.16 (1H, m), 8.19-8.20 (1H, m), 8.63 (1H, s), 8.92-8.95 (1H, m), 11.87 (1H, brs). MS: 409 (M + H)+ 389 22 1H-NMR (400 MHz, d6-DMSO)δ: 1.41-1.46 (2H, m), 1.69-1.79 (4H, m), 1.96-2.08 (3H, m), 2.31-2.37 (2H, m), 2.67-2.70 (2H, m), 4.48 (1H, s), 4.57 (1H, s), 6.3 (1H, d, J = 3.4 Hz), 7.45-7.45 (1H, m), 7.89 (1H, s), 10.75 (1H, s), 11.57 (1H, s). MS: 325 (M + H)+ 390 22 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.49 (2H, m), 1.63-1.79 (4H, m), 1.92-1.98 (2H, m), 2.14-2.34 (3H, m), 2.78-2.81 (1H, m), 4.37 (1H, s), 4.39 (1H, s), 6.33-6.35 (1H, m), 6.55 (1H, s), 7.43 (1H, t, J = 2.9 Hz), 7.89 (1H, s), 10.75 (1H, s), 11.56 (1H, s). MS: 325 (M + H)+ 391 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.57-1.63 (2H, m), 1.75-2.11 (8H, m), 2.44-2.59 (4H, m), 4.55 (1H, s), 6.34 (1H, dd, J = 1.4 Hz, 3.3 Hz), 7.43 (1H, t, J = 2.9 Hz), 7.89 (1H, s), 10.74 (1H, s), 11.56 (1H, s). MS: 309 (M + H)+ 392 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.42-3.57 (13H, m), 4.37-4.61 (2H, m), 3.29-3.36 (1H, m), 7.42-7.46 (1H, m), 7.90 (1H, s), 10.75-10.77 (1H, m), 11.56 (1H, s). MS: 325 (M + H)+ 393 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.54-1.68 (12H, m), 1.86-1.91 (3H, m), 3.71 (2H, s), 6.65 (1H, dd, J = 1.8 Hz, 3.5 Hz), 7.39 (1H, t, J = 3.1 Hz), 7.91 (1H, s), 10.86 (1H, s), 11.52 (1H, s). MS: 323 (M + H)+ 394 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-1.59 (2H, m), 2.03-2.14 (5H, m), 2.33-2.52 (4H, m), 2.63-2.68 (2H, m), 3.90 (1H, s), 4.76 (1H, d, J = 3.1 Hz), 6.64-6.65 (1H, m), 7.47 (1H, t, J = 3.1 Hz), 7.90 (1H, s), 10.78 (1H, s), 11.61 (1H, s. MS: 325 (M + H)+ 395 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.56-1.79 (5H, m), 2.31-2.55 (9H, m), 4.75 (1H, s), 6.61 (1H, s), 7.48 (1H, t, J = 3.1 Hz), 7.91 (1H, s), 10.78 (1H, s), 11.61 (1H, s). MS: 325 (M + H)+ 396 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.51-1.60 (2H, m), 1.71-1.84 (4H, m), 1.95-2.02 (2H, m), 2.20-2.25 (1H, m), 2.39-2.45 (2H, m), 2.79-2.84 (2H, m), 3.11 (3H, s), 4.42 (1H, s), 6.35-6.38 (1H, m), 7.44 (1H, t, J = 3.1 Hz), 7.90 (1H, s), 10.76 (1H, s), 11.57 (1H, s). MS: 338 (M + H)+ 397 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.50 (2H, m), 1.74-1.77 (2H, m), 1.83-1.88 (2H, m), 2.02-2.15 (3H, m), 2.72-2.37 (2H, m), 2.75-2.79 (2H, m), 3.19 (3H, s), 4.50 (1H, s), 6.34 (1H, dd, J = 1.7 Hz, 3.6 Hz), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.77 (1H, s), 11.56 (1H, s). MS: 339 (M + H)+ 398 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.53-1.60 (2H, m), 1.85-1.92 (2H, m), 1.97-2.09 (3H, m), 2.18-2.26 (2H, m), 2.38-2.45 (2H, m), 2.65-2.71 (2H, m), 3.64 (3H, s), 4.54 (1H, s), 6.30-6.31 (1H, m), 7.43 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.78 (1H, s), 11.57 (1H, s). MS: 367 (M + H)+ 399 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.17 (3H, t, J = 7.1 Hz), 1.69-1.93 (6H, m), 2.03-2.11 (2H, m), 2.37-2.47 (2H, m), 2.71-2.75 (2H, m), 3.73 (2H, d, J = 5.8 Hz), 4.06 (2H, q, J = 7.1 Hz), 4.49 (1H, s), 6.34-6.36 (1H, m), 7.44 (1H, t, J = 3.0 Hz), 7.81 (1H, t, J = 5.8 Hz), 7.90 (1H, s), 10.75 (1H, s), 11.57 (1H, s). MS: 438 (M + H)+ 400 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.2 (3H, t, J = 7.1 Hz), 1.50-1.58 (2H, m), 1.84-1.88 (2H, m), 1.95-2.03 (3H, m), 2.18-2.26 (2H, m), 2.38-2.46 (2H, m), 2.63-2.70 (2H, m), 3.8 (2H, d, J = 5.8 Hz), 4.09 (2H, q, J = 7.1 Hz), 4.55 (1H, s), 6.36-6.38 (1H, m), 7.45 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 8.07 (1H, t, J = 6.1 Hz), 10.78 (1H, s), 11.58 (1H, s). MS: 438 (M + H)+ 401 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.67-1.73 (2H, m), 1.78-1.82 (2H, m), 1.84-1.91 (2H, m), 2.00-2.10 (3H, m), 2.37-2.44 (2H, m), 2.68-2.72 (2H, m), 4.48 (1H, s), 6.34-6.35 (1H, m), 6.70 (1H, s), 6.91 (1H, s), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.75 (1H, s), 11.56 (1H, s). MS: 352 (M + H)+ 402 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.55 (2H, m), 1.81-1.85 (2H, m), 1.93-2.00 (3H, m), 2.16-2.21 (2H, m), 2.38-2.45 (2H, m), 2.61-2.66 (2H, m), 4.53 (1H, s), 6.38-6.39 (1H, m), 6.80 (1H, s), 7.15 (1H, s), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.76 (1H, s), 11.56 (1H, s). MS: 352 (M + H)+ 403 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.35-1.40 (9H, m), 1.45-2.13 (7H, m), 2.25-2.40 (4H, m), 2.64-2.77 (2H, m), 4.41-4.49 (1H, m), 6.27-6..34 (1H, m), 6.39-6.58 (1H, m), 7.42-7.47 (1H, m), 7.89 (1H, s), 10.75-10.76 (1H, m), 11.54-11.59 (1H, m). MS: 424 (M + H)+ 404 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.57-1.63 (2H, m), 1.74-1.85 (4H, m), 1.95-2.02 (2H, m), 2.21-2.26 (1H, m), 2.42-2.48 (2H, m), 2.65 (2H, t, J = 6.0 Hz), 2.79-2.83 (2H, m), 3.55 (2H, t, J = 6.0 Hz), 4.44 (1H, s), 6.38-6.40 (1H, m), 7.46 (1H, t, J = 3.0 Hz), 7.92 (1H, s), 10.83 (1H, s), 11.65 (1H, s). MS: 378 (M + H)+ 405 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.52 (2H, m), 1.75-1.81 (2H, m), 1.86-1.92 (2H, m), 2.08-2.17 (3H, m), 2.31-2.37 (2H, m), 2.71 (2H, t, J = 6.0 Hz), 2.75-2.79 (2H, m), 3.65 (2H, t, J = 6.0 Hz), 4.53 (1H, s), 6.38 (1H, s), 7.45 (1H, t, J = 3.0 Hz), 7.91 (1H, s), 10.82 (1H, s), 11.62 (1H, s). MS: 378 (M + H)+ 406 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.58-1.67 (2H, m), 2.06-2.11 (1H, m), 2.30-2.59 (6H, m), 2.66-2.78 (4H, m), 4.68 (1H, s), 6.34-6.36 (1H, m), 7.44 (1H, t, J = 3.1 Hz), 7.90 (1H, s), 10.79 (1H, s), 11.58 (1H, s). MS: 387, 389 (M + H)+ 407 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.59-1.69 (2H, m), 2.07-2.14 (1H, m), 2.36-2.47 (6H, m), 2.65-2.72 (2H, m), 2.86-2.92 (2H, m), 4.98 (1H, s), 7.99 (1H, s), 8.35 (1H, s), 10.98 (1H, s), 13.00 (1H, s). MS: 388, 390 (M + H)+ 408 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.17-2.47 (9H, m), 2.93-3.00 (1H, m), 4.36-4.42 (1H, m), 6.54-6.57 (1H, m), 7.42-7.44 (1H, m), 7.88 (1H, s), 10.77 (1H, brs), 11.58 (1H, brs). MS: 269 (M + H)+ 409 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.20-1.86 (7H, m), 2.32-2.42 (1H, m), 3.05-3.17 (1H, m), 4.71-4.84 (1H, m), 6.49-6.55 (1H, m), 6.91 (1H, s), 7.40-7.46 (1H, m), 7.90 (1H, s), 10.77 (1H, brs), 11.56 (1H, brs). MS: 269 (M + H)+ 410 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.01 (3H, d, J = 7.2 Hz), 1.24 (3H, s), 1.30 (3H, s), 1.88-2.09 (3H, m), 2.29-2.52 (4H, m), 4.81-4.92 (1H, m), 6.44-6.49 (1H, m), 7.43-7.47 (1H, m), 7.92 (1H, s), 10.92 (1H, brs), 11.64 (1H, brs). MS: 311 (M + H)+ 411 23 1H-NMR (400 MHz, d6-DMSO)δ: 0.78 (3H, s), 0.91 (3H, s), 1.14 (3H, s), 1.21-1.31 (1H, m), 1.63-1.73 (1H, m), 1.80-1.88 (2H, m), 1.97-2.11 (2H, m), 2.75 (1H, dd, J = 5.3, 12.5 Hz), 4.80 (1H, ddd, J = 2.4, 5.3, 12.0 Hz), 6.45 (1H, dd, J = 1.7, 3.6 Hz), 7.40-7.43 (1H, m), 7.91 (1H, s), 10.89 (1H, brs), 11.58 (1H, brs). MS: 311 (M + H)+ 412 23 1H-NMR (400 MHz, d6-DMSO)δ: 1.15-3.14 (13H, m), 4.41-4.60 (1H, m), 6.35-6.40 (1H, m), 7.43-7.47 (1H, m), 7.90-7.92 (1H, m), 10.80-10.87 (1H, m), 11.62 (1H, brs). MS: 327 (M + H)+ 413 24 MS: 330 (M + H)+ 414 24 1H-NMR (400 MHz, d6-DMSO)δ: 1.46 (2H, d, J = 12.3 Hz), 1.63 (2H, s), 1.72 (2H, d, J = 12.1 Hz), 1.92 (2H, d, J = 12.1 Hz), 1.99 (1H, s), 2.39 (2H, d, J = 12.3 Hz), 2.96 (2H, s), 4.34 (1H, s), 4.67 (1H, s), 7.97 (1H, s), 8.31 (1H, s), 10.9 (1H, s), 13.0 (1H, s). MS: 348 (M + Na)+ 415 24 1H-NMR (400 MHz, d6-DMSO)δ: 1.42 (2H, d, J = 12.5 Hz), 1.68 (2H, s), 1.72 (2H, d, J = 12.0 Hz), 2.00 (2H, d, J = 12.0 Hz), 2.08 (1H, s), 2.39 (2H, d, J = 12.5 Hz), 2.79 (2H, s), 4.49 (1H, s), 4.88 (1H, s), 7.97 (1H, s), 8.32 (1H, s), 10.9 (1H, brs), 13.0 (1H, brs). MS: 348 (M + Na)+ 416 25 1HNMR (400 MHz, d6-DMSO)δ: 1.38-2.18 (11H, m), 3.33-3.40 (1H, m), 4.47 (1H, s), 4.92-5.05 (1H, m), 7.05 (1H, br), 7.82 (1H, br), 8.05 (1H, s), 8.45 (1H, s), 9.97 (1H, d, J = 9.2 Hz), 11.5 (1H, s), 12.8 (1H, br). MS: 328 (M + H)+ 417 25 1HNMR (400 MHz, d6-DMSO)δ: 1.32 (3H, t, J = 7.1 Hz), 1.56 (2H, t, J = 10.7 Hz), 1.80-1.83 (2H, m), 1.92-2.08 (4H, m), 3.20 (2H, brs), 3.57 (2H, s), 4.28 (2H, q, J = 7.1 Hz), 5.30-5.45 (1H, brs), 7.20-7.24 (1H, m), 7.32 (2H, dd, J = 7.2, 7.8 Hz), 7.39 (2H, d, J = 7.2 Hz), 8.14 (1H, s), 8.48 (1H, d, J = 8.8 Hz), 8.60 (1H, s), 13.0 (1H, brs). MS: 406 (M + H)+ 418 25 1HNMR (400 MHz, d6-DMSO)δ: 1.11 (6H, t, J = 6.8 Hz), 1.50-2.31 (13H, m), 3.46-3.68 (4H, m), 4.11-4.12 (1H, m), 4.57 (1H, s), 6.65-6.66 (1H, m), 6.74 (1H, s), 7.38-7.39 (1H, m), 8.54 (1H, s), 8.88 (1H, d, J = 8.0 Hz), 9.30 (1H, s). MS: 454 (M + H)+ 419 26 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-1.52 (2H, m), 1.64-1.66 (2H, m), 1.78-1.84 (2H, m), 2.01-2.06 (2H, m), 2.18-2.27 (3H, m), 3.10-3.12 (2H, m), 4.40 (1H, s), 4.76 (1H, br), 6.53-6.55 (1H, m), 7.61-7.63 (1H, m), 8.56-8.59 (1H, s), 12.09 (1H, brs), 13.14 (1H, brs). MS: 442 (M + Na)+ 420 26 1H-NMR (400 MHz, d6-DMSO)δ: 1.39 (3H, t, J = 7.1 Hz), 1.48-1.53 (2H, m), 1.62-1.65 (2H, m), 1.69-1.74 (2H, m), 1.81-1.93 (4H, m), 2.09-2.12 (1H, m), 2.29-2.33 (2H, m), 4.22-4.26 (1H, m), 4.47 (2H, q, J = 7.1 Hz), 4.54 (1H, brs), 6.56-6.58 (1H, m), 7.26-7.27 (1H, m), 7.80-7.83 (1H, m), 8.71 (1H, s), 11.71 (1H, brs). MS: 424 (M + H)+ 421 26 1H-NMR (400 MHz, d6-DMSO)δ: 1.48-2.31 (13H, m), 4.24 (1H, m), 4.52 (1H, s), 6.55 (1H, m), 7.23 (1H, m), 7.86 (1H, m), 8.75 (1H, s), 9.67 (1H, s), 11.63 (1H, s). MS: 352 (M + H)+ 422 26 1HNMR (400 MHz, d6-DMSO)δ: 1.34 (3H, t, J = 7.1 Hz), 1.45-1.84 (10H, m), 2.06 (1H, brs), 2.22 (2H, brs), 4.31 (2H, q, J = 7.1 Hz), 4.53 (1H, s), 5.04 (1H, d, J = 8.7 Hz), 8.12 (1H, s), 8.64 (1H, s), 9.16 (1H, d, J = 8.7 Hz), 12.8 (1H, brs). MS: 357 (M + H)+ 423 26 1HNMR (400 MHz, d6-DMSO)δ: 1.32 (3H, t, J = 7.1 Hz), 1.42-1.90 (10H, m), 2.15 (1H, brs), 2.22 (2H, brs), 3.15 (3H, s), 4.31 (2H, q, J = 7.1 Hz), 5.12 (1H, d, J = 8.7 Hz), 8.14 (1H, s), 8.64 (1H, s), 9.14 (1H, d, J = 8.7 Hz), 13.0 (1H, brs). MS: 371 (M + H)+ 424 26 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-1.67 (10H, m), 1.88-1.94 (1H, m), 2.02 (2H, brs), 3..03 (2H, d, J = 5.5 Hz), 4.37 (1H, t, J = 5.5 Hz), 5.05 (1H, d, J = 8.9 Hz), 7.04 (1H, brs), 7.82 (1H, brs), 8.03 (1H, s), 8.45 (1H, s), 10.0 (1H, d, J = 8..9 Hz), 12.7 (1H, brs). MS: 342 (M + H)+ 425 26 1H-NMR (400 MHz, d6-DMSO)δ: 1.22-1.84 (10H, m), 1.94 (1H, brs), 2.06 (2H, brs), 2.98 (2H, d, J = 5.7 Hz), 4.36 (1H, t, J = 5.7 Hz), 5.06 (1H, d, J = 8.7 Hz), 7.10 (1H, brs), 7.82 (1H, brs), 8.04 (1H, s), 8.45 (1H, s), 10.0 (1H, d, J = 8.7 Hz), 12.7 (1H, brs). MS: 342 (M + H)+ 426 26 MS: 337 (M + H)+ 427 27 1H-NMR (400 MHz, d6-DMSO)δ: 1.36-1.41 (2H, m), 1.64-1.70 (4H, m), 1.80-1.93 (4H, m), 2.04-2.07 (1H, m), 2.11-2.14 (2H, m), 4.13-4.16 (1H, m), 4.44 (1H, s), 5.82 (2H, brs), 6.37-6.38 (1H, m), 7.09-7.11 (1H, m), 8.13 (1H, s), 8.97 (1H, d, J = 8.2 Hz), 9.54 (1H, s), 11.23 (1H, brs). MS: 342 (M + H)+ 428 28 1H-NMR (400 MHz, d6-DMSO)δ: 1.39 (3H, t, J = 7.2 Hz), 1.46-1.54 (2H, m), 1.58-1.77 (4H, m), 1.80-1.90 (2H, m), 1.97-2.14 (3H, m), 2.28-2.35 (2H, m), 4.18-4.25 (1H, m), 4.42 (1H, s), 4.43 (2H, q, J = 7.2 Hz), 6.60 (1H, d, J = 3.5 Hz), 7.29 (1H, d, J = 3.5 Hz), 8.65 (1H, s), 9.04 (1H, d, J = 7.7 Hz), 11.91 (1H, brs). MS: 424 (M + H)+ 429 28 1H-NMR (400 MHz, d6-DMSO)δ: 1.30-1.36 (3H, m), 1.63-1.72 (2H, m), 1.93-2.04 (2H, m), 2.07-2.49 (6H, m), 2.75-2.84 (3H, m), 4.37-4.45 (2H, m), 4.61-4.68 (1H, m), 6.36-6.41 (1H, m), 7.43-7.47 (1H, m), 7.91 (1H, s), 10.82 (1H, s), 11.58-11.61 (1H, m). MS: 449 (M + H)+ 430 28 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.29 (13H, m), 3.42 (3H, s), 4.21-4.22 (1H, m), 4.46 (1H, s), 4.65 (2H, s), 6.58-6.59 (1H, m), 7.26-7.27 (1H, m), 8.60 (1H, s), 9.04 (1H, d, J = 8.0 Hz), 11.84 (1H, s). MS: 396.3 (M + H)+ 431 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.39 (20H, m), 2.60 (1H, s), 2.69 (1H, m), 3.22 (3H, s), 3.69 (1H, m), 4.44 (1H, m), 4.77 (1H, s), 6.64 (1H, m), 7.45 (1H, m), 8.74 (1H, m), 8.78 (1H, m), 10.83 (1H, s), 12.05 (1H, s). MS: 507 (M + H)+ 432 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.67 (18H, m), 3.12 (2H, m), 4.02 (2H, m), 4.44 (1H, m), 4.77 (1H, s), 6.66 (1H, m), 7.46 (1H, m), 8.73 (1H, s), 9.21 (1H, m), 10.94 (1H, m), 12.07 (1H, m). MS: 549 (M + Na)+ 433 32 MS: 543 (M + Na)+ 434 32 MS: 505 (M − H)− 435 32 MS: 467 (M + H)+ 436 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.69 (21H, m), 3.89 (1H, m), 4.42 (1H, m), 4.76 (1H, s), 6.65 (1H, m), 7.45 (1H, m), 8.74 (1H, s), 9.02 (1H, m), 10.88 (1H, s), 12.05 (1H, s). MS: 513 (M + H)+ 437 32 1H-NMR (400 MHz, d6-DMSO)δ: 0.85-2.61 (21H, m), 3.63-3.79 (2H, m), 4.35 (1H, m), 4.44 (1H, m), 4.76 (1H, s), 6.65 (1H, m), 7.46 (1H, m), 8.72 (1H, s), 8.74 (1H, s), 10.86 (1H, s), 12.07 (1H, s). MS: 493 (M + H)+ 438 32 MS: 464 (M + H)+ 439 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.50 (2H, m), 1.65-1.68 (2H, m), 1.77-2.04 (6H, m), 2.17-2.21 (1H, m), 2.33-2.40 (2H, m), 2.59-2.64 (2H, m), 3.35-3.48 (1H, m), 3.77-3.88 (3H, m), 4.46-4.48 (1H, m), 4.67-4.69 (1H, m), 4.75-4.77 (1H, m), 4.89, 5.18 (1H, m), 6.64-6.65 (1H, m), 7.44-7.46 (1H, m), 8.74, 8.78 (1H, m), 11.03-11.19 (1H, m), 12.10 (1H, brs). MS: 499 (M + N)+ 440 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.44-1.49 (2H, m), 1.65-1.68 (2H, m), 1.77-1.83 (2H, m), 1.99-2.05 (2H, m), 2.17-2.21 (1H, m), 2.35-2.40 (2H, m), 2.58-2.62 (2H, m), 4.45 (1H, s), 4.75-4.77 (1H, m), 6.65-6.67 (1H, m), 7.45-7.47 (1H, m), 8.03 (1H, brs), 8.39 (1H, brs), 8.74 (1H, s), 10.82 (1H, brs), 12.08 (1H, brs). MS: 417 (M + Na)+ 441 32 1H-NMR (400 MHz, d6-DMSO)δ: 0.77-3.54 (22H, m), 4.84 (1H, brs), 6.82-6.86 (1H, m), 7.49-7.53 (1H, m), 8.64 (1H, s), 8.87-8.93 (1H, m), 12.12 (1H, brs). MS: 453 (M + H)+ 442 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-1.44 (2H, m), 1.71-1.73 (2H, m), 1.78-1.83 (2H, m), 2.04-2.09 (2H, m), 2.11-2.15 (1H, m), 2.38-2.44 (2H, m), 2.49-2.51 (2H, m), 4.56 (1H, s), 4.88-4.89 (1H, m), 6.60-6..62 (1H, m), 7.45-7.47 (1H, m), 8.01 (1H, brs), 8.36 (1H, brs), 8.74 (1H, s), 10.85-10.90 (1H, m), 12.07 (1H, brs). MS: 417 (M + Na)+ 443 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.39 (13H, m), 3.16 (2H, d, J = 5.2 Hz), 3.50 (2H, q, J = 5.6 Hz), 4.07 (1H, q, J = 5.6 Hz), 4.76 (1H, brs), 4.78 (1H, t, J = 5.2 Hz), 6.65-6.66 (1H, m), 7.45-7.47 (1H, m), 8.71 (1H, s), 8.88-8.90 (1H, m), 10.89 (1H, s), 12.07 (1H, brs). MS: 439 (M + H)+ 444 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.37 (13H, m), 2.94 (3H, s), 3.12 (3H, s), 4.46-4.47 (1H, m), 4.75 (1H, brs), 6.63-6.64 (1H, m), 7.45-7.46 (1H, m), 8.78 (1H, s), 11.36 (1H, s), 12.16 (1H, s). MS: 423.3 (M + H)+ 445 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.15-2.45 (13H, m), 2.49-2.51 (6H, m), 4.21 (4H, brs), 4.76 (1H, brs), 6.55-6.55 (1H, m), 7.45-7.46 (1H, m), 8.56 (1H, s), 8.72 (1H, s), 8.83-8.87 (1H, m), 11.44 (1H, s), 12.07 (1H, brs). MS: 466.3 (M + H)+ 446 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.39 (11H, m), 2.49-2.45 (m, 3H), 2.60 (2H, brs), 3.16-3.20 (2H, m), 3.81-3.82 (1H, m), 4.45 (1H, s), 4.76 (1H, brs), 4.85 (1H, d, J = 4.8 Hz), 6.65-6.67 (1H, m), 7.45-7.46 (1H, m), 8.72 (1H, s), 8.82-8.82 (1H, m), 10.90 (1H, s), 12.07 (1H, brs). MS: 453 (M + Na)+ 447 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.04-2.38 (17H, m), 3.46-3.70 (5H, m), 4.35-4.36 (1H, m), 4.45 (1H, q), 4.57-4.59 (1H, m), 4.76 (1H, brs), 6.65-6.66 (1H, m), 7.45-7.46 (1H, m), 8.72 (1H, s), 8.82 (1H, d, J = 8.0 Hz), 10.88 (1H, s), 12.06 (1H, brs). MS: 515 (M + H)+ 448 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.60 (17H, m), 3.45-4.00 (6H, m), 4.47 (1H, s), 4.76 (1H, brs), 6.56-6.57 (1H, m), 7.45-7.46 (1H, m), 8.71 (1H, s), 10.93 (1H, brs), 12.07 (1H, brs). MS477 (M − H)− 449 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.39 (17H, m), 3.43-3.99 (5H, m), 4.34-4.54 (1H, m), 4.76 (1H, brs), 6.65-6.66 (1H, m), 7.45-7.46 (1H, m), 8.73 (1H, s), 9.02 (1H, d, J = 8.0 Hz), 10.91 (1H, brs), 12.07 (1H, brs). MS: 477 (M − H)− 450 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.56-1.59 (2H, m), 2.03-2.08 (3H, m), 2.22-2.25 (2H, m), 2.46-2.57 (6H, m), 3.28 (3H, s), 3.39-3.40 (2H, m), 3.48-3.49 (2H, m), 5.04 (1H, s), 6.78 (1H, s), 7.46 (1H, s), 8.73 (1H, s), 8.95 (1H, m), 10.99 (1H, s), 12.05 (1H, s). MS: 462 (M + H)+, 484 (M + Na)+ 451 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.36-2.37 (17H, m), 3.43-3.60 (7H, m), 4.48 (1H, brs), 4.75 (1H, brs), 6.64 (1H, brs), 7.45 (1h, brs), 8.81-8.83 (1H, m), 11.45 (1H, brs), 12.11 (1H, brs). MS: 506 (M + H)+ 452 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.39 (18H, m), 3.42-4.01 (6H, m), 4.47 (1H, s), 4.76 (1H, brs), 6.56-6.57 (1H, m), 7.45-7.46 (1H, m), 8.71 (1H, s), 8.95-8.96 (1H, m), 10.93 (1H, brs), 12.07 (1H, brs). MS: 515 (M + Na)+ 453 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.56 (2H, m), 1.75-1.77 (1H, m), 1.88-1.95 (4H, m), 2.04-2.12 (4H, m), 2.29-2.33 (2H, m), 3.28 (3H, s), 3.38-3.42 (2H, m), 3.47-3.49 (2H, m), 3.59 and 3.65 (total 3H, eachs), 4.90 and 4.96 (total 1H, eachs), 6.66-6.77 (1H, m), 7.44-7.47 (1H, m), 8.71 and 8.72 (total 1H, eachs), 8.97 (1H, m), 11.00 (1H, s), 12.07 (1H, s). MS: 517 (M + Na)+ 454 32 1H-NMR (400 MHz, d6-DMSO)δ: 52-1.55 (3H, m), 1.74-1.84 (5H, m), 2.04-2.07 (2H, m), 2.25 (1H, s), 2.64 (2H, s), 3.13 (3H, s), 3.28 (3H, s), 3.39-3.42 (2H, m), 3.47-3.50 (2H, m), 4.81 (1H, s), 6.68 (1H, dd, J = 1.9, 3.3 Hz), 7.40 (1H, t, J = 3.0 Hz), 8.71 (1H, s), 8.94 (1H, t, J = 5.8 Hz), 11.02 (1H, s), 12.06 (1H, s). MS: 467 (M + H)+, 489 (M + Na)+ 455 32 1H-NMR (400 MHz, d6-DMSO)δ: 1.27-1.32 (2H, m), 1.45-1.55 (4H, m), 1.68-1.71 (2H, m), 1.84-1.91 (2H, m), 2.00 (1H, s), 2.09-2.17 (2H, m), 3.03 and 3.13 (total 2H, eachd, J = 5.5 and 5.5 Hz), 3.28 (3H, s), 3.39-3.42 (2H, m), 3.47-3.50 (2H, m), 4.30 and 4.47 (total 1H, eacht, J = 5.5 and 5.5 Hz), 4.85 and 4.87 (total 1H, eachs), 6.60 and 6.65 (total 1H, eachm), 7.46 (1H, t, J = 3.0 Hz), 8.71 and 8.72 (total 1H, s), 8.97 (1H, m), 10.96 and 10.97 (total 1H, s), 12.07 (1H, s). MS: 467 (M + H)+, 489 (M + Na)+ 456 33 MS: 646 (M + H)+ 457 33 MS: 506 (M + H)+ 458 33 1H-NMR (400 MHz, d6-DMSO)δ: 1.01 (3H, d, J = 7.6 Hz), 1.24 (3H, s), 1.30 (3H, s), 1.88-2.83 (7H, m), 4.80-4.90 (1H, m), 6.45-6.48 (1H, m), 7.43-7.46 (1H, m), 7.92 (1H, s), 10.91 (1H, brs), 11.63 (1H, brs). MS: 311 (M + H)+ 459 33 MS: 465 (M + H)+ 460 33 MS: 497 (M + H)+ 461 33 MS: 509 (M + H)+ 462 33 MS: 509 (M + H)+ 463 33 MS: 478 (M + H)+ 464 33 MS: 465 (M + H)+ 465 33 MS: 463 (M + H)+ 466 33 MS: 434 (M + H)+ 467 33 MS: 499 (M + H)+ 468 33 MS: 541 (M + H)+ 469 33 MS: 477 (M + H)+ 470 33 MS: 449 (M + H)+ 471 33 MS: 546 (M + H)+ 472 33 MS: 506 (M + H)+ 473 33 MS: 453 (M + H)+ 474 33 MS: 504 (M + H)+ 475 33 MS: 453 (M + H)+ 476 34 1H-NMR (400 MHz, d6-DMSO)δ: 1.75-1.90 (4H, m), 2.00-2.10 (2H, m), 2.14-2.28 (3H, m), 2.37-2.54 (4H, m), 4.21-4.27 (1H, m), 6.36 (1H, d, J = 6.8 Hz), 6.73-6.78 (1H, m), 7.27-7.31 (1H, m), 8.11 (1H, s), 11.86 (1H, brs). MS: 427 (M + Na)+ 477 35 MS: 314 (M + H)+ 478 35 MS: 393 (M + H)+ 479 35 MS: 382 (M + H)+ 480 35 1H-NMR (400 MHz, d6-DMSO)δ: 1.39-1.46 (2H, m), 1.56-1.87 (8H, m), 2.07 (1H, m), 2.18 (3H, s), 2.25 (2H, m), 4.03 (1H, m), 4.47 (1H, s), 4.77 (1H, d, J = 7.2 Hz), 6.38 (1H, d, J = 3.6 Hz), 7.13 (1H, d, J = 3.6 Hz), 7.71 (1H, s), 8.32 (1H, s), 11.156 (1H, s). MS: 298 (M + H)+ 481 35 MS: 378 (M + Na)+ 482 35 MS: 420 (M + Na)+ 483 35 1H-NMR (400 MHz, d6-DMSO)δ: 1.22-2.24 (13H, m), 3.20-3.40 (2H, m), 4.42-4.65 (2H, m), 6.44-6.48 (1H, m), 6.82-7.09 (1H, br), 7.16-7.19 (1H, m), 7.56-7.84 (1H, br), 8.34 (1H, s), 9.45 (1H, d, J = 8.0 Hz), 11.48 (1H, brs). MS: 329 (M + H)+. 484 35 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-1.51 (2H, m), 1.61-1.63 (2H, m), 1.68-1.73 (2H, m), 1.81-1.87 (2H, m), 1.91-1.96 (2H, m), 2.08-2.12 (1H, m), 2.28-2.31 (2H, m), 4.19-4.23 (1H, m), 4.46 (1H, brs), 4.66-4.68 (2H, m), 5.68-5.71 (1H, m), 6.58-6.60 (1H, m), 7.25-7.26 (1H, m), 8.60 (1H, s), 9.07 (1H, d, J = 7.8 Hz), 11.83 (1H, brs). MS: 382 (M + H)+ 485 35 1H-NMR (400 MHz, d6-DMSO)δ: 1.31-1.35 (2H, m), 1.47-1.50 (2H, m), 1.61-1.98 (7H, m), 2.07-2.12 (2H, m), 2.96-2.99 (2H, m), 4.11-4.16 (1H, m), 4.35-4.39 (1H, m), 6.42-6.46 (1H, m), 6.80-7.09 (1H, br), 7.10-7.13 (1H, m), 7.52-7.88 (1H, br), 8.36 (1H, s), 10.13 (1H, d, J = 8.0 Hz), 11.43 (1H, brs). MS: (M + H)+. 486 35 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.70 (8H, m), 1.89-1.96 (3H, m), 2.05-2.10 (2H, m), 3.03-3.08 (2H, m), 4.08-4.15 (1H, m), 4.39-4.44 (1H, m), 6.40-6.44 (1H, m), 6.95-7.19 (2H, m), 7.68-7.96 (1H, br), 8.38 (1H, s), 10.27 (1H, d, J = 8.0 Hz), 11.55 (1H, brs). MS: 341 (M + H)+. 487 35 1H-NMR (400 MHz, d6-DMSO)δ: 1.34-1.44 (2H, m), 1.58-1.72 (4H, m), 1.80-1.90 (2H, m), 2.00-2.11 (3H, m), 2.33-2.44 (2H, m), 4.18-4.28 (3H, m), 6.59-6.60, (1H, m), 6.90-6.98 (1H, m), 7.20 (1H, brs), 7.33 (1H, brs), 7.38-7.39 (1H, m), 7.46 (1H, brs), 8.19 (1H, s), 8.61 (3H, br), 12.63 (1H, brs). MS: 313 (M − 3HCl + H)+ 488 39 1H-NMR (400 MHz, d6-DMSO)δ: 1.85-2.25 (8H, m), 2.37-2.41 (1H, m), 2.53-2.57 (2H, m), 2.91-2.96 (1H, m), 3.11-3.18 (1H, m), 4.74 (1H, s), 6.55-6.59 (1H, m), 7.37 (1H, t, J = 2.7 Hz), 8.51-8.52 (1H, m), 10.89 (1H, s), 11.94 (1H, s). MS: 387, 389 (M + H)+ 489 39 1H-NMR (400 MHz, d6-DMSO)δ: 1.10-1.28 (2H, m), 1.36-2.38 (7H, m), 2.54 (1H, brs), 5.02-5.08 (1H, m), 6.72-6.74 (1H, m), 7.35-7.37 (1H, m), 8.47 (1H, s), 10.9 (1H, brs), 12.0 (1H, s). MS: 269 (M + H)+ 490 39 1H-NMR (400 MHz, d6-DMSO)δ: 1.54-1.64 (2H, m), 2.10-2.63 (9H, m), 2.75-2.83 (2H, m), 4.91 (1H, s), 6.64-6.66 (1H, m), 7.37 (1H, t, J = 3.0 Hz), 8.50 (1H, s), 10.81 (1H, s), 11.93 (1H, s). MS: 387, 389 (M + H)+ 491 39 1H-NMR (400 MHz, d6-DMSO)δ: 1.55-1.60 (2H, m), 1.77-1.80 (2H, m), 1.90-2.02 (4H, m), 2.06-2.13 (2H, m), 2.32-2.36 (2H, m), 2.52-2.57 (2H, m), 4.75-4.77 (1H, m), 6.53-6.56 (1H, m), 7.35-7.38 (1H, m), 8.50 (1H, s), 10.78 (1H, brs), 11.92 (1H, brs). MS: 309 (M + H)+. 492 40 1H-NMR (400 MHz, d6-DMSO)δ: 1.38-1.48 (2H, m), 1.64-1.81 (4H, m), 1.93-2.05 (2H, m), 2.11-2.19 (1H, m), 2.37-2.57 (4H, m), 4.44 (0.34H, brs), 4.56-4.59 (1H, m), 4.70 (0.66H, brs), 6.50-6.52 (0.66H, m), 6.54-6.56 (0.34H, m), 7.36-7.38 (1H, m), 8.50 (0.66H, s), 8.51 (0.34H, s), 10.78 (1H, brs), 11.92 (1H, brs). MS: 325 (M + H)+. 493 40 MS: 325 (M + H)+. 494 40 1HNMR (400 MHz, d6-DMSO)δ: 0.88 (3H, d, J = 6.9 Hz), 1.72-1.92 (2H, m), 2.15-2.26 (1H, m), 3.55-3.70 (4H, m), 5.30-5.40 (1H, m), 7.01 (1H, d, J = 9.2 Hz), 7.15 (1H, brs), 7.76 (1H, d, J = 9.2 Hz), 7.90 (1H, brs), 8.09 (1H, s), 8.39 (1H, s), 8.48 (1H, s), 9.89 (1H, d, J = 9.0 Hz), 12.9 (1H, brs). MS: 420 (M + H)+ 495 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.52 (2H, m), 1.76-1.91 (6H, m), 2.10-2.16 (1H, m), 2.27-2.33 (3H, m), 2.68 (2H, t, J = 6 Hz), 3.59 (2H, t, J = 6 Hz), 4.76-4.85 (1H, m), 6.09 (1H, d, J = 7.3 Hz), 8.25-8.27 (3H, m), 13.21 (1H, br). MS: 363 (M + H)+ 496 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.00-1.59 (13H, m), 2.64-2.75 (2H, m), 3.54-3.69 (2H, m), 4.63-4.76 (1H, m), 6.55-6.64 (1H, m), 7.35-7.39 (1H, m), 8.50 (1H, s), 10.79-10.83 (1H, m), 11.91 (1H, s). MS: 378 (M + H)+ 497 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.54-1.62 (2H, m), 1.73-1.86 (4H, m), 1.96-2.27 (4H, m), 2.54-2.61 (3H, m), 2.67 (2H, t, J = 6.0 Hz), 3.57 (2H, t, J = 6.0 Hz), 4.63 (1H, s), 6.56-6.59 (1H, m), 7.36-7.39 (1H, m), 8.49-8.51 (1H, m), 10.83 (1H, s), 11.93 (1H, s). MS: 378 (M + H)+ 498 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.41-1.49 (2H, m), 1.77-1.82 (2H, m), 1.84-1.89 (2H, m), 2.15-2.22 (4H, m), 2.41-2.48 (3H, m), 2.71 (2H, t, J = 6.0 Hz), 3.66 (2H, t, J = 6.0 Hz), 4.76 (1H, s), 6.61-6.63 (1H, m), 7.36-7.37 (1H, m), 8.50 (1H, s), 10.79 (1H, s), 11.92 (1H, s). MS: 378 (M + H)+ 499 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.42-1.49 (2H, m), 1.73-1.80 (4H, m), 1.83-1.89 (2H, m), 1.97-2.03 (2H, m), 2.09-2.13 (1H, m), 2.18-2.23 (2H, m), 2.68 (2H, t, J = 6.0 Hz), 3.61 (2H, t, J = 6.0 Hz), 4.17-4.21 (1H, m), 6.48 (1H, dd, J = 1.9, 3.5 Hz), 6.99 (1H, br), 7.12 (1H, dd, J = 2.5, 3.5 Hz), 7.79 (1H, br), 8.37 (1H, s), 10.11 (1H, d, J = 8.3 Hz), 11.46 (1H, s). MS: 390 (M + H)+ 500 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.42-1.48 (2H, m), 1.71-1.90 (7H, m), 2.10-2.20 (4H, m), 2.68 (2H, t, J = 5.9 Hz), 3.59 (2H, t, J = 5.9 Hz), 5.07 (1H, d, J = 8.7 Hz), 7.12 (1H, br), 7.86 (1H, br), 8.05 (1H, s), 8.45 (1H, s), 9.97 (1H, d, J = 8.7 Hz), 12.78 (1H, br). MS: 381 (M + H)+ 501 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.53-1.60 (2H, m), 1.70-1.79 (6H, m), 1.87-1.95 (2H, m), 2.08-2.15 (1H, m), 2.21-2.27 (2H, m), 2.69 (2H, t, J = 6 Hz), 3.58 (2H, t, J = 6 Hz), 4.99 (1H, d, J = 8.6 Hz), 7.18 (1H, br), 7.89 (1H, br), 8.06 (1H, s), 8.46 (1H, s), 10.05 (1H, d, J = 8.6 Hz), 12.79 (1H, br). MS: 381 (M + H)+ 502 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.51 (2H, m), 1.77-1.80 (2H, m), 1.83-1.90 (2H, m), 2.03-2.09 (2H, m), 2.12-2.17 (1H, m), 2.33-2.40 (3H, m), 2.70 (2H, t, J = 6.0 Hz), 2.89-2.93 (2H, m), 3.61 (2H, t, J = 6.0 Hz), 4.87 (1H, s), 7.98 (1H, s), 10.94 (1H, s), 12.95 (1H, br). MS: 379 (M + H)+ 503 41 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.52 (2H, m), 1.79-1.84 (2H, m), 1.87-1.95 (2H, m), 2.06-2.10 (2H, m), 2.14-2.19 (1H, m), 2.28-2.38 (2H, m), 2.95-3.02 (2H, m), 4.48 (2H, s), 4.82 (1H, s), 7.98 (1H, s), 8.33 (1H, s), 10.95 (1H, s), 12.99 (1H, br). MS: 356 (M + H)+ 504 43 1H-NMR (400 MHz, d6-DMSO)δ: 1.83-1.90 (2H, m), 1.93-1.99 (2H, m), 2.08-2.13 (1H, m), 2.23-2.29 (5H, m), 2.32-2.36 (3H, m), 4.27 (1H, d, J = 7.8 Hz), 6.6 (1H, d, J = 1.9 Hz), 7.3 (1H, t, J = 2.3 Hz), 7.53 (1H, br), 8.16 (1H, br), 8.47 (1H, s), 10.94 (1H, s), 12.11 (1H, s). MS: 389, 391 (M + H)+ 505 43 1H-NMR (400 MHz, d6-DMSO)δ: 1.22-2.33 (10H, m), 4.12 (1H, m), 6.44 (1H, m), 7.03 (1H, m), 7.14 (1H, m), 7.64 (1H, m), 8.39 (1H, s), 10.25 (1H, m), 11.48 (1H, s). MS: 345 (M + H)+ 506 43 1H-NMR (400 MHz, d6-DMSO)δ: 1.68-2.38 (13H, m), 4.98-5.02 (1H, m), 7.08 (1H, brs), 7.90 (1H, brs), 8.06 (1H, s), 8.47 (1H, s), 10.4 (1H, d, J = 8.6 Hz), 12.7 (1H, brs). MS: 330 (M + H)+ 507 45 MS: 366 (M + H)+ 508 46 MS: 388 (M + H)+ 509 46 MS: 387 (M + H)+ 510 46 MS: 397 (M + H)+ 511 46 MS: 363 (M + H)+ 512 46 MS: 405 (M + H)+ 513 46 MS: 749 (M + H)+ 514 46 MS: 381 (M + H)+ 515 46 MS: 314 (M + H)+ 516 46 MS: 328 (M + H)+ 517 46 MS: 356 (M + H)+ 518 46 MS: 368 (M + H)+ 519 46 MS: 370 (M + H)+ 520 46 MS: 377 (M + H)+ 521 46 MS: 379 (M + H)+ 522 46 MS: 382 (M + H)+ 523 46 MS: 394 (M + H)+ 524 46 MS: 378 (M + H)+ 525 46 MS: 378 (M + H)+ 526 46 MS: 393 (M + H)+ 527 46 MS: 426 (M + H)+ 528 46 MS: 342 (M + H)+ 529 46 MS: 384 (M + H)+ 530 47 MS: 368 (M + H)+ 531 47 MS: 354 (M + H)+ 532 47 MS: 354 (M + H)+ 533 47 MS: 354 (M + H)+ 534 47 MS: 368 (M + H)+ 535 47 1H-NMR (400 MHz, d6-DMSO)δ: 1.13-1.27 (1H, m), 1.43-1.52 (2H, m), 1.62-1.73 (4H, m), 1.78-1.91 (5H, m), 2.07-2.42 (6H, m), 3.54-3.67 (5H, m), 4.00-4.13 (1H, m), 4.53 (1H, brs), 6.35-6.43 (1H, m), 7.18-7.20 (1H, m), 7.70 (1H, s), 7.82 (1H, m), 11.64 (1H, brs). MS: 383 (M + H)+ 536 49 MS: 440 (M + H)+ 537 47 1H-NMR (400 MHz, d6-DMSO)δ: 1.58-2.42 (8H, m), 3.04-3.66 (4H, m), 4.19-4.38 (1H, m), 6.37-6.54 (1H, m), 6.87-7.96 (8H, m), 8.36 (1H, s), 10.08-10.26 (1H, m), 11.42 (1H, brs). MS: 376 (M + H)+ 538 49 MS: 421 (M + H)+ 539 49 MS: 408 (M + H)+ 540 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-2.22 (9H, m), 4.59 (1H, m), 4.83 (2H, m), 6.59 (1H, m), 6.98 (1H, m), 7.20 (1H, m), 7.73 (1H, m), 8.33 (1H, m), 8.37 (1H, m), 9.34 (1H, m), 11.53 (1H, s). MS: 389 (M + H)+ 541 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.49-2.36 (7H, m), 4.63 (1H, m), 4.91 (2H, m), 6.61 (1H, m), 6.98 (1H, m), 7.21 (1H, m), 7.77 (1H, m), 8.32 (1H, m), 9.15 (2H, m), 9.39 (1H, m), 11.54 (1H, s). MS: 409 (M + H)+ 542 49 MS: 442, 444 543 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.41-2.33 (8H, m), 4.61 (1H, m), 4.86 (2H, m), 6.60 (1H, m), 6.95 (1H, m), 7.21 (1H, m), 7.32 (1H, m), 7.74 (1H, m), 7.88 (1H, m), 8.32 (1H, m), 9.34 (1H, m), 11.53 (1H, s). MS: 389 (M + H)+ 544 49 MS: 394 (M + H)+ 545 49 MS: 389 (M + H)+ 546 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-1.51 (2H, m), 1.59-1.62 (2H, m), 1.66-1.71 (2H, m), 1.81-1.92 (4H, m), 2.07-2.10 (1H, m), 2.28-2.31 (2H, m), 3.69-3.87 (8H, m), 4.20-4.24 (1H, m), 4.47 (1H, s), 6.59-6.61 (1H, m), 6.96 (1H, d, J = 9.0 Hz), 7.28-7.29 (1H, m), 7.91 (1H, dd, J = 2.4, 9.1 Hz), 8.52-8.53 (1H, m), 8.66 (1H, s), 8.86-8.89 (1H, m), 11.90 (1H, brs). MS: 566 (M + H)+ 547 49 MS: 405 (M + H)+ 548 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.75-1.87 (2H, m), 1.98-2.14 (2H, m), 2.14-2.33 (4H, m), 4.25-4.35 (1H, m), 4.50-4.83 (2H, m), 6.38-6.45 (1H, m), 6.85 (1H, d, J = 9.0 Hz), 7.03-7.10 (1H, m), 7.05 (1H, br), 7.83 (1H, br), 7.85 (1H, dd, J = 9.0, 2.2 Hz), 8.38 (1H, s), 8.51 (1H, d, J = 2.2 Hz), 10.36 (1H, d, J = 7.7 Hz), 11.43 (1H, s) MS: 388 (M + H)+ 549 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.75-1.87 (2H, m), 1.98-2.14 (2H, m), 2.14-2.33 (4H, m), 4.25-4.35 (1H, m), 4.50-4.83 (2H, m), 6.38-6.45 (1H, m), 6.85 (1H, d, J = 9.0 Hz), 7.03-7.10 (1H, m), 7.05 (1H, br), 7.83 (1H, br), 7.85 (1H, dd, J = 9.0, 2.2 Hz), 8.38 (1H, s), 8.51 (1H, d, J = 2.2 Hz), 10.36 (1H, d, J = 7.7 Hz), 11.43 (1H, s). MS: 388 (M + H)+ 550 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.83-1.94 (2H, m), 2.01-2.18 (2H, m), 2.18-2.36 (4H, m), 4.27-4.38 (1H, m), 4.46-5.09 (2H, m), 6.38-6.45 (1H, m), 6.87 (1H, d, J = 9.5 Hz), 7.04-7.11 (1H, m), 7.05 (1H, br), 7.83 (1H, br), 8.24 (1H, dd, J = 9.5, 2.8 Hz), 8.39 (1H, s), 9.01 (1H, d, J = 2.8 Hz), 10.38 (1H, d, J = 7.7 Hz), 11.45 (1H, s). MS: 408 (M + H)+ 551 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.69-1.84 (2H, m), 1.99-2.14 (2H, m), 2.14-2.36 (4H, m), 4.24-4.34 (1H, m), 4.54-4.75 (2H, m), 6.38-6.44 (1H, m), 6.88 (1H, d, J = 8.9 Hz), 7.02-7.07 (1H, m), 7.06 (1H, br), 7.79 (1H, dd, J = 8.9, 2.5 Hz), 7.80 (1H, br), 8.38 (1H, s), 8.42-8.45 (1H, m), 10.35 (1H, d, J = 7.7 Hz), 11.42 (1H, s). MS: 431 (M + H)+ 552 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.83-1.95 (2H, m), 2.05-2.21 (2H, m), 2.21-2.41 (4H, m), 2.45 (3H, s), 4.42-4.52 (1H, m), 4.58-4.85 (2H, m), 6.54-6.60 (1H, m), 6.89 (1H, d, J = 8.9 Hz), 7.17-7.22 (1H, m), 7.87 (1H, dd, J = 8.9, 2.4 Hz), 8.53 (1H, dd, J = 2.4, 0.4 Hz), 8.59 (1H, s), 9.26 (1H, d, J = 7.6 Hz), 11.79 (1H, s). MS: 427 (M + H)+ 553 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.80-2.00 (4H, m), 2.11-2.22 (2H, m), 2.29-2.42 (2H, m), 4.28-4.40 (3H, m), 6.42-6.48 (1H, m), 6.89 (1H, dd, J = 8.0, 4.6 Hz), 7.04 (1H, br), 7.05-7.10 (1H, m), 7.74 (1H, br), 8.21 (1H, dd, J = 8.0, 1.7 Hz), 8.37 (1H, s), 8.42 (1H, dd, J = 4.6, 1.7 Hz), 10.27 (1H, d, J = 7.7 Hz), 11.41 (1H, s). MS: 408 (M + H)+ 554 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.55-1.65 (2H, m), 2.02-2.25 (6H, m), 4.38-4.44 (2H, m), 5.55-5.65 (1H, m), 7.10 (1H, brs), 7.82 (1H, brs), 8.05 (1H, s), 8.11 (1H, s), 8.42 (1H, s), 9.18 (1H, d, J = 8.5 Hz), 12.9 (1H, brs). MS: 395 (M + H)+ 555 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.60-1.67 (2H, m), 1.96-2.06 (4H, m), 2.16-2.21 (2H, m), 4.50-4.60 (2H, m), 4.99 (1H, brs), 6.59 (1H, s), 7.00 (1H, brs), 7.20 (1H, s), 7.80 (1H, brs), 8.22 (1H, d, J = 1.9 Hz), 8.34 (1H, s), 8.55 (1H, d, J = 1.9 Hz), 9.43 (1H, d, J = 8.5 Hz), 11.5 (1H, s). MS: 422 (M + H)+ 556 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.22-2.03 (8H, m), 4.58-4.67 (5H, m), 5.38 (1H, brs), 6.58-6.59 (1H, m), 6.97 (1H, brs), 7.19-7.25 (2H, m), 7.44-7.46 (1H, m), 7.75 (1H, brs), 8.31 (1H, s), 9.30 (1H, d, J = 8.0 Hz), 11.54 (1H, s). MS: 394 (M + H)+ 557 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.30-2.15 (8H, m), 4.34 (2H, brs), 4.55-4.56 (1H, m), 6.57-6.58 (1H, m), 6.95 (1H, brs), 7.18-7.20 (1H, m), 7.86 (1H, brs), 8.00 (1H, s), 8.34 (1H, s), 9.39 (1H, d, J = 8.0 Hz), 11.55 (1H, brs). MS: 394 (M + H)+ 558 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.56-2.56 (8H, m), 3.69 (3H, s), 4.66-4.85 (3H, m), 6.66 (1H, s), 7.25-7.35 (2H, m), 7.85-7.94 (1H, m), 8.35-8.43 (1H, m), 9.33-9.45 (1H, m), 11.53 (1H, m). MS: 422 (M + H)+ 559 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.23-2.32 (8H, m), 4.60-4.80 (3H, m), 6.61 (1H, s), 7.24-7.36 (2H, m), 7.85-8.40 (6H, m), 9.27-9.37 (1H, m), 11.53 (1H, brs). MS: 405 (M − H)− 560 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.96-1.98 (2H, m), 2.15-2.20 (2H, m), 2.31-2.37 (2H, m), 2.51-2.58 (2H, m), 4.33 (1H, m), 5.00 (2H, s), 5.96 (1H, s), 6.94-6.97 (1H, m), 7.37 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 8.14 (1H, dd, J = 1.8, 7.7 Hz), 8.47 (1H, dd, J = 2.0, 4.8 Hz), 10.95 (1H, s), 11.60 (1H, s). MS: 386 (M + H)+ 561 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.71-1.73 (2H, m), 1.98-1.99 (2H, m), 2.13 (2H, m), 2.43-2.54 (4H, m), 4.81 (2H, s), 5.10 (1H, brs), 7.07 (1H, d, J = 4.9 Hz), 7.44 (1H, s), 7.90 (1H, s), 8.41 (1H, d, J = 5.1 Hz), 10.97 (1H, s), 11.52 (1H, s). MS: 386 (M + H)+, 408 (M + Na)+ 562 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.94-1.96 (2H, m), 2.15 (2H, m), 2.26-2.32 (2H, m), 2.47-2.54 (2H, m), 4.04 (1H, m), 4.77 (1H, s), 5.59 (1H, brs), 7.06 (1H, d, J = 5.2 Hz), 7.32 (1H, brs), 7.48 (1H, s), 7.88 (1H, s), 8.39 (1H, d, J = 5.0 Hz), 10.92 (1H, s), 11.58 (1H, s). MS: 386 (M + H)+ 563 49 1H-NMR (400 MHz, d6-DMSO)δ: 1.97-1.99 (2H, m), 2.16 (2H, brs), 2.28-2.35 (2H, m), 2.46-2.54 (2H, m), 4.03 (1H, m), 4.83 (2H, s), 5.70 (1H, s), 7.70 (1H, d, J = 9.0 Hz), 7.33 (1H, s), 7.88 (1H, s), 7.98 (1H, dd, J = 2.4, 9.0 Hz), 8.60 (1H, d, J = 2.4 Hz), 10.94 (1H, s), 11.60 (1H, s). MS: 386 (M + H)+ 564 50 MS: 394 (M + H)− 565 50 1H-NMR (400 MHz, d6-DMSO)δ: 1.46-2.22 (13H, m), 2.59 (3H, s), 4.09 (1H, m), 4.55 (1H, s), 6.49 (1H, m), 7.16 (1H, m), 8.58 (1H, s), 10.67 (1H, m), 11.71 (1H, s). MS: 326.2 (M + H)+ 566 50 MS: 410 (M + H)+ 567 50 1H-NMR (400 MHz, d6-DMSO)δ: 1.43-1.50 (4H, m), 1.63 (6H, s), 1.65-1.74 (3H, m), 1.87-1.94 (3H, m), 2.03-2.11 (1H, m), 2.21-2.24 (2H, m), 4.30-4.34 (1H, m), 4.53 (1H, s), 6.06 (1H, s), 6.49-6.51 (1H, m), 7.23-7.25 (1H, m), 7.84-7.87 (1H, m), 8.71 (1H, s), 11.63 (1H, brs). MS: 410 (M + H)+ 568 53 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.33 (7H, m), 3.80 (3H, s), 4.07 (1H, m), 4.46 (1H, m), 6.07 (2H, s), 6.43 (1H, m), 7.11 (1H, m), 8.13 (1H, s), 8.84 (1H, m), 11.31 (1H, s). MS: 356 (M + H)+ 569 53 1H-NMR (400 MHz, d6-DMSO)δ: 1.40-2.45 (13H, m), 4.11 (1H, m), 4.44 (1H, s), 6.45 (1H, m), 7.14 (1H, m), 7.86 (1H, s), 8.32 (1H, s), 8.60 (1H, m), 10.77 (1H, s), 11.41 (1H, s). MS: 327 (M + H)+ 570 53 1H-NMR (400 MHz, d6-DMSO)δ: 1.47-2.25 (7H, m), 2.31 (3H, s), 3.96 (3H, s), 4.10 (1H, m), 4.50 (1H, s), 6.46 (1H, m), 7.13 (1H, m), 8.16 (1H, s), 9.12 (1H, m), 11.39 (1H, s). MS: 328 (M + H)+ 571 53 1H-NMR (400 MHz, d6-DMSO)δ: 1.29-2.27 (12H, m), 2.31 (3H, s), 4.09 (1H, m), 4.32-4.37 (2H, m), 6.44 (1H, m), 7.12 (1H, m), 8.11 (1H, s), 9.33 (1H, m), 10.88 (1H, s), 11.32 (1H, s). MS: 341 (M + H)+ 572 54 MS: 398 (M + H)+ 573 54 MS: 366 (M + H)+ 574 54 MS: 439 (M − H)+ 575 54 MS: 384 (M + H)+ 576 54 MS: 440 (M − H)− 577 54 MS: 384 (M + H)+ 578 55 1H-NMR (400 MHz, d6-DMSO)δ: 1.36-1.42 (2H, m), 1.57-1.69 (4H, m), 1.73-1.79 (2H, m), 1.93-1.99 (2H, m), 2.05-2.09 (1H, m), 2.27-2.31 (2H, m), 4.00-4.04 (1H, m), 4.48 (1H, s), 6.11 (1H, d, J = 16.1 Hz), 6.10-6.13 (1H, m), 6.42-6.44 (1H, m), 7.16-7.18 (1H, m), 7.91 (1H, d, J = 16.1 Hz), 8.21 (1H, s), 11.53 (1H, brs). MS: 335 (M + H)+ 579 61 1H-NMR (400 MHz, d6-DMSO)δ: 1.45-2.69 (13H, m), 4.19 (1H, m), 4.53 (1H, s), 6.54 (1H, m), 7.25 (1H, m), 8.43 (1H, s), 8.75 (1H, m), 11.68 (1H, s), MS: 367 (M + H)+, 365 (M − H)− 

1. A condensed pyridine compound represented by formula (I), or a pharmaceutically acceptable salt thereof:

wherein X is N or CR³, M is (CH₂)_(m); m is 0 or 1, R¹ is —H or lower alkyl which may be substituted, R² is —H or lower alkyl which may be substituted, R³ is —H, halogen, or lower alkyl which may be substituted, R⁴¹ is —H or heteroaryl which may be substituted, R⁴² is polycyclic bridged cyclic hydrocarbon having three rings or aza-bridged cyclic hydrocarbon, each of which may be substituted, R⁵ is a group selected from the group consisting of cyano, acyl, acylamino, lower alkyl, lower alkenyl, —O-lower alkyl, 5- or 6-membered heterocycloalkyl, 5- or 6-membered heterocycloalkenyl, and 5-membered heteroaryl, each of which may be substituted, provided that when R⁵ is 5-membered heteroaryl, X is —CR³, or R⁴¹ and R⁵ may be linked via a specific functional group to form bivalent group selected from:

wherein R^(A) is —H or acyl which may be substituted, wherein “which may be substituted” in definitions of R¹, R², R³, R⁴¹, R⁴² and R⁵, consisting of the groups described in items (a) to (g), (a) halogen; (b) —OH, —O—R^(Z), —O-phenyl, —OCO—R^(Z), —OCONH—R^(Z), oxo (═O); (c) —SH, —S—R^(Z), —S-phenyl, —S-heteroaryl, —SO—R^(Z), —SO-phenyl, —SO-heteroaryl, —SO₃H, —SO₂—R^(Z), —SO₂-phenyl, —SO₂-heteroaryl, sulfamoyl which may be substituted with one or two R^(Z) groups; (d) amino which may be substituted with one or two R^(Z) groups, —NHCO—R^(Z), —NHCO-phenyl, —NHCO₂—R^(Z), —NHCONH₂, —NHCONH—R^(Z), —NHSO₂-phenyl, —NHSO₂NH₂, —NO₂, ═N—O—R^(Z); (e) —CHO, —CO—R^(Z), —CO₂H, —CO₂—R^(Z), carbamoyl which may be substituted with one or two R^(Z) groups, —CO-cyclic amino, —COCO—R^(Z), cyano; (f) R^(Z); and (g) phenyl which may be substituted with one or more groups selected from the substituents described in the above items (a) to (f), 5- or 6-membered heterocycloalkyl, or 5- or 6-membered heteroaryl; wherein R^(Z) is cyano; —OH; and lower alkyl which may be substituted with one to three groups selected from the group consisting of —O-lower alkyl, —NH-lower alkyl, —CONH-lower alkyl, 5- or 6-membered heterocycloalkyl, and 5- or 6-membered heteroaryl.
 2. The compound according to claim 1, or a pharmaceutical acceptable salt thereof, wherein R¹ is —H or lower alkyl which may be substituted with a group selected from the group consisting of mono- or di-lower alkylamino and —O-lower alkyl, R² is —H or lower alkyl, R³ is —H or lower alkyl substituted with a group selected from the group consisting of halogen, mono- or di-lower alkylamino, and cyclic amino, R⁴¹ is —H or heteroaryl which may be substituted with cyano, R⁴² is polycyclic bridged cyclic hydrocarbon having three rings or aza-bridged cyclic hydrocarbon, each of which may be substituted, R⁵ is a group selected from the group consisting of cyano, lower alkylcarbonyl, lower alkyloxycarbonyl, hydroxycarbonyl, formyl, amidinooxycarbonyl, guanidinooxycarbonyl, guanidino, carbamoyl, —C (═O)-5- or -6-membered heterocycloalkyl, —C(═O)-5- or -6-membered heteroaryl, lower alkyl, lower alkenyl, —O-lower alkyl, 5- or 6-membered heterocycloalkyl, and 5-membered heteroaryl, each of which may be substituted, provided that when R⁵ is 5-membered heteroaryl, X is —CR³.
 3. The compound according to claim 1, or a pharmaceutical acceptable salt thereof, wherein R⁴² is adamantyl or tropanyl, each of which may be substituted.
 4. The compound according to claim 1, or a pharmaceutical acceptable salt thereof, wherein R⁵ is carbamoyl, 5-membered heteroaryl, lower alkylcarbonyl, each of which may be substituted with NH₂, hydroxymethyl or OH; or R⁴¹ and R⁵ may be linked via a specific functional group to form (I-A); or R⁴¹ and R⁵ may be linked via a specific functional group to form (I-B); or R⁴¹ and R⁵ may be linked via a specific functional group to form (I-C), wherein R^(A) is —C(═O)—C(═O)NH-lower alkyl which may be substituted with lower alkyloxy.
 5. The compound according to claim 1, or a pharmaceutical acceptable salt thereof, wherein R⁵ is oxadiazole or thiadiazole, each of which may be substituted.
 6. The compound according to claim 1, or a pharmaceutical acceptable salt thereof, wherein R⁴² is polycyclic bridged cyclic hydrocarbon having three rings and which may be substituted.
 7. The compound according to claim 6, or a pharmaceutical acceptable salt thereof, wherein R⁴² is adamantyl which may be substituted.
 8. The compound according to claim 1, or a pharmaceutical acceptable salt thereof, wherein R⁴² is aza-bridged cyclic hydrocarbon having three rings and which may be substituted.
 9. The compound according to claim 8, or a pharmaceutical acceptable salt thereof, wherein R⁴² is tropanyl which may be substituted.
 10. The compound according to claim 1, or a pharmaceutical acceptable salt thereof, wherein X in the formula (I) is CH, R¹ is —H, R² is —H or CH₃, R⁴¹ is —H, R⁴² is adamantyl or tropanyl and each of which may be substituted with OH, R⁵ is carbamoyl which may be substituted or —C(═O)-lower alkyl which may be substituted by OH.
 11. The compound according to claim 10, or a pharmaceutical acceptable salt thereof, wherein R⁵ is —CONH₂ or hydroxyacetyl.
 12. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
 13. A method of inhibiting janus kinase 3 activity in a patient with diseases or conditions caused by undesirable cytokine signal translations mediated by janus kinase 3, comprising administering to said patient a compound according to claim 1, or a pharmaceutical acceptable salt thereof.
 14. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering an effective amount of a compound according to claim 1, or a pharmaceutical acceptable salt thereof, to said human being or animal in need thereof.
 15. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administering an effective amount of a compound according to claim 1, or a pharmaceutical acceptable salt thereof, to said human being or animal in need thereof.
 16. The method of claim 15, wherein said autoimmune disease is rheumatoid arthritis.
 17. The method of claim 15, wherein the autoimmune disease is psoriasis.
 18. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a compound, a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, of a compound selected from the group consisting of:


19. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a compound selected from the group consisting of:


20. The method of claim 19, wherein said autoimmune disease is rheumatoid arthritis.
 21. The method of claim 19, wherein the autoimmune disease is psoriasis.
 22. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


23. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


24. The method of claim 23, wherein said autoimmune disease is rheumatoid arthritis.
 25. The method of claim 23, wherein the autoimmune disease is psoriasis.
 26. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


27. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


28. The method of claim 27, wherein said autoimmune disease is rheumatoid arthritis.
 29. The method of claim 27, wherein the autoimmune disease is psoriasis.
 30. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


31. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


32. The method of claim 31, wherein said autoimmune disease is rheumatoid arthritis.
 33. The method of claim 31, wherein the autoimmune disease is psoriasis.
 34. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


35. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


36. The method of claim 35, wherein said autoimmune disease is rheumatoid arthritis.
 37. The method of claim 35, wherein the autoimmune disease is psoriasis.
 38. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


39. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


40. The method of claim 39, wherein said autoimmune disease is rheumatoid arthritis.
 41. The method of claim 39, wherein the autoimmune disease is psoriasis.
 42. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


43. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


44. The method of claim 43, wherein said autoimmune disease is rheumatoid arthritis.
 45. The method of claim 43, wherein the autoimmune disease is psoriasis.
 46. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


47. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


48. The method of claim 47, wherein said autoimmune disease is rheumatoid arthritis.
 49. The method of claim 47, wherein the autoimmune disease is psoriasis.
 50. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


51. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


52. The method of claim 51, wherein said autoimmune disease is rheumatoid arthritis.
 53. The method of claim 51, wherein the autoimmune disease is psoriasis.
 54. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


55. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


56. The method of claim 55, wherein said autoimmune disease is rheumatoid arthritis.
 57. The method of claim 55, wherein the autoimmune disease is psoriasis.
 58. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


59. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


60. The method of claim 59, wherein said autoimmune disease is rheumatoid arthritis.
 61. The method of claim 59, wherein the autoimmune disease is psoriasis.
 62. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


63. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


64. The method of claim 63, wherein said autoimmune disease is rheumatoid arthritis.
 65. The method of claim 63, wherein the autoimmune disease is psoriasis.
 66. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


67. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


68. The method of claim 67, wherein said autoimmune disease is rheumatoid arthritis.
 69. The method of claim 67, wherein the autoimmune disease is psoriasis.
 70. A method for treating a rejection during organ/tissue transplantation in a human being or animal in need thereof, wherein said method comprises administering to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


71. A method for treating an autoimmune disease in a human being or animal in need thereof, wherein said method comprises administrating to said human being or animal in need thereof an effective amount of a pharmaceutically acceptable salt form of a compound having the formula:


72. The method of claim 71, wherein said autoimmune disease is rheumatoid arthritis.
 73. The method of claim 71, wherein the autoimmune disease is psoriasis. 